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Abstract
In addition to their bactericidal effects, antibiotics are potent signal mediators at subinhibitory levels in the environment. The ability to modulate community structure in this
niche raises concerns over their capacity to influence pathogenesis in patients during
antibiotic therapy. This concept forms the basis of this thesis, and is explored using
models of prophylactic therapy for recurrent urinary tract infection (UTI) management.
Sub-inhibitory ciprofloxacin, ampicillin, and gentamicin were found to augment
virulence in vitro, increasing adherence and urothelial cell invasion in uropathogenic
Escherichia coli (UPEC) and Staphylococcus saprophyticus. In addition, biofilm
formation was increased, and swarming motility decreased. In UPEC, the effect of
antibiotics on these processes was abolished in SOS-deficient strains.
Trans-urethral inoculation of mice with ciprofloxacin-primed S. saprophyticus or UPEC
significantly increased bacterial burden in both bladders and kidneys at one and 14 days
post-inoculation (dpi). Sub-therapeutic ciprofloxacin supplemented in the drinking water
of chronically infected mice significantly increased bacterial urine load. In addition, mice
previously infected but clinically resolved suffered recurrences. These mice had impaired
urinary polymorphonuclear leukocyte infiltrates, in part due to antibiotic-dependent
cytokine suppression during initial infection. Prophylactic intervention had no significant
effect on UPEC clearance, but did significantly increase bacterial intracellular bladder
reservoirs, raising concerns over the clinical efficacy of this management strategy and
risks of promoting persistent infection.

ii

The inability of antibiotics to clear infection in prophylaxis models was attributed to the
presence of MDT persister cells. Sub-inhibitory antibiotic pre-treatments were found to
increase persister fractions, but this effect was abolished in SOS-deficient strains.
Conducting these assays with UPEC isolated from recurrent UTI patients revealed an
enriched persister fraction compared to organisms cleared with standard antibiotic
therapy, suggesting persister traits are either selected for during prolonged antibiotic
treatment or initially contribute to therapy failure.
This work represents the first attempt to illustrate that observed sub-inhibitory, pathogen
associated antibiotic-dependent changes in vitro have significant in vivo consequences. It
is hoped that this research will lead to a re-examination of how antibiotics are
administered for management of patients suffering from recurrent UTI and other chronic
diseases.

Keywords
Staphylococcus saprophyticus, Escherichia coli, UPEC, MDT, recurrent UTI, antibiotic,
urothelium, murine model, uropathogenesis, hormesis, urothelial immunity.
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INTRODUCTION
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1

INTRODUCTION

1.1 THE INFLUENCE OF ANTIBIOTICS ON HOST AND
PATHOGENS
Since their discovery, antibiotics have been used with overwhelming success in treating
and preventing infections, saving countless lives along the way. However, in recent
times, questions have been raised about not only adverse effects and multi-drug
resistance, but also the natural role of antibiotics in the environment and the potential role
in complicating disease (Yim et al., 2007; Romero et al., 2011) and affecting long term
health (Blaser, 2011). Thus, a potential paradigm shift is emerging on how we view
antibiotics. A number of case reports and clinical trials corroborate this shift, with a
growing regimen of antimicrobials associated with increased morbidity and mortality
when used for purposes outside their recommended guidelines (Harbarth et al., 2003). It
is critical that inappropriate prescription practices cease and that the current issues
associated with antibiotic misuse be brought to light.

1.1.1

A wider perspective
microorganisms

of

how

antibiotics

affect

Following Alexander Fleming's discovery that microorganisms secrete antimicrobial
agents (Fleming, 1929), there has been an explosion in the number of compounds and
synthetic derivatives that have become available for therapeutic use. Unsurprisingly, soil
organisms such as Streptomyces spp. and the penicillin-producing Penicillium notatum,
first observed by Fleming have been the indispensible work-horses of the
chemotherapeutic field, supplying the vast majority of antimicrobial compounds used
clinically today. However, it is surprising, perhaps even unnerving, that the natural roles
of these small molecules in the environment from which they are derived are still largely
unknown, with only a fraction of natural therapeutic products having been extensively
studied (Romero et al., 2011). It had long been thought that antibiotics functioned simply
as molecular weapons, whose inhibitory properties we readily take advantage of
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clinically. We now know that they have diverse effects on microorganisms, depending on
the dose administered (Davies et al., 2006). Many of these compounds are stimulatory at
doses of less than the minimal inhibitory concentration (MIC) and are capable of
modulating the expression of upwards of 5-10% of the entire bacterial genome (Goh et
al., 2002) in a bimodal dose-response relationship referred to as hormesis (Southam and
Erlich, 1943). A growing body of literature now supports their role as interspecies
signalling molecules involved in optimizing multi-organism community structure and
function (Bernier et al., 2013).
Antibiotics can meet many of the criteria for functioning as signalling agents, whose
production occurs during tightly regulated stages of growth, under certain physiological
conditions, with accumulation generating a concerted response once a certain population
threshold is achieved (Keller and Surette, 2006; Winzer et al., 2002; Hibbing et al.,
2010). The utility of this tight regulation is that antibiotics are delivered by an entire
population at a very specific concentration, often which is many fold-lower than what is
prescribed therapeutically and insufficient for antibiosis (Yim et al., 2007). Recent
investigation of natural populations of Streptomyces spp. demonstrated that subinhibitory antibiotics are important regulators of interspecies nutrient utilization
strategies, and are effective in reducing niche overlap in mixed populations (Jauri et al.,
2013). In a seminal paper, Hoffman et al. (2005) demonstrated that sub-inhibitory
aminoglycosides were capable of inducing bacterial biofilm formation in Pseudomonas
aeruginosa. This response was mediated by the aminoglycoside response regulator (arr)
gene, whose activity modulated levels of the major regulator c-di-GMP, influencing
several genes important to motility and pili production amongst others. This interaction
with a specific regulator supports the claim that antibiotics can have precise signalling
targets.
Other agents have similar effects but also up-regulate expression of secretion system
genes. This increases cytotoxicity when challenged against a macrophage cell line and
increases competition against other organisms in the environment (Linares et al., 2006;
Jones et al., 2013). Antibiotics can influence the larger microbial community structure by
hijacking inter-species regulatory systems of niche inhabitants. In Streptococcus
pneumoniae, sub-inhibitory penicillin stimulates the production of the inter-bacterial
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signalling agent autoinducer-2 (AI-2), a factor important in biofilm formation in many
species (Rogers et al., 2007). The culmination of these responses in the environment may
be to repel or defend against predatory eukaryote attack, which may be stimulated by
'sensing' streptomyces, providing an obvious benefit to multispecies community
lifestyles. Clearly, such antibiotic-induced changes may also have significant
ramifications for patients receiving antibiotic therapy. This new understanding of
antibiotic functions in natural environments necessitates a re-evaluation of their use in the
clinical setting.

1.1.2

Sub-inhibitory antibiotics are capable of modulating
bacterial virulence and pathogenesis

Clinicians are well aware of the common side-effects of antibiotic therapy which may
include microbiota dysbiosis (gastro-intestinal distress, oral and vaginal candidiasis,
bacterial vaginosis, skin rashes), the establishment of resistant variants and host toxicity
(Dancer et al., 2004). Worsening patient prognosis is often attributed to confounding
factors such as patient immune status, while the actual cause may be the prescribed agent
itself. Here, the effects that antibiotics have on bacterial virulence will be explored, citing
patient trials when possible, but relying mostly on the growing body of in vitro data.
Effects on modulation of toxin production
Since Julian Davies' group began the first serious investigations of sub-inhibitory
antibiotic hormetic effects using promoter-luciferase expression libraries over a decade
ago (Goh et al., 2002), there has been an increasing focus on characterizing phenotypes
relevant to pathogenesis. The changes that sub-inhibitory antibiotics invoke can be
dramatic and highly variable depending on the class and the organism challenged. Even
slight modifications of chemical groups within the same antibiotic can affect its ability to
augment pathogenesis (Nielsen et al., 2012). However, some antibiotic classes are
associated with specific responses. For example, protein synthesis inhibitors generally
suppress toxin expression while DNA and cell wall acting agents enhance it. These
differences are likely attributed to their mechanism of action, with protein synthesis
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inhibitors preventing toxin mRNA translation and subsequent release when supplied at
appropriate levels. There may be several routes by which antibiotics modulate gene
expression, involving specific signalling and general stress response systems (Hoffman et
al., 2005; Kelley, 2006). Knowledge of how these responses augment pathogenesis will
aid physicians in disease management for various infection milieu.
The most characterized case of antibiotics directly influencing bacterial virulence is
through the upregulation of shiga-toxin (Stx) production in enterohemorrhagic
Escherichia coli (EHEC) and induced onset of hemolytic-uremic syndrome (HUS). This
medical emergency carries a 5-10% mortality rate, and inappropriate antibiotic
application is significantly associated with increased HUS risk from ~15 to ~50% (Wong
et al., 2000; Serna IV and Boedeker, 2008). Antibiotic stress can drive bacteriophages
from lysogeny, resulting in phage replication during the lytic cycle and concurrent
production of phage related genes such as Stx. In the EHEC epidemic strain O157:H7,
sub-inhibitory fluoroquinolone and co-trimoxazole drive Stx production, while antibiotics
that target cell-wall, transcription and translation do not (McGannon et al., 2010).
Conversely, other agents are capable of inhibiting Stx production even at low levels
(McGannon et al., 2010). The reaction of organisms to antibiotics is highly variable, and
is determined by the agent provided and targeted strain. Importantly, phage activation is
not a requirement of antibiotic-induced virulence. Other mechanisms appear to exist
which are much less well characterized but believed to be driven by changes in stress
response-related systems.
Non-phage associated virulence traits can also be induced with antibiotics. In group A
streptococci (GAS), clindamycin and benzylpenicillin are commonly used therapeutics
for ameliorating toxic shock-like syndromes by suppressing exotoxin SpeA/B production
(Mascini et al., 2001). However, these and protein synthesis-inhibitors also increase
levels of other potent toxins including streptolysin and streptococcal inhibitor of
complement at sub-inhibitory levels (Tanaka et al., 2005). The effect of these agents is
abrogated when supplied at levels higher than the MIC, highlighting the importance of
maintaining therapeutic levels during treatment. This may be difficult when organisms
are either highly tolerant or resistant, such as in methicillin resistant Staphylococcus
aureus (MRSA). In these scenarios a combination of antibiotic ineffectiveness and
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induced virulence expression could easily exacerbate an already complicated infection.
The observation that resistant organisms are also in many cases hypervirulent may be a
direct, yet unexplored consequence of inappropriate antibiotic therapy (Fluit, 2005).
Indeed, there is a trend linking inappropriate therapy of resistant infections with negative
outcomes in patients, and not just because of antibiotic failure (Dancer et al., 2004).
Dumitrescu et al. (2011) demonstrated the induction of Panton-Valentine leukocidin
(PVL) toxin in MRSA when various antibiotics interfered with penicillin binding
proteins. Conversely, clindamycin and linezolid inhibit the release of PVL and other
toxins (Dumitrescu et al., 2007; Otto et al., 2013). Some protein synthesis inhibitors
increase expression of the agr virulence gene regulator in MRSA (Joo et al., 2010),
resulting in the production of phenol-soluble modulins (PSM) responsible for neutrophil
lysis and pro-inflammatory responses. Toxin production is likely attributable to subinhibitory dosing which induces gene expression but is inadequate to prevent ribosomal
translation (Joo et al., 2010). This could be clinically relevant during infections caused by
resistant organisms which have a greater threshold for tolerating therapeutic dosing.
Because there is a strong epidemiological link between PVL/PSM and severe infections
such as necrotizing pneumonia, recurrent complicated osteomyelitis and sepsis (Mitchell
et al., 2007), empirical use of certain antibiotics in locations with high MRSA incidence
should be avoided.

Effects on bacterial adherence, invasion and biofilm formation
In resistant and non-resistant organisms, many antibiotics induce a hyper-adhesive
phenotype that is characterized by an increase in surface adhesin production (Rasigade et
al., 2011; Bisogano et al., 2000; Denève et al., 2009; Erdeljan et al., 2012). The increased
capacity to adhere to tissues and medical device surfaces are of particular concern as it
potentiates the formation of antibiotic tolerant biofilms (Hoffman et al., 2005). Once a
biofilm is established, MIC shifting occurs, which may permit increased toxin production
in the now tolerant organisms. In addition, sub-inhibitory antibiotics can promote the
rapid formation of planktonic S. aureus aggregates with lowered susceptibility to
antibiotic killing (10-100x less susceptible) (Haaber et al., 2012; McNabe et al., 2011).
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These biofilm-like communities may be less susceptible to phagocytic immune predation
(Foster, 2005), providing multivariate benefits to survival and persistence within the host.
Kaplan et al., (2012) demonstrated that resistant isolates had higher fold-change in
biofilm formation compared to sensitive strains following antibiotic exposure. In biofilmassociated pathogens, such as Staphylococcus spp., antibiotic-induced biofilm formation
likely occurs in both icaADBC-dependent (polysaccharide intercellular adhesin - PIA)
and independent (proteinaceous and eDNA) manners (Wang et al. 2010; Rachid et al.,
2000), involving activation of both specific sensors (Hoffman et al., 2005) and general
stress responses (Li et al., 2005a). Additionally, increased adherence also potentiates
hyperinvasive phenotypes in some organisms including multidrug resistant (MDR)
Salmonella enterica serovar Typhimurium (Brunelle et al., 2013). In this case, antibiotics
cause the circumvention of temporally-regulated gene expression, inducing early and
fully invasive phenotypes by upregulating hilA, prgH and invF. Similar to several other
cases, this phenotype was found not to be ubiquitous, and did not occur in all S. enterica
strains. Increasing the ability of organisms to adhere, internalize, and form antibiotic
tolerant biofilms subverts early immune responses and increases infection severity. Of
note, the vast majority of studies conducted thus far have relied on in vitro models, with
in vivo characterization not considered. Clearly, the latter types of investigation are
required to ensure the clinical relevancy of these observations, and to raise concern over
the legitimacy of these claims. This formed a component of the current thesis.

1.1.3

Immunomodulatory effects of antibiotics

In addition to their potent bactericidal properties, some antibiotics have been
demonstrated to have immunomodulatory functions which can affect the host. The
majority of these responses seem to limit immune activation, and have been demonstrated
primarily in macrolide and quinolone agents (Kanoh and Rubin, 2010; Dalhoff and
Shalit, 2003). Most antibiotics which demonstrate immunomodulatory properties appear
to function by augmenting the release of pro-inflammatory cytokines. Specifically,
macrolides are well documented in dampen the release of interleukin (IL)-8 and tumor
necrosis factor alpha (TNFα) (Čulić et al., 2001), while fluoroquinolones are capable of
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suppressing IL-1α and TNFα, and superinducing IL-2 (Araujo et al., 2002; Riesbeck et
al., 1998; Anderson et al., 2010). Although it is largely unknown how antibiotics
modulate these processes, interruption of normal protein kinase A (PKA) activity is
believed to play a role (Song et al., 2007). Antibiotics exhibiting immunomodulation
often demonstrate phosphodiesterase inhibition which results in cellular cAMP
accumulation, superoxide anion generation and subsequent inhibition of cytokine
production (Blaine et al., 1997; Ono et al., 2000). Macrolides have been shown to reduce
the stability and translation of cytokine transcripts resulting in decreased production
(Wax et al., 2003). This in turn results in decreased immune cell infiltrate to the sites of
infection or damage. It appears as though antibiotics do not suppress the immune
response per se, but rather normalize it to basal activation levels, effectively dampening
otherwise normal responses following stimulation (Shinkai et al., 2008).
The modulatory properties of several antibiotics have already been taken advantage of
clinically. For example, macrolide application has demonstrated improved outcome in
patients suffering with chronic inflammatory pulmonary diseases (Cameron et al., 2012).
These agents were also associated with decreased in-hospital mortality during treatment
of community-acquired pneumonia compared to other antibiotics (Martinez, 2004).
Direct effects on autoimmune diseases such as rheumatoid arthritis have been
demonstrated, with minocycline decreasing disease activity and tender joint count (Stone
et al., 2003). Together, these studies suggest that immune-related influences can be
capitalized

upon

to

yield

positive

outcomes

for

many diseases.

However,

immunosuppression also comes at a price, introducing a greater risk of patients going on
to develop more severe infections including chronic disease, bacteremia, and potentially
fatal sepsis (Gea-Banacloche et al., 2004). Therefore, characterization of these agents in
different disease milieu is certainly warranted.

1.1.4

Clinical implications of inadequate antibiotic therapy

When antibiotics are prescribed, there are many pharmacokinetic, pharmacodynamic,
host, and bacterial properties which can keep them from either reaching their full
therapeutic potential, or decrease the period that they remain at levels greater than the
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MIC (Ambrose et al., 2007). These transient non-suppressive periods provide pathogens
with a window to replicate, evolve resistance and potentially express toxins. Therefore,
outlining and understanding factors which limit these periods are critical for improving
efficacy. A major problem with antibiotic administration today is that many management
strategies are based on expert opinions and not empirical evidence indicating positive
outcomes. For example, long-term, prophylactic approaches have not been altered in
decades despite questionable efficacy and long-term effectiveness (Mattoo et al., 2009),
and most of the ‘recommended’ drugs have not been formally approved by the US FDA
for prophylaxis (Enzler et al., 2011). This could lead to inappropriate or unnecessary
administration of antibiotics for problems that could have been resolved by different
approaches. Therefore, it is critical for clinicians to understand how the antibiotics that
they prescribe concentrate in the body and identify and address factors which might
influence this process.
The concentration of antibiotics at therapeutic sites is not always determined during drug
development, with plasma concentration regarded as an appropriate marker for the
provision of efficacious dose, despite reportedly high interpersonal variation (Drusano,
2004). Recent studies have revealed poor correlation between vascular concentrations
and those within the soft-tissue of patients for some antibiotics, with levels often never
reaching therapeutic potential in certain sites (Matzneller et al., 2013). The situation is
worse in patients undergoing prophylactic therapy, where antibiotics are present at low
levels for extended periods (Pomeranz et al., 2000). Single dose therapies are at particular
risk of falling below the organism's MIC threshold (Dvorchik et al., 2003). It is surprising
that many prophylactic therapies are still used in practice despite their questionable
effectiveness and demonstrated potential to increase the risk of developing resistant
infections (Conway et al., 2007; Mattoo et al., 2009). Counter-intuitively, some
preventative prophylactic strategies aimed at reducing hospital-acquired infections have
resulted in more severe and numerous complications (Madden et al., 2010). Similarly,
perioperative systemic prophylaxis does not necessarily reach uniformly therapeutic
levels at all anatomical districts and may introduce the potential for off-target effects
(Campoccia et al., 2010). Physician compliance in following dosing guidelines is
reportedly poor, with many failing to cease therapy after surgery (Namias et al., 1999), or
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disregarding intraoperative re-dosing when recommended (Miliani et al., 2009).
Inadequate intraoperative or excessive post-surgery dosing is associated with increased
patient risk of bacteremia, and line and surgical site infections (Namias et al., 1999;
Miliani et al. 2009). Although these authors conclude no causative relationship for
increased infection risk following inadequate or inappropriate therapy, it is possible that
the sub-inhibitory levels achieved in situ are modulating the virulence potential of wouldbe pathogens. This may explain why short courses of antibiotic therapy can increase the
risk of developing secondary infections, for example sepsis following transrectal
ultrasonography-guided biopsy (Patel et al. 2011). In addition, patients having received
antibiotics within a month prior to sepsis onset are less responsive to therapy and
associated with worse prognosis (Garnacho-Montero et al., 2003). It is perhaps not
surprising that the increasing incidence of sepsis over the last 40-50 years may be a result
of increasing antibiotic use (Martin et al., 2003; Roumie et al., 2005; McCaig and
Hughes, 1995).
Other overlooked factors which can influence the levels of antibiotics in the body include
patient health (diabetes, ischemia, hepatic/renal dysfunction, sepsis), compliance and size
(Patel et al., 2010; Ambrose et al., 2007). Diseases such as obesity which are becoming
epidemic worldwide merit special consideration as physiological alterations can occur
which affect distribution and clearance of antibiotics (Janson and Thursky, 2012). This
suggests that the 'one-size-fits-all' dosing strategies are outdated, but can be improved
upon by considering individual patient parameters to arrive at appropriate dosing
regimens (Falagas and Karageorgopolos, 2010). Studies of the antibiotic-pathogen
microenvironment indicate factors affecting bodily distribution need to be addressed, as
the niche occupied by an organism influences its specific response to antibiotics (Zhang
et al., 2011; Frisch et al., 2011). Recently, the development of antibiotic-leaching
medical devices has been proposed to deliver agents at local wound sites while avoiding
the unfavourable side-effects of systemic therapy. However, as is the case with many
prophylactic therapies, there is an absence of strict harmonized guidelines for the use of
these coated biomaterials (Campoccia et al., 2010). Specifically, there is no guarantee
that the desired delivery curve is achieved and that adequate antibiotics diffuse into the
surgical site in the appropriate period of time. It is possible that organisms could tolerate
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therapy in what has been referred to as persister states until the device elutes subinhibitory antibiotics and trigger a new infection. This seems to be the case for one
patient, who was left with gentamicin eluting beads in situ for several years and went on
to develop resistant infection at the implant site (Neut et al., 2003). For these reasons, it
has been suggested that the personal and financial ramifications of using antibioticimpregnated devices may outweigh any associated benefits (Cummins et al., 2010).
Together, these studies present overwhelming evidence that the types of antibiotics and
dosages prescribed by primary caregivers can have broad ranging adverse side effects on
patients. Inappropriate antibiotic prescriptions have resulted in the loss of life and
prolonged hospitalization in the past and are unfortunate but avoidable consequences of
non-specific guidelines and outdated policies (Dancer et al., 2004; Spoorenberg et al.,
2014). Of particular concern is the proposed capacity of antibiotic to propagate chronic
disease such as recurrent urinary tract infection (UTI) through prophylactic application, a
practice which is still widely adopted today despite questionable efficacy. Indeed,
anecdotal evidence has suggested that increased frequency of recurrent UTI correlates
with widespread antibiotic use (Nickel, 2005). Therefore, the capacity of antibiotics to
affect disease severity during recurrent UTI is considered in this work.

12

1.2 URINARY TRACT INFECTIONS
UTIs represent one of the most common diseases caused by bacteria. In 2006 alone, UTIs
were the cause of 11 million physician visits, 1.7 million emergency room visits and cost
the US health care system 3.5 billion dollars (Nielubowicz and Mobley, 2010). In
addition to their high community incidence rate, at 40%, UTIs are also the most common
cause of hospital acquired infection (Klevens et al., 2002). The female lifetime incidence
is roughly 50%, with 44% of those infected going on to suffer recurrences within one
year of initial infection (Raz et al., 2000). Infections in the elderly and prepubescent are
also common, with subsequent potential for renal scarring in infants carrying severe
consequences later in life. Comparatively, men suffer from UTI much less often, with
most infection episodes related to anatomical abnormalities.
Risk factors for uncomplicated UTI in otherwise healthy individuals include intercourse
frequency, spermicide use, and familial or personal history of UTI (Foxman, 2010).
Lower tract involvement includes bladder (cystitis) and urethral infection, while upper
tract infections involve the kidneys (pyelonephritis) and ureters. Sub-populations of
individuals with underlying urological abnormalities, spinal cord injury, medical device
implantation, and diabetes are further susceptible to UTI and classified as complicated
cases (Foxman, 2010). Cystitis symptoms, which in part are due to mucosal immune
responses, often include burning and painful micturition, cloudy and odorous urine,
frequent voiding, urgency and abdominal discomfort, while pyelonephritis is also
characterized by fever, nausea, vomiting, and flank pain. These symptoms are often
accompanied by additional signs including gross hematuria (bloody urine) and pyuria
(the presence of 6-10 polymorphonuclear leukocytes per high powered field of unspun,
voided midstream urine).
Although UTI’s can develop into potentially life threatening conditions (eg.
pyelonephritis, sepsis, kidney failure), most are relatively benign and often self-resolve
without the need for clinical intervention (Christiaens et al., 2002; Reid et al., 2010).
Despite this, the sheer number of people affected [150 million UTIs per annum
worldwide (Stamm and Norrby, 2001)], the economic burden from antibiotic
prescriptions [one fifth of all oral antibiotics prescribed in Ontario are for treatment of
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UTI (Daneman et al., 2011)], and capacity to cause serious deterioration in the quality of
life supports the need for continued research in this field.

1.2.1

Contribution of host immune function to infection risk

Host genetics strongly influence an individual's susceptibility of developing recurrent,
chronic and severe UTI. For example, one study found that 42% of family members of
patients with a history of UTI were UTI-prone compared to only 11% for controls who
did not have a history of UTI (Stauffer et al., 2004). These hereditary links are believed
to manifest in part due to the immune functionality of the host. Therefore, significant
research focus is dedicated to flushing out genetic links which dictate UTI susceptibility,
with recent studies yielding perplexing findings. Primary resistance to UTI is determined
by the innate immune system, especially during acute phases of infection. Alterations in
innate immune functionality can either exacerbate infection or impart protective benefits.
For example, polymorphisms in genes which affect Toll-like receptor (TLR)-4 signalling
are associated with decreased immune infiltration and resulting tissue damage. Despite
their immunodeficiencies, rather than developing more severe infection these individuals
are often associated with asymptomatic carrier states devoid of typical UTI pathology
(Fischer et al., 2006). In addition, a polymorphism which decreased TLR4 signalling in
vitro reduced the risk of recurrent UTI in premenopausal women (Hawn et al., 2009).
Conversely, children prone to pyelonephritis typically demonstrate a reduced neutrophil
infiltrate following E. coli infection, often due to deficiencies in the CXCR1 receptor
(Svensson et al., 2011). These patients are at high risk of going on to suffer from severe
complications of infection including the development of urosepsis. This dichotomy
reveals the sensitivity of disease outcome to initial stages of infection, and are likely
dependent on the cytokine profiles which are generated in response to UTI. This has been
confirmed in mouse studies which reveal early severe inflammatory responses to
infection predispose to chronic and recurrent disease. In these mice, elevated IL-6, GCSF, and IL-8 analog KC biomarkers were strong predictors of chronic cystitis
development (Hannan et al., 2010). Conversely, treatment with immunosuppressive
compounds prior to infection is sufficient to curtail this response and is protective against
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UTI in this model. It is postulated that the severe collateral damage caused to mucosal
surfaces by the immune cell infiltrate are responsible for disease sensitization (Hannan et
al., 2010).

1.2.2

Management strategies for recurrent and chronic UTI

In general, UTI can be treated readily with short course antibiotic therapy (~3-7 days).
This is primarily due to their very high urinary concentrations and the widely accepted
superficial nature of bladder infections (Nickel, 2007). The effectiveness of single-dose
therapies attest to this, with most antibiotics capable of clearing 90% of episodes (Nickel,
2007). However, available data support three day, short course therapy for best outcome
of acute, uncomplicated UTI management. In some cases recalcitrance occurs following
therapy cessation, resulting in recurrent or persistent infections and warranting the
application of additional agents. There are various strategies available to manage patients
with recurrent UTI, including culture directed therapy, long-term, low-dose antimicrobial
prophylaxis, and post-coital antimicrobial prophylaxis (Nickel, 2005; Barber et al.,
2013). During therapy, symptoms abate and bacterial loads in voided urine decrease.
However, it has been shown that prophylactic strategies do not alter the long-term risk of
recurrence, as infection rates return to pre-treatment levels following therapy (Nickel,
2005) and device associated organisms are rarely cleared (Warren, 2001). In 2007
Conway et al. showed in a retrospective study that antimicrobial prophylaxis did not
reduce risk of recurrence after initial infection, and actually increased the risk of
producing resistant organisms. Problems such as these question the effectiveness of
antimicrobial prophylaxis in managing device-related and recurrent infections, and
whether the benefits of such treatments outweigh the risk of promoting resistance.

1.2.3

Issues with antibiotic therapy strategies and resistance

In general, UTIs receive little recognition in the infectious disease research community.
This is likely due to the perception that although common, UTI pose little individual risk
of complication. However, issues with UTI extend far beyond individual morbidity. As
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they are one of the largest contributors of antibiotic prescription (Daneman et al., 2011),
it is not unreasonable to recognize UTI as one of the greatest driving forces behind
antibiotic resistance (Johansen et al., 2006). Unsurprisingly, countries with a higher
consumption of antimicrobials have a higher incidence of resistance (Mackenzie et al.,
2007). This is reflected clinically, and despite their historic success in ameliorating acute
cases, antibiotic therapy failure for UTI is on the rise (Pallett et al., 2010; Gupta et al.,
2001). For example, current first-line empiric therapy has largely included the use of
trimethoprim-sulfamathoxazole (co-trimoxazole). However, this agent is associated with
a high resistance potential, and communities are experiencing unparalleled rates of highly
resistant and untreatable strains (Manges et al., 2001). Physicians have responded to this
all-too-common problem by turning to fluoroquinolones for relief (Hooton, 2003). This
practice has in turn resulted in increasing resistance rates against this important drug class
(Johnson et al., 2008).
Bacteria are able to take advantage of antibiotics to increase de novo mutation frequency
and resistance, but are also able to enhance the acquisition of foreign resistance and
virulence elements (Blazquez et al., 2012). The impressive plasticity and adaptability of
these organisms is realised when considering the multiple approaches used to increase
their chance of surviving lethal antibiotic dosing. For example, antibiotic stress often
results in the egress of mobile genetic elements such as IS-, phage-encoded virulence
genes, integrating conjugative elements and phage-related pathogenicity islands,
permitting their transfer to new organisms via horizontal gene transfer (HGT) (Schreiber
et al., 2013; Beaber et al., 2004). Generally, mobilization is accomplished through the
activation of the ubiquitous, general stress response system SOS, which is involved in
double-strand DNA break repair. This results in the transcription of integrase, and
cleavage of phage repressors via activated RecA and subsequent egress of mobile
elements (Cambray et al., 2011). However, antibiotic stress in organisms lacking SOS
response systems can also potentiate transformation through the establishment of
complement-type states and release of DNA via in trans allolysis (Prudhomme et al.,
2006). These processes could hypothetically contribute to the increasing frequency of
recurrent UTI that has been observed since the widespread use of antibiotics.
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Activation of SOS, and other general stress response systems such as RpoS results in
low-fidelity PolIV expression, depletion of MutS and a reduction in mismatch-repair
activity which induces hypermutator phenotypes (Gutierrez et al., 2013; Kahrstrom,
2013).

Beta-lactam,

fluoroquinolones,

aminoglycosides,

tetracyclines

and

chloramphenicol all activate these systems to some degree in most organisms (Gutierrez
et al., 2013; Kahrstrom, 2013; Foster, 2007; Baharoglu and Mazel, 2011). Pathogens
appear to have adapted to antibiotic stress by increasing their genetic flexibility, which
results in acquisition of resistance through a number of mechanisms. Concentrations of
antibiotics several hundred times lower than the MIC can enrich resistant mutants and
result in development of de novo resistant strains (Gullberg et al., 2011). Additionally,
the acquisition of multiple copies of resistance elements can be accomplished through
fluoroquinolone-dependent homologous recombination and homologous, redundant
expansion of resistance determinants (López et al., 2009). The importance of such
genetic changes extends beyond the test tube, and has been shown to promote resistance
and epidemic hospital infections (Hocquet et al., 2012). Perhaps most worrisome is that
these changes are cross-adaptive; that is, one antibiotic is capable of improving resistance
against the same and multiple agents. In many cases, this occurs through the antibioticdependent expression of endogenous efflux pumps which indiscriminately clear noxious
agents from the intracellular environment (Mc Cay et al., 2010). Sub-inhibitory antibiotic
treatments also have the capacity to increase tolerance through slight, stepwise changes to
MICs often resulting in cross-resistance (Kohanski et al., 2010). This is in contrast to
highly-resistant mutants that appear spontaneously through selection and demonstrate
little-to-no cross-resistance (Kaufmann and Hung, 2010). These problems are often
recurring themes in the prophylactic management of recurrent UTI, as antibiotics are
present throughout the course of dosing at concentration below the therapeutic threshold.

1.2.4

The importance in characterizing recurrences: relapse
versus re-infection

Recurrences in the absence of resistance are believed to occur via one of two ways. The
first involves re-inoculation of the bladder with organisms derived from the
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gastrointestinal environment (re-infection). Indeed, transfer of organisms via the fecalperineal-urethral route is common and supported with genetic evidence (Yamamoto et
al., 1997). These types of infection are identified using genome sequencing, designating
new pathogens through strain variation from previous infection episodes. When reinfected patients are followed over a period of three months with daily urine and
periurethral cultures, 75% of the strains causing recurrences were found to originate from
the gut (Nickel, 2007; Chen et al., 2013). Although it can be concluded that reinoculation occurs in the vast majority of cases, it is also postulated that uropathogens
can persist in dormant states within the urinary tract from previous infections, even with
antibiotic intervention, and relapse (persistent infection) (Schilling et al., 2002). In this
manner, organisms may be present within the urinary mucosa but not detected by
standard culturing techniques. Evidence supporting this hypothesis is also generated
through sequencing, which delineates genetically identical organisms from previous
infection episodes (same-strain recurrent UTI) (Jantunen et al., 2002). In addition to
increasing the risk of recurrence, these intracellular communities may explain other
diseases whose aetiology remains unknown such as interstitial cystitis and overactive
bladder. This is supported in murine studies which demonstrate animals resistant to
antibiotic-clearance present with micro-abscesses in their urothelial tissue (Hannan et al.,
2010), albeit these findings do not disprove re-inoculation of the same organism from the
gut.
Although it might seem trivial, differentiating infection sources is critical for outlining
the problem of recurrence, and in designing an appropriate management strategy.
Continuous re-inoculation of pathogens from the gastrointestinal tract could theoretically
be curtailed through alterations in hygienic practices, but studies have shown that
cleanliness of the genitalia alone is not to blame for females suffering from repeated UTI.
On the other hand, sexual activity is influential by depositing urethral and vaginal
organisms into the bladder (Stauffer et al., 2004). In general, application of prophylactic
antibiotics in this patient cohort is unwarranted, and may actually make conditions worse
through the selection of resistant organisms (Kodner et al., 2010). However, physicians
still prescribe long-term extended use prophylactic therapy for such cases (Enzler et al.,
2011). Alternatively, and especially in situations where sexual activity is believed to be a
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major driving factor for recurrence, post-coital or patient directed therapies have been
met with success (Kodner et al., 2010; Nickel, 2005). In this manner, the antibiotic is
only supplied when it is perceived to be required, but depending on the frequency of
sexual encounters, this could accumulate to be a lot of antibiotic use over time, all with
consequences for the organisms and patient. In the case of persistent UTI, recurrences are
thought to be driven by deficient host immune status or enhanced pathogen virulence, and
long-term, prophylactic therapy is relied upon to decrease pathogen burden while
ameliorating symptoms. However, whilst the desirable outcome of decreased symptoms
and ameliorating infection can be achieved, breakthrough infections still occur and the
treatment may be forcing bacteria to become more recalcitrant within the bladder, as will
be discussed later.
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1.3 PATHOGENIC
MECHANISMS
UROPATHOGENS

1.3.1

OF

COMMON

Pathogenesis of Gram-negative UTI

Although host factors certainly contribute to infection risk and severity, it is generally the
virulence traits of pathogen which dictates disease progression. Enteric bacteria are the
leading cause of UTI, the foremost of which is uropathogenic Escherichia coli (UPEC)
which represents the cause of 75-90% of uncomplicated infections (Laupland et al.,
2007). E. coli is a Gram-negative, facultatively anaerobic, non-sporulating, rod shaped
organism which is also a normal constituent of the gut microbiota. These traits, in
addition to its resourcefulness in utilizing a diverse array of carbon sources, rapid
replication rate and ability to survive in a wide variety of unfavourable environments are
all factors that make this organism an important uropathogen. In addition to its high
incidence, UPEC are often associated with recurrence and chronic lower tract infection
(cystitis), necessitating application of long-term, prophylaxis management. The ability of
UPEC to initiate such deep-rooted and stubborn infections is attributed to the wide array
of virulence factors at its disposal (Norinder et al., 2012). While genetic studies of
organisms isolated from human subjects have assisted in the search for critical
uropathogenic virulence traits, murine models of disease which have been instrumental in
elucidating the complicated interplay between host and pathogen.
Murine models provide an ideal stage with which to study uropathogenesis. Mice are
readily inoculated, easily monitored in time with urinalysis, and flexible with regards to
the wide array of established genetic backgrounds which are available (Hung et al.,
2009). The biology of their urinary tracts, methods of urine voiding and host defense
strategies are analogous to those found in humans. Prior to initiating infection, UPEC
must ascend the urethra against urine flow in order to access the bladder. Deficiencies in
this aspect of host defense are common in incontinent patients, and predispose to
recurrent cystitis (Raz et al., 2000). In murine models of UTI, uropathogens are directly
inoculated into the bladder, effectively subverting this aspect of host defense. Rapid
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adhesion to the bladder mucosa is essential to avoid clearance during urine voiding
(Thomas et al., 2002).
The urinary tract is characterized by a pseudostratified epithelial layer containing the
transitional epithelium, with the bladder covered with a single layer of unique, terminally
differentiated superficial umbrella cells (urothelium) (Wu et al., 2009). Superficial
umbrella cells are coated in a plaque of uroplakin which constitutes the asymmetrical unit
membrane (AUM), and consists of four proteins, UPIa, UPIb, UPII, and UPIIIa, in
addition to the extracellular proteoglycan mucin layer (Wu et al., 1994). Together, the
role of the AUM is to provide structural support to superficial umbrella cells during times
of bladder distension as well as regulating membrane permeability (Sun et al., 1996).
These urothelial components are also thought to play an integral role in preventing
intimate bacterial contact with the host. This is achieved through the negative charge
imparted by the highly sulfated and carboxylated glycosaminoglycans of the AUM
(Parsons et al., 1990). However, these defenses can be overcome by UPEC which express
type 1 fimbriae, capable of binding mannosylated residues of the uroplakin UPIa using
the tip adhesin FimH (Connell et al., 1996; Xie et al., 2006). Type 1 fimbriae are
demonstrated to be critical to establishment of UTI and found in 80% of UPEC strains
(Buchanan et al., 1985; Keith et al., 1986), and are highly upregulated in the urinary
environment (Gunther et al., 2001). Type 1 fimbriae are phase variable, and the presence
of both fimbriated and afimbriated organisms contributes to UTI in adherent and
planktonic phases respectively, with both states of colonization important for
pathogenesis (Lim et al., 1998). The production of highly mannosylated Tamm-Horsfall
protein (THP - uromodulin) in the urine is a host defense component which capitalizes on
the critical nature of type 1 fimbriae to UPEC infection, by binding and sequestering
organisms from the host surface (Pak et al., 2001). On the other hand, it has been
suggested that in some cases, THP can act as a substrate to which the UPEC adhere,
thereby enhancing the risk of infection (Hawthorn et al., 1991)
Once UPEC have accessed the urothelial surface, they rapidly invade superficial umbrella
cells. This process is critical to the establishment of acute infection, and is thought to be
mediated by the interaction of type 1 fimbriae with UPIa as it is the primary target of
FimH. Binding then results in phosphorylation of the uroplakin receptor complex which
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triggers invasion (Martinez et al., 2000; Zhou et al., 2001; Thumbikat et al., 2009; Wang
et al., 2009). Internalization is mediated by the activation of Rho GTPases which triggers
actin rearrangement and UPEC engulfment via a zippering mechanism (Martinez and
Hultgren, 2002). Upon accessing the cytoplasmic environment, UPEC begin to
proliferate rapidly, forming large, multicellular aggregates dubbed intracellular bacterial
communities (IBCs) (Anderson et al., 2003). Although IBC formation has been observed
in several species of Enterobacteriaciae, Gram-positive organisms do not appear to
possess this pathogenic mechanism. These unique bacterial aggregates do not form in
undifferentiated urothelial cells, making study of this process in vitro difficult. It is
believed that the dense actin networks within undifferentiated cells (such as those found
in immortalized lines) hinder this aspect of UPEC pathogenesis as actin destabilization
agents induce the formation of IBC-like bodies in vitro (Mulvey et al., 2001; Berry et al.,
2009; Eto et al., 2006).
Within this intracellular niche, UPEC are resistant to both the host immune system and
antibiotics. This has been confirmed in vivo, as UPEC reservoirs in murine bladder
tissues were not eradicated against a panel of 16 antibiotics representing several distinct
drug classes (Blango and Mulvey, 2010). Generally, IBC formation begins immediately
following invasion, and continues until 16-24 hours post infection, with the majority of
UPEC found intracellularly at 12 hours post inoculation (Mulvey et al., 1998). During
these later time points, UPEC undertake a filamentous morphology, fluxing away from
the core IBC into neighbouring cells or emerging from the apical surface of dying
urothelial cells (Justice et al., 2004). The process of umbrella cell evacuation also
coincides with exfoliation of this urothelial layer (Mulvey et al., 1998; Justice et al.,
2006). This host immune mechanism is thought to expel adherent and IBC contained
UPEC through urination, which is frequent during infection. As umbrella cells are lost,
basal elements of the urothelium differentiate to fill their void. These pseudo-differentiate
cells might hinder further rounds of UPEC invasion and IBC formation, and are thought
to contribute to pathogen clearance in mice which spontaneously resolve infection
(Justice et al., 2004). However, it is possible that UPEC are capable of invading distal
layers of the urothelium through filamentation, resulting in formation of quiescent
intracellular reservoirs (QIRs) which could feasibly contribute to future episodes of UTI
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(Mysorekar and Hultgren, 2006). The dynamic interplay between host mucosal immunity
and UPEC pathogenesis represents an elegant example of a co-evolutionary process.

1.3.2

Pathogenesis of Gram-positive UTI

Staphylococcus saprophyticus is the second leading cause of uncomplicated UTI and is
implicated in approximately 10-15% of cases, affecting roughly 1 million women in the
US alone each year (Schneider and Riley, 1996). It is a Gram-positive, coagulase
negative uropathogen which is identified clinically on the basis of endogenous
novobiocin resistance and lack of hemolysin activity (Raz et al., 2005; Mctaggart and
Elliot, 1989). Compared to UPEC, the mechanisms involved in S. saprophyticus
pathogenesis are not well understood. However, like E. coli, the major reservoir for this
uropathogen is the gastrointestinal tract and perineal skin (Latham et al., 1983). The
majority of infections caused by S. saprophyticus occur in young, sexually active women,
with colonization more frequent during the summer and fall (Wallmark et al., 1978).
A high infection frequency is likely due to the wide array of virulence factors at S.
saprophyticus’ disposal that grant it tropism to the urogenital tract, specifically the
kidneys (Kline et al., 2010). Reports have placed S. saprophyticus as causing ~13% of
upper UTI, a higher incidence than that communicated for other uropathogens (Hedman
and Ringertz, 1991). Urease is highly expressed in this organism and appears to be an
important virulence trait, resulting in more severe infection when present (Gatermann et
al., 1989). Some other important factors include a fimbrial surface-associated lipase
(Ssp), lipoteichoic acid, hemagglutinin/autolysin/adhesin fibronectin binding protein, uroadherence factors A and B (UafA/UafB), and a surface-associated collagen-binding
protein (SdrI) (Kline et al., 2010; Matsuoka et al., 2011; Gatermann et al., 1992; Sakinc
et al., 2005; Sakinc et al., 2006). Of these, the uro-adherence factors appear to play the
most critical role in pathogenesis, with adhesion greatly reduced in their absence (Kuroda
et al., 2005). Despite their importance, the ligand for these adhesins is currently
unknown. To complicate matters further, murine infection models for investigating
pathogenic mechanisms of S. saprophyticus cystitis are not ideal as Uaf adhesins do not
interact well with the murine urothelium, indicating the absence of ligand in this
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organism (King et al., 2011). However, S. saprophyticus is still capable of colonizing the
kidneys of mice for extended periods of time, and SdrI and Ssp are important for
persistence in this organ (Kline et al., 2010). Although IBC formation is not observed in
Gram-positive uropathogens, S. saprophyticus is capable of internalizing into bladder
cells, presumably representing an important step in pathogenesis and persistence
(Szabados et al., 2008). Unlike E. coli, the mechanisms for S. saprophyticus
internalization are not characterized, but are thought to be distinct from those of other
staphylococci (Szabados et al., 2008). Kidney invasion has not been investigated despite
the importance of this organ in S. saprophyticus uropathogenesis and persistence. This
forms a component of studies performed in this thesis.
Whole genome analysis has revealed an abundance of open reading frames (ORFs)
important for osmoregulation and ion transport, giving this organism the unique ability to
persistently colonize the urinary tract despite lacking the extensive arsenal of virulence
determinants found in S. aureus (Kuroda et al. 2005). S. saprophyticus carries a capsular
element which appears to have been acquired through HGT due to its lower than average
GC content. Characterization of this capsule has demonstrated an important role in
immune evasion through resistance to complement-mediated opsonophagocytosis by
neutrophils (Park et al., 2010). Encapsulation appears to come at a price, as its presence
decreases the interaction of Uaf proteins with cellular targets resulting in a reduced
adherence potential.
Approximately 10% of S. saprophyticus UTI will result in recurrent infection following
antimicrobial therapy (Fowler et al. 1981). Although re-infection could explain
recurrence, intracellular organisms have been implicated in persistent colonization and
re-emergent infections (Hunstad and Justice, 2010; Szabados et al., 2008). Furthermore,
S. saprophyticus’ propensity to colonize medical devices resulting in recalcitrant
infections is reminiscent of other coagulase negative staphylococci (Lang et al. 1999).
Often, treatment of colonized devices involves removal and stringent antimicrobial
therapy. Device replacement of chronically implanted individuals can occur quite
frequently, greatly increasing patient morbidity and decreasing quality of life.
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1.4 MECHANISMS OF BACTERIAL PERSISTENCE AND
ANTIBIOTIC TOLERANCE
In addition to achieving persistence in the urinary tract through pathogenic mechanisms,
infecting organisms must also be able to withstand exposure to antibiotics. Bacterial
survival following appropriate therapy is normally attributed to genetically resistant
organisms; however, nearly all species also possess transient, phenotypic, multidrugtolerant (MDT) members called persister cells, named for their capacity to persist despite
exposure to a lethal antibiotic dose. Although the evidence has been largely
circumstantial, persisters are thought to play a role in treatment failure and in further
pathogenesis of chronic diseases such as cystic fibrosis, recurrent UTI and tuberculosis
(Goneau et al., 2014; Blango et al., 2010; Keren et al., 2011; Mulcahy et al., 2010). The
role of persisters in such infections may largely be overlooked as they are not tested for
during routine clinical microbiology diagnostic procedures.

1.4.1

The nature of MDT

Since their discovery by Joseph Bigger in 1944, persisters have remained largely
unclassified and poorly characterized (Bigger, 1944). However, they are generally
believed to comprise a fraction of the overall population (~0.01%), and are thought to
have suppressed metabolic activity and replicative capacity which prevents antibiotic
activity (Lewis, 2010). The bactericidal nature of antibiotics is thought to be mediated
through the corruption of cellular machinery, preventing them from performing their
normal functions required for homeostasis. Genetic resistance is achieved by preventing
this interaction, either by altering target antibiotic binding sites, destroying or modifying
the drug, or active removal via cellular efflux (Wright, 2005). Conversely, it is postulated
that reduced activity would confer a protective phenotype (Lewis, 2010). Thus,
physiological changes are thought to confer MDT in persisters.
A consensus regarding the nature of MDT has yet to be reached, with two scientific
camps disputing whether persisters represent truly dormant bacterial variants or simply a
slow growing sub-population of the greater culture (Goneau et al., 2014; Balaban el al.,
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2004; Wakamoto et al., 2013; Johnson and Levin, 2013). Initial experiments involved
sorting dormant organisms from the remaining, metabolically active population.
Importantly, these sorting experiments successfully demonstrated that dormancy
correlated with persistence, as dormant populations had 20-times more persisters than
normally growing populations (Shah et al., 2006). However, the authors also conclude
that dormancy alone is not necessary and sufficient to explain persistence. In addition,
most persisters demonstrate levels of mRNA which can be extracted and amplified. With
its short half-life, the presence of mRNA is indicative of active transcription, suggesting
at least some level of physiological activity is present in persisters (Hu et al., 2000).
Distinguishing between these two proposed models is critical in evaluating new
therapeutic targets focused at persister eradication and the amelioration of chronic
disease. The issue will lie in either learning how to potentiate antibiotics against already
active persisters, or figuring out how to 'wake them up' from dormancy to enable killing
(Allison et al., 2011a; Allison et al., 2011b). The presence of antibiotics within even
slowly replicating persisters may potentiate hypermutator phenotypes, acquisition of
resistance traits and establishment of breakthrough infections. Organisms in persisterrelated infections such as cystic fibrosis are capable of mutagenesis and increasing their
persister fraction >100-fold from pre-antibiotic levels (Mulcahy et al., 2010). Since
persister traits are under antibiotic selective pressure, it is possible that organisms with
large persister fractions may be refractory to antibiotic therapy in severe infections such
as sepsis where rapid, successful antimicrobial intervention is critical to patient survival.

1.4.2

Mechanisms and genetics of persister formation

Although MDT is conferred through physiological changes, genetics certainly dictate the
dynamics of persistence. Formation is believed to be driven by two processes, with Type
I persisters classified as non-growing variants which are enriched naturally during late
exponential and stationary phases (Luidalepp et al., 2011), and slowly-growing and
dividing Type II persisters whose formation occurs stochastically during exponential
phase due to random fluctuations in transcriptional and translational noise (Balaban et al.,
2004; Balaban, 2011; Kussel and Leibler, 2005). Enrichment of Type II persisters can
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occur through various stressors such as antibiotics, resulting in fractions that can range
from 10-100% of the overall population (Kwan et al., 2013). Such stressors generally
result in MDT through the activation of various toxin/antitoxin (TA) systems, which are
believed to provide a common 'emergency stop' response mechanism to halt
environmental stress (Dörr et al., 2010; Kint et al., 2012; Moyed et al., 1983; Allison et
al., 2011). This is an intriguing model as TA systems appear to be ubiquitous in
prokaryotes (Grønlund and Gerdes, 1999; Schuster and Bertram, 2013). TA systems
usually consist of a stable toxin protein, and a labile RNA or protein antitoxin which
prevents toxicity. The toxin is involved in disruption of an essential cellular process, such
as translation interruption via mRNA degradation or decoupling of the proton motive
force and ATP production (Gerdes et al., 2005). Mutagenesis studies were the first to
identify the role of TA systems in persister formation, identifying alterations in the hipBA
locus as predisposing to persistence (Moyed et al., 1983). Characterization of the mutant
strains, specifically the hipA7 gain of function variant, revealed that decreasing binding
affinity of the toxin (HipA) for its cognate antitoxin (HipB) was responsible for increased
persistence and drug tolerance (Korch and Hill, 2006). Since identification of this TA
system's role in persistence, numerous other TA pairs have been implicated including
YafQ/DinJ, RelE/RelB, MazF/MazE, TisB/IstR-1 and others, with overproduction of
RelE increasing persistence as much as 10,000-fold (Keren et al., 2004). The wide array
of TA pairs involved in persistence demonstrates the redundancy of these systems,
suggesting no single drug will be capable of overcoming all these bacterial fail-safes.
Additionally, different mechanisms of onset might indicate that persister cells are
distinct, and represent a heterogeneous sub-population with unique susceptibilities to
antibiotics (Allison et al., 2011). In this sense, MDT might not be a function of individual
persister states, but rather the combined influence of multiple persisters with unique
susceptibility profiles which contributes to the tolerance of the entire population.
Activation of TA systems is intimately connected to induction of the SOS response,
which is also a common mechanism for the establishment of genetic resistance. In fact,
cells appear to react to stress by either: i) activating stress response elements in hopes of
resisting it, or ii) converting part of the population to persister states through the
activation of TA modules. Together, these represent a bet-hedging strategy which permits
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survival of at least a fraction of the population (Dörr et al., 2010). Dynamic heterogeneity
within individual cells determines which outcome is selected, and involves the SOSinducible Lon protease and subsequent degradation of antitoxin elements (Maisonneuve
et al., 2011). Several agents appear to induce persister formation in this manner,
including DNA gyrase, transcription, translation, ATP synthesis and transpeptidase
inhibitors (Dörr et al., 2009; Miller et al., 2004; Kwan et al., 2013). In this way,
antibiotics may be capable of propagating chronic and recurrent infections by
continuously stimulating the formation of persisters.
Persister cells are also intimately linked to high-density growth states, such as those
found during stationary phase, increasing in frequency from ~0.01% of the population
during early-exponential phase to over 10% at later stages of growth (Tashiro et al.,
2012). Persister cells are also enriched in biofilms, where they are thought to contribute
to antibiotic tolerance which can be up to 1000-times higher than their planktonic
counterparts (Roberts and Stewart, 2005; Lewis, 2001). When found in biofilms, persister
cells are not only refractory to antibiotic therapy, but also to immune detection and
clearance (Lewis, 2007). In many cases, biofilm infections are deep-rooted, associated
with medical devices or other complicated patient cohorts, and are incurable.
Surprisingly, quorum sensing does not seem to contribute to formation, as the addition of
spent culture supernatants containing high concentrations of quorum-sensing compounds
did not appreciably increase the number of persisters isolated for E. coli (Lewis, 2007).
Thus, the mechanisms underlying persister formation during these growth stages remains
a puzzle.
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1.5 HYPOTHESIS AND OBJECTIVES

It is hypothesized that low-dose antibiotic therapy will increase the risk of chronic
and recurrent UTI through the modulation of both host and pathogen responses.

As outlined above, the management of patients with recurrent UTI remains a challenge
due to pathogen re-emergence, resistance and the risk of potentially fatal sepsis.
Strategies typically rely on the long-term application of low-dose antibiotics as a means
of discouraging pathogen re-propagation within the urinary tract while avoiding the
unfavourable side-effects of prolonged exposure at higher doses. Unfortunately, this
dosing regimen potentiates the presence of antibiotics at sub-therapeutic and subinhibitory concentrations, which appear to influence microorganisms in unexpected ways,
potentially causing unpredicted changes to virulence traits including adherence,
invasiveness, and persistence. These changes may be reflected in the questionable
benefits of prophylaxis which do not seem to alter long-term recurrence risk while also
often failing to resolve established infection (Nickel, 2005; Williams and Craig, 2009).
Bacterial changes in response to therapy may also explain cases of antibiotic failure
despite the absence of resistant organisms (Mulcahy et al., 2010; Levin and Rozen,
2006).
This thesis explores these clinical observations in the context of inappropriate
antimicrobial therapies including prophylaxis by evaluating whether they have the
capacity to negatively influence host-pathogen interactions during UTI. Agents used
throughout include ciprofloxacin, ampicillin, and gentamicin, for their extensive clinical
use and distinct targeting mechanisms. Specifically, the fluoroquinolone antibiotic
ciprofloxacin targets and corrupts DNA topoisomerases II and IV by selectively
inhibiting ligase activity while leaving nuclease functionality unhindered (Drlica and
Zhao, 1997). Constant nuclease activity combined in the absence of ligation introduces
double-strand DNA breaks resulting in fragmentation. Ampicillin is a beta-lactam
antibiotic which irreversibly binds to and inhibits the transpeptidase enzyme (Waxman
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and Strominger, 1983). Continued autolysin activity at the cell wall results in lysis.
Lastly, gentamicin functions by binding to and inhibiting the 30S subunit of the bacterial
ribosome. Interruption of protein synthesis and production and intracellular accumulation
of corrupted protein products results in cell death (Davis, 1987). All three agents share
characteristic broad-spectrum activity and are bactericidal.

Objectives:
(1) Examine the effects of sub-inhibitory antibiotics on uropathogen virulence
Only recently has the capacity of antibiotics to modulate aspects of bacterial virulence
been explored, and never in the context of uropathogens. As UTI is a major reason for
antibiotic prescription and results in complicated and debilitating disease in hundreds of
millions of women worldwide, it is critical to understand how pathogenesis is affected
during treatment. Thus, the ability of sub-inhibitory antibiotics, targeting distinct cellular
processes, was assessed for virulence-modulating capacity on both the phenotypic and
gene expression levels.

(2) Demonstrate the influence of sub-inhibitory ciprofloxacin on uropathogenesis in
a murine model of UTI
Although transcriptomic studies are abundant, none have explored the changes in
pathogenesis which follow sub-inhibitory treatment. Mouse models of UTI are a well
established experimental system which permit the investigation and characterization of
antibiotic-induced changes in vivo. Using this model, experiments were conducted to
demonstrate that in vitro alterations in virulence factor expression are mirrored in vivo
and influence the ability of the host to clear infection.

30
(3) Understand the ability of uropathogens to persist despite adequate antibiotic
intervention during infection
The role of persister cells in chronic diseases is not well documented, and the nature of
MDT is not clearly defined. However, these unique physiological variants are thought to
play an important role in recurrence risk following UTI antibiotic management. Thus, the
importance of persister states in recurrent UTI were investigated using clinical isolates. In
addition, the contribution of dormancy toward MDT in uropathogens was explored, and
took into account the dynamics of antibiotic-dependent persister cell induction as well as
maintenance by analyzing both Type I and Type II persister fractions.
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CHAPTER TWO

MATERIALS AND METHODS
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2

MATERIALS AND METHODS

2.1 BACTERIAL STRAINS AND CULTURE CONDITIONS
All media were acquired from BDH (Toronto, ON) or Becton and Dickinson (BD;
Oakville, ON), with supplements from BDH or Sigma (Mississauga, ON). Bacterial
strains were cultured from -80°C stocks and routinely grown at 37°C using media and
conditions conducive to each strains' growth requirements. Unless stated otherwise,
staphylococci and Escherichia were grown using lysogeny Broth (LB), supplemented
with antibiotics when appropriate. Minimal inhibitory concentration (MIC) determination
and antibiotic susceptibility experiments were performed at 37°C in cation-adjusted
Mueller Hinton (MH) II medium (BDH). Human pooled urine (HPU) was also used as a
growth substrate. Preparation involved pooling the urine from at least three volunteers,
filter sterilization using a 250 mL Nalgene Rapid-Flow vacuum filter unit equipped with
0.22 µm PES membrane (Thermo Scientific, Ottawa, ON), and pH adjustment to 6.5.
Enumeration of bacterial colony-forming units (cfu) was performed using LB agar
(Bacto-agar; BD) plates prepared as per the manufacturer's instructions and supplemented
with antibiotics when required. All experiments made use of cultures grown in 15 mL BD
Falcon tubes, excluding those involving murine infection models which made use of 100
mL Erlenmeyer flasks. Cultures were grown statically unless stated otherwise. If shaking
was implemented it was done so at 200 rpm.
All strains are listed in Table 2.1. Both E. coli CFT073 [isolated from a woman with
acute pyelonephritis (Kao et al., 1997)] and S. saprophyticus 15305 [UTI isolate (Shaw et
al., 1951) - type strain] were purchased from the American Type Culture Collection
(ATCC, Manassas, VA, USA), while the UPEC clinical isolates E. coli TOP277,
TOP263, TOP379, TOP344, TOP345, PUTS277, PUTS278, PUTS1127, PUTS1236 and
UTI89 (attHK022::COM-GFP; kanamycin-resistant, KanR) were kindly provided by Dr.
Scott Hultgren (Washington University School of Medicine, St Louis, MO). Briefly, each
strain was derived from a distinct patient presenting with recurrent UTI. Patients were
sampled over time and organisms isolated from each infection episode were sequenced
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Table 2.1 Bacterial strains used in this study
Strain (type)
S. saprophyticus strains
15305
15305:C1
7108
E. coli strains
CFT073
UTI89 attHK022::COM-GFP:KanR
UTI89 pANT4::GFP
UTI89 ΔfimS (ΔfimA-fimH)
UTI89 ΔfimH
UTI89 ΔrecA
UTI89 lexAT355G
TOP277
TOP263
TOP379
TOP344
TOP345
PUTS278
PUTS1127
PUTS1236
PUTS277
a
American Type Culture Collection (ATCC)

Source
ATCCa
Toshiko laboratory
Hultgren laboratory
Our laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Justice laboratory
Justice laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
Hultgren laboratory
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(Garofalo et al., 2007). If repeat recurrences were caused by the same strain the isolate
was assigned an SSR designation. Conversely, infections caused by a strain which varied
from previous infections were designated as AI. SOS-deficient strains E. coli PAS0209
(ΔrecA) and PAS0211 (lexAT355G; also referred to as lexAG85D or Ind- mutant) derived
from the UTI89 background were provided by Dr. Sheryl Justice (The Research Institute
at Nationwide Children's Hospital, Columbus, OH). The acapsular S. saprophyticus C1
strain derived from the 15305 background was provided by Dr. Toshiko Ohta (Graduate
School of Comprehensive Human Science, University of Tsukuba, Tsukuba, Japan).

2.2 ANTIBIOTIC SUSCEPTIBILITY TESTING
Susceptibility testing was performed using the Kirby-Bauer method as per standard
Clinical and Laboratory Standards Institute (CLSI) guidelines (2007). Briefly, strains
were grown in MH broth overnight in a shaking incubator (200 rpm) at 37oC. Cultures
were diluted five-fold in phosphate buffered saline (PBS; pH 7.4) and streaked across the
entire surface of an MH agar plate using a cotton-tipped swab. Ciprofloxacin (CIP-5 µg),
ampicillin (AMP-10 µg), and gentamicin (GEN-10 µg) test discs (VWR, Mississauga,
ON) were added each to one third of the plate. Zones of growth inhibition (ZOI - mm)
around each disk were determined following overnight incubation. The ZOI for each
strain was compared to referenced standards to determine the clinically relevant category
of susceptibility for each antibiotic.

2.3 MINIMAL INHIBITORY CONCENTRATION
DETERMINATION
The MICs to ciprofloxacin, ampicillin, and gentamicin (Sigma) was determined for all
organisms using the broth microdilution technique outlined by the CLSI (2007). Briefly,
strains were grown in MH broth overnight in a shaking incubator (200 rpm) at 37oC.
Cultures were then inoculated into MH broth containing various two-fold dilutions of
antibiotics and grown statically for 24 hours in a 96-well plate. The MIC was regarded as
the last well demonstrating growth based on turbidity. Experiments were carried out with
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at least three independent replicates. MIC quality control was performed using control
organisms recommended by the National Committee for Clinical Laboratory Standards
with known MIC values for antibiotics used in this study. Optimal sub-inhibitory
antibiotic dosing strategies were evaluated to determine concentrations which confer
phenotypic effects without perturbing growth. Although a range of concentrations were
considered, 1/4MIC levels were the maximal dose that organisms could tolerate without
loss of fecundity. Therefore, this dose was used throughout unless stated otherwise.

2.4 MICROSCOPE SLIDE ADHERENCE ASSAY
Overnight (24 hour) cultures of S. saprophyticus 15305 grown in HPU were diluted 100fold into fresh HPU and incubated for three hours. Ciprofloxacin, ampicillin, gentamicin
or vehicle were applied at 1/4MIC levels and incubated for one hour to permit
establishment of physiological changes. Following this period, 100 µL of culture were
transferred to the surface of uncoated glass microscope slides. Slides were covered and
incubated for 30 minutes to permit organism adhesion. Experiments were conducted in
duplicate. Slides were rinsed gently for 5-10 seconds with PBS to remove weakly
adherent or unbound organisms, heat fixed, and stained for two minutes with crystal
violet. The number of adherent S. saprophyticus 15305 was determined by enumerating
the number of clearly defined organisms in at least five representative fields of view
(FOVs) at a magnification of 1000x on an Axioskop microscope (Carl Zeiss, Toronto,
ON).

2.5 STENT AND CATHETER ADHERENCE ASSAY
Overnight (24 hour) cultures of S. saprophyticus 15305 grown in LB were reconstituted
1000-fold in fresh media. After a three hour recovery period, 1 mL of culture was
transferred to a microfuge tube containing 1 cm segments of either Foley urethral catheter
(BARD Medical, Covington, GA) or InLay Optima® ureteral stents (BARD Medical).
Ciprofloxacin, ampicillin, gentamicin, or vehicle were applied at 1/4MIC levels to the
cultures, and incubated for one hour at 37°C. At this point, 10 µL of cultures were
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extracted from each treatment group and dilution plated to obtain total population
numbers (each sample served as its own control). Stents and catheters were removed,
washed twice with PBS to remove loosely attached organisms, and placed in fresh
microfuge tubes containing 1 mL of PBS. These tubes containing the washed stents and
catheters were transferred to a Branson 1200 ultrasonic water-bath (Emerson, Danbury,
CT) and sonicated for 10 minutes to liberate adherent organisms. Samples were extracted
from each tube and dilution plated to determine the number of adherent S. saprophyticus
15305.

2.6 BIOFILM FORMATION ASSAYS
Since, ciprofloxacin, ampicillin and gentamicin are capable of inducing the SOS
response, it is reasonable to postulate that observed antibiotic-dependent modulation of
adherence and biofilm formation is driven through the activation of this regulon. This
hypothesis was tested by comparing the biofilm-priming potential of antibiotics in wildtype and SOS deficient strains of E. coli UTI89. SOS-deficient strains consisted of
PAS0209 (ΔrecA) and PAS0211 (lexAT355G - has T-to-G change at position 355 of
encoded by lexA; also referred to as LexAG85D or Ind mutant) derived from the UTI89
background. Both strains were utilized in order to compare and contrast the contribution
of severe (ΔrecA) and moderate (lexAT355G) double-strand DNA break repair and SOS
deficiencies.
Overnight (24 hour) cultures of S. saprophyticus 15305 or E. coli strains UTI89,
PAS0209, and PAS0211 grown in LB were reconstituted 1000-fold in fresh media but
not incubated further. The wells of a 96-well plate were prepared by loading with various
sub-inhibitory concentrations of either ciprofloxacin, ampicillin, gentamicin, or vehicle in
100 µL of LB. Organisms were added at 10 µL per well, plates were sealed, then
incubated for either 24 or 48 hours at 37°C. If incubation periods continued for longer
than 24 hours, wells were washed and replaced with fresh LB containing the appropriate
concentration of antibiotic. Following these incubation periods, wells were washed with
PBS three times to remove planktonic and weakly adherent organisms, stained with
crystal violet for two minutes, washed again with cold dH20 and decolorized with 100 µL
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70% ethanol. Biofilm abundance was determined by measuring the absorbance at 600 nm
(OD600).

2.7 SCANNING ELECTRON MICROSCOPY PROTOCOL
Samples examined using scanning electron microscopy (SEM) were prepared as
described above (stent and catheter adherence assay). Once organisms had adhered and
stent and catheter material had been washed, samples were exposed to a pre-fixative
solution containing 2.5% glutaraldehyde (Sigma), 50 mM L-lysine monohydrochloride
(Sigma), and 0.75% Ruthenium Red (Sigma), in 0.2 M cacodylate buffer (pH 7.4), as
described by Williams et al. (2010). Material segments were soaked in pre-fixative for a
period of 20 minutes, then transferred to a fresh pre-fixative solution excluding the 50
mM L-lysine for 24 hours, as per the protocol of Priester et al. (2007). Following prefixative treatment, samples were rinsed in cacodylate buffer three times for 10 minutes,
placed in a 2% solution of osmium tetroxide (OsO4; Sigma) in cacodylate buffer for two
hours, then rinsed with cacodylate buffer three times for 10 minutes. Following rinsing,
stent and catheter segments were placed in increasing concentrations of ethanol, from
70% to 95% to 100%, three times for 20 minutes each. Samples were placed in a
desiccator following critical point drying for at least 24 hours or until imaged.
Imaging of samples was conducted at Surface Science Western (Western University,
ON). Prior to imaging, stent and catheter segments were coated using platinum
sputtering. All samples were imaged using a Hitachi S-4500 field emission SEM with
Quartz XOne EDX system (at 10 kV. Energy dispersive X-ray (EDX) spectroscopy was
used to determine the elemental composition of surfaces in different treatment groups.

2.8 NEGATIVE STAINING AND ANALYSIS BY
TRANSMISSION ELECTRON MICROSCOPY
Bacteria were allowed to absorb onto Formvar® (SPI-Supplies, Toronto, ON), or carboncoated copper grids for one minute. Grids were washed in dH2O and stained with 1%
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aqueous uranyl acetate (Ted Pella Inc., Redding, CA) for one minute. Excess liquid was
gently wicked off and grids were allowed to air dry. Samples were viewed on a JEOL
1200EX transmission electron microscope (JEOL USA, Peabody, MA) equipped with an
AMT 8 megapixel digital camera (Advanced Microscopy Techniques, Woburn, MA) at
80 kV.

2.9 IN VITRO UROTHELIUM ADHERENCE AND
INVASION PROTOCOL

2.9.1

Kidney and bladder cell maintenance

A498 kidney cells (ATCC HTB-44) were maintained in Eagle's minimum essential
medium (EMEM; Gibco, Burlington, ON) supplemented with 10% fetal bovine serum
(FBS) (Gibco), 1% L-glutamine (Gibco), 1% sodium pyruvate (Gibco), and 1% nonessential amino acids (Gibco). 5637 (ATCC HTB-9) and T24 bladder cells (ATCC HTB4) were maintained in RPMI-1640 medium (Gibco) supplemented with 10% FBS and 1%
L-glutamine. All cells were maintained in T75 flasks, in a 5% CO2 tissue culture
incubator at 37°C. Cells were routinely passed when confluency reached greater than
90%. This was accomplished by briefly washing with warm PBS followed by 0.05%
trypsinization (Gibco) for 6-8 minutes at 37°C and cell dislodgement via gentle tapping.
After trypsin treatment, cells were either maintained by reconstituting five-fold in a new
T75 flask with fresh media, or 48 hours prior to infection, 2 x 104 cells were transferred
to a 24-well plate and grown to confluency.

2.9.2

In vitro tissue culture infection protocol

Overnight (24 hour) cultures of S. saprophyticus 15305 or the acapsular C1 strain were
grown in LB were reconstituted 100-fold in fresh supplemented EMEM for A498 kidney
infections, or supplemented RPMI-1640 medium for 5637 and T24 bladder infections.
Samples were grown statically for three hours at 37°C with relevant antibiotic treatments
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at 1/4MIC or vehicle. A498, 5637, or T24 were maintained in 24-well plates and infected
with pathogen when achieving at least 90% confluency (~1.1 x 105 cells). Prior to
infection, cells were washed at least thrice with warm PBS, with warm, fresh media
replaced after the final wash. Infections were conducted at a multiplicity of infection
(MOI) of 25:1 for S. saprophyticus 15305 per host cell, and carried out for four hours in a
bacterial cell culture incubator with 5% CO2 at 37°C.

2.9.3

Determining adherence frequency

Adherence was determined by removing planktonic cells with two PBS washes. Each
well was then replaced with fresh PBS, and cells lysed with the application of triton X100 (Fisher Scientific, Ottawa, ON) solution at 0.1% for 15 minutes at 37°C. Dilution
plating of the resulting lysate permitted enumeration of the combined 'adherent' and
'internalized' bacterial populations. As internalization occurred much less frequently than
adhesion the relative contribution of intracellular organisms to the overall adherent
population was negligible. Therefore, this value was taken to represent the adherent
population. This was compared to the total population numbers to determine percent
adherence.

2.9.4

Determining internalization frequency

Internalization frequency was determined using gentamicin protection assays. Cells were
washed two times with PBS to remove planktonic organisms, with wells subsequently
refilled with fresh media containing 10 µg/mL gentamicin. Samples were incubated for
three hours in a bacterial tissue culture incubator with 5% CO2 at 37°C in order to kill
non-internalized organisms. Cells were then washed thrice with PBS, and lysed as
described. The percentage of intracellular organisms was determined by spread plating
100 µL of lysate and comparing to total population numbers.
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2.10 HEMAGGLUTINATION ASSAYS
Type 1 fimbriae and UafA adhesins readily agglutinate guinnea pig and sheep
erythrocytes respectively, providing a means for the rapid quantification of surface
expression following sub-inhibitory antibiotic treatment (Salit and Gotshclich, 1977;
Kuroda et al., 2005). This assay has the added benefit of directly measuring adhesin
levels at the bacterial surface which is advantageous over other techniques involving
RNA expression analysis which might not correlate with true protein expression levels.
However, this benefit can also be influenced by false negatives when surface components
interfere with the process of hemagglutination. This has been shown to occur when
capsule is present (Kuroda et al., 2005; Park et al., 2010). Thus any observable changes
in hemagglutination could presumably be due to UafA upregulation, or capsule
downregulation. Therefore, the acapsular S. saprophyticus strain C1, derived from the
15305 background, was also utilized in addition to the well-characterized capsuledeficient strain 7108 (Park et al., 2010).

2.10.1 Blood preparation
Alsevers guinea pig red blood cells (RBC) (Colorado Serum Company, Denver, CO) (E.
coli

hemagglutination)

or sheep RBCs

(Fisher Scientific) (S.

saprophyticus

hemagglutination) were swirled to mix prior to use. An erythrocyte suspension was
created by diluting RBCs 10-fold in chilled PBS, inverting several times to mix to avoid
lysis. Erythrocytes were washed by repeated pelleting (spinning in a clinical centrifuge
for ~1-2 minutes) and resuspension in chilled PBS until supernatants were clear and
colourless (usually 1-2 washes). Once clear, supernatant was aspirated, and RBCs were
resuspended in ~7 mL PBS until OD640 of 2.0 was achieved. RBC suspensions were
placed on ice until needed. Absorbance was measured using a Eon microplate
spectrophotometer (BioTek, Winooski, VT).
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2.10.2 Bacterial and plate preparation, and assay
E. coli UTI89, PAS0209, or PAS0211, and S. saprophyticus 15305, or C1 were
reconstituted 1000-fold from overnight (24 hour) cultures into fresh LB media containing
1/4MIC of relevant antibiotics or vehicle. In addition to the wild-type strain, the
acapsular S. saprophyticus C1 strain was used as a positive control for UafA-dependent
hemagglutination. Organisms were grown in their respective treatment for four hours at
37°C. Following this period, bacteria were pelleted at 6500 rpm for three minutes and
resuspended in PBS to OD600 of 1.0. 1 mL of the resulting suspension was transferred to a
1.5 mL microfuge tube, and centrifuged at 6500 rpm for two minutes using a Sorvall
Legend Micro 21 centrifuge (Thermo Scientific) to pellet. Supernatants were then
aspirated, and pellets resuspended in 100 µL of PBS.
V-bottom, 96-well plates were prepared by transferring 25 µL of PBS into each well.
Additionally, % (w/v) a-methyl-D-+-mannopyranoside (Sigma) was also prepared in a
second plate in a similar manner, and served as a negative control for type 1 fimbriaedependent hemagglutination. In duplicate, 25 µL of each suspension was transferred to
the first column of the plate, and serially diluted two-fold into each subsequent well to
create a dilution gradient of organisms. 25 µL of the prepared blood suspension was
added per well, and mixed by gently tapping the plate. Plates were then sealed, covered,
and placed at 4°C for 2-3 hours prior to analysis. Titers were read by determining the last
well to display RBC agglutination.

2.11 TYPE 1 FIMBRIAE PHASE VARIATION
The expression of type 1 fimbriae fim genes is finely regulated by environmental signals
including growth phase, nutrient abundance and culture flow (Abraham et al., 1985).
Combined, these signals dictate the percentage of fimbriated cells in the overall
population, a process which is phase variable and associated with the inversion of a short
DNA fim-switch element which grants the transcriptional machinery promoter accession.
The proportion of E. coli UTI89 type 1 fimbriae in the phase ON and OFF orientation
was assessed using PCR. Antibiotic-dependent induction of the SOS response has been
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linked to adhesin upregulation in S. aureus (Bisognano et al., 2000). Additionally, SOSdeficient E. coli UTI89 strains demonstrate decreased virulence potential in a murine
model of UTI (Justice et al., 2006). Importantly, type 1 fimbriae saturation occurs in
static cultures, while shaking cultures are generally comprised of phase OFF variants.
Therefore, shaking cultures were also taken advantage of to permit more sensitive
identification of antibiotic-dependent phase switching by avoiding the saturation effects
of static cultures. Organisms were incubated with antibiotic or vehicle for 4, 8, or 24
hours as previously described prior to phase analysis. At these time points, 1 µL of
culture would be extracted, and used as DNA template during PCR reactions.

2.11.1 PCR mixes and protocols
PCR recipe included 5 µL of 10x PCR buffer, 2.5 µL of 50 mM MgCl 2, 1 µL of 10 mM
dNTPs, 1 µL of 10 µM Phase Left Primer, 1 µL of 10 µM Phase Right Primer, 38 µL of
dH2O, and 0.2 µL Taq DNA polymerase (Thermo Scientific). The master mix was
prepared for n-reactions by multiplying each reagent by n+1 (not template) and
transferring 25 µL of the resulting mix to PCR tubes for amplification. PCR primers A
(5'-GAGAAGAGGTTTGATTTAACTTATTG-3')

and

B

(5'-

AGAGCCGCTGTAGAACTGAGG-3') were used for amplification of the fim switch
region as described by Roesch and Blomfield (1998).
PCR amplification protocol included the following steps: i) 95°C for 5 minutes, ii) 95°C
for 1 minute, iii) 55°C for 1 minute, iv) 72°C for 1 minute. Steps ii) through iv) were
repeated 35 times for amplification, followed by a final 72°C elongation step for 10
minutes. If samples were not immediately analysed, they were held at 4°C until required.
Reactions were carried out on a MyCycler Thermal Cycler (Bio-Rad, Mississauga, ON).
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2.11.2 Restriction digestion, gel electrophoresis, and ImageJ
analysis to detect phase
PCR reactions were split into another tube, so as to permit one tube for restriction digest
and one tube as an undigested control. 1 uL of HinfI (New England Biolabs, Whitby,
ON) was added to each tube to be cut, and incubate at 37°C for two hours. 5 uL of each
digest and 5 uL of the original PCR reaction on was run on a 2.0% agarose gel (in TBE
with ethidium bromide added directly to gel once sufficiently cooled). The full PCR
product is 559 base-pairs. HinfI digestion yields 70 base-pair and 489 base-pair products
for Phase ON, while 200 base-pair and 359 base-pair products are observed for Phase
OFF. The intensity of the 489 and 359 base-pair products were analyzed and compared
via densitometric analysis using ImageJ software (http://rsb.info.nih.gov/ij/).

2.12 SOFT-AGAR MOTILITY ASSAY
Flagella are the driving force behind bacterial motility, and are generally suppressed as
organisms' transition from planktonic to adherent states (Pesavento et al., 2008). The
activity of flagella can be measured by assessing bacterial swarming over the surface of
soft-agar plates. Soft-agar plates (0.3% agar) were prepared by either loading with
1/4MIC levels of antibiotic or vehicle. This concentration of agar was previously found to
be ideal for investigating bacterial swarming motility (Croze et al., 2011). E. coli UTI89,
PAS0209, or PAS0211 were reconstituted 1000-fold in fresh LB without antibiotic,
incubated at 30°C with shaking (200 rpm) for four hours , and adjusted to OD600 of 1.0
before being spot-plated onto the surface of antibiotic loaded or unloaded soft-agar
plates. Organisms were also pre-treated with 1/4MIC levels of relevant antibiotics for 4
hours as described previously, and spot plated onto the surface of unloaded soft-agar
plates. These approaches permitted analysis of how antibiotics influence the expression
and activity of flagella in planktonic phase and surface-bound E. coli. Organisms were
incubated for 24 hours at 30°C to allow the formation of a swarming zone on the surface
of soft-agar plates. At this time, the radius of the swarming zone (mm) was measured for
quantification of swarming motility.
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2.13 MURINE INFECTION PROTOCOLS
Murine infections models (Hung et al., 2009) routinely made use of 7-9 week old female
C3H/HeN or C57BL/6 mice. The animals were obtained from Harlan laboratories
(Harlan Sprague Dawley® Inc.; Indianapolis, IN) at 6-7 weeks of age, and allowed a 5-7
day rest period prior to experimentation as stress can have a significant impact on
reproducibility. For this reason, use of mice greater than nine weeks of age was avoided.
All animal studies were conducted in accordance to the Guide for the Care and Use of
Laboratory Animals under the Animal Welfare Assurance number A3381-01, at the
Washington University School of Medicine, St. Louis (St. Louis, MO). The Washington
University School of Medicine Animal Study Committee approved all the experimental
procedures described. Mice were housed in micro-isolator cages in a BSL2 barrier animal
facility and fed autoclaved standard laboratory rodent diet (Purina) and autoclaved tap
water ad libitum.

2.13.1 Bacterial and syringe preparation for infection
E. coli UTI89 and S. saprophyticus 15305 used for infections were inoculated into 10 mL
LB directly from -80°C freezer stocks, grown statically overnight at 37°C, reconstituted
in fresh LB media with or without ciprofloxacin and grown for another four hours at
37°C. These cultures were then centrifuged for 10 minutes at 3000xG, resuspended in 10
mL of PBS, and diluted to OD600 of 1.0 (~2.0 x 108 cfu/mL). 50 µL of this suspension
was used to inoculate the bladders of mice via transurethral catheterization.
Syringes were prepared for infection by applying segments of polyethylene tubing to the
end of a sterile 30-G hypodermic needle until fully covered. The ethylene tubing was cut
such that one needle-length was still present after. Enough catheterized needles would be
prepared such that one catheter was made available per experimental group. Prepared
catheters were exposed to UV radiation for at least 30 minutes for sterilization. If not
used immediately, sterile catheters were housed in sterile petri dishes until needed.
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2.13.2 Murine sedation, infection, urine collection, and sacrifice
Prior to infection, C3H/HeN mice were exposed to 4% isoflurane for induction of
anesthesia, and subsequently 2.5%-3% isoflurane for maintenance of the anaesthetic state
with an oxygen flow rate of 0.5 L/minute. However, C57BL/6 mice were induced using
the above protocol, but maintained at isoflurane levels no higher than 2%.
Anaesthetization was accomplished using a mobile respirator unit containing an Ecylinder oxygen tank, gas regulator, and anesthetic vaporizer with reservoir and waste
anesthetic gas scavenging containers. Five mice could be sedated at any one time using
this set-up. Mice were constantly monitored for breathing rate to avoid death by
asphyxiation. If breathing rate dropped to more than four seconds between breaths mice
were removed from anesthetization. Once a breathing rate of ~1 breath per second was
achieved, individual mice were removed from the induction chamber and placed flat on
their back under an anesthetic nose cone to maintain sedation. Anesthetization was
adjusted accordingly if mice showed signs of waking up (for example, rapid breathing
and limb movement). Urine was manually expressed by gently massaging and pushing on
the bladder. Once urine had been voided, a lubricated, catheterized inoculating syringe
containing the bacterial inoculum was fully inserted into the urethra without resistance.
Once the catheter was inserted, 50 µL of the bacterial inoculum (~1-2 x 107 cfu) was
delivered into the bladder at a rate of ~10 µL/second. Following inoculation mice were
transferred back into the cage and awoken.
Urine was collected prior to infection, in addition to during the course of infection until
sacrifice. This was done by applying suprapubic pressure with proper hand-held restraint
to murine bladders and collecting the urine stream in sterile, 1.5 mL eppendorf tubes. At
least 20 µL of urine was collected from each mouse. Urine bacterial load (titer) was
determined via serial dilution in PBS and spot plating (10 µL per drop, 50 µL total per
plate, per sample).
Bladders and kidneys were harvested from mice in order to permit determination of
bacterial load in these organs. Prior to sacrifice, mice were transferred glass jars
containing cotton balls soaked in isoflurane. Up to five mice were placed into the jar and
maintained under anesthetic until agonal breathing was observed or breathing ceased in
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all animals. At this time, all animals were removed from the jar, placed stomach down,
and sacrificed via cervical dislocation. Sacrificed mice were then placed on their backs,
and abdominal regions sprayed thoroughly with 95% ethanol to sterilize the site of
incision. The lower abdomen was cut open using surgical scissors, and manipulated using
sterile forceps. Bladders and kidneys were excised and placed in either 1 mL or 800 µL
of sterile PBS respectively for future homogenization and subsequent bacterial
enumeration. Tissues were mechanically homogenized to liberate bacteria, with
homogenates maintained on ice until dilution plated (10 µL per drop, 50 µL total per
plate, per sample).

2.13.3 Ex vivo gentamicin protection assay
S. saprophyticus 15305 were reconstituted 1000-fold from overnight (24 hour) cultures
into fresh LB media containing 1/4MIC of relevant antibiotics or vehicle. Samples were
incubated at 37°C for four hours and transurethrally infected into C3H/HeN mice as
described. Mice were sacrifice at 3.5 hours post-inoculation (hpi), and bladders were
excised, bisected twice, and placed in 0.5 mL of PBS. Bladder segments were washed
three times with PBS to remove luminal S. saprophyticus 15305, then transferred to
microfuge tubes containing 1 mL of PBS and 100 µg/mL gentamicin. Samples were
incubated for 90 minutes at 37°C on a rocker. After gentamicin treatment, bladder
segments were washed two times and placed in 1 mL fresh PBS and homogenized.
Whole bladders were plated (250 µL/plate) and incubated for 48 hours at 37°C. Isolated
colonies were confirmed as S. saprophyticus by spraying plates with a combination
solution of isopropyl β-D-1-thiogalactopyranoside (IPTG) (Thermo Scientific) and 5bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal) (Thermo Scientific). As S.
saprophyticus 15305 contains endogenous β-galactosidase, conversion of colonies from
white to blue ensured correct identification.
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2.13.4 IBC visualization using light-microscopy
E. coli UTI89 were reconstituted 1000-fold from overnight (24 hour) cultures into fresh
LB media containing 1/4MIC of relevant antibiotics or vehicle. Samples were incubated
at 37°C for 4 hours and transurethrally infected into C3H/HeN mice as described. The
animals were sacrificed 6 hpi, and bladders were excised, bisected longitudinally, and
placed onto a silicone bladder pinning pad. Silicone pads were prepared using silicone
elastomer (SYLGARD 184; Dow Corning, Columbia City, IN) poured into a 6-well plate
to about half the well height as per the manufacturer's instructions. Bladders were
stretched, flattened and pinned in place to the silicone pad luminal side up. They were
then fixed with 3% paraformaldehyde (Sigma), washed thrice with 2 mM MgCl2 (Sigma),
0.01% sodium deoxycholate (Sigma), and 0.02% Nonidet P-40 (Roche, Mississauga,
ON) in PBS. Staining was performed using 25 mg/mL X-gal (Sigma), and a solution
containing 1 mM potassium ferrocyanide and 1 mM potassium ferricyanide (Sigma).
After an incubation period of 16 hours at 30°C, bladders were visualized under an
Olympus SZX12 dissecting microscope (Olympus America, Center Valley, PA), and
appear as punctate blue stains.

2.13.5 IBC visualization and volumetric analysis using confocal
microscopy
IBCs were also visualized using confocal microscopy to permit a more accurate
determination of size and morphology. Infections and bladder fixation were conducted as
described, with the exception that E. coli UTI89 carrying the green fluorescent protein
(GFP)-expressing plasmid pANT4 was utilized. pANT4 is stably harbored during acute
infection stages (Justice et al., 2004). Fixed bladders were washed and counterstained for
20 minutes with nuclear ToPro3 (Molecular Probes) stain, and recombinant wheat germ
agglutinin (r-WGA) to outline superficial umbrella cells (1:700 dilution for each).
Bladders were imaged using a Zeiss LSM 510 Meta Laser Scanning inverted confocal
microscope (Thornwood, NY). IBCs were rendered in three-dimensions (3D) via
reconstructive Z-stacking of images using Volocity 4 image analysis software
(PerkinElmer, Waltham, MA). Volumetric analysis was also conducted using Volocity
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software, which calculates GFP volume by counting the number of green pixels within a
given area of the region defined as an IBC (Anderson et al., 2010).

2.13.6 Empiric ciprofloxacin therapeutic dose determination for
murine UTI
Human dosing parameters were used to determine the empiric ciprofloxacin daily dose in
mice (Iravani et al., 1999). Recommended dosing for humans is set at ~10 mg/kg
(drug/weight), taken bi-daily for typical therapeutic ciprofloxacin treatment of
uncomplicated UTI. The average weight of a C3H/HeN mouse is ~20 g. Therefore, these
mice required a total daily dose of ~400 µg ciprofloxacin for UTI treatment. The average
water intake for a 20 g mouse was empirically determined to be ~10 mL/day. Thus, the
drinking water of mice was supplemented with 40 µg/mL of ciprofloxacin to achieve a
daily therapeutic dose over the course of 24 hours.

2.13.7 Sub-therapeutic ciprofloxacin and UPEC urine titer
The effect of sub-therapeutic ciprofloxacin dosing on murine response to UTI was
investigated in both previously inoculated, but resolved mice in addition to chronically
infected mice. The animals were prepared by inoculating with a dose of 10 8 cfu of E. coli
UTI89 as described previously, and were left for at least 30 days to either spontaneously
resolve infection, or develop chronic cystitis, defined as urine titers of >104 cfu/mL for ≥
14 dpi (Hannan et al., 2010). The mice that resolved (<104 cfu/mL ≥ 14 dpi) were
separated from those that developed chronic infection into cages containing up to five
mice from the same group.
The urine titers of mice were monitored for three days prior to initiation of subtherapeutic ciprofloxacin supplementation as previously described. This was done to
ensure that infections had stabilised in each mouse. Ciprofloxacin was supplemented into
the drinking water for ad libitum consumption. Water intake was monitored and did not
differ between antibiotic-supplemented and control groups indicating ciprofloxacin did
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not alter palatability (data not shown). Dosing ranges of <1/25 the empirical therapeutic
dose were found to not significantly decrease bacterial urine titer over a three day period
(data not shown). Following optimization of dosing parameters, such that UPEC were not
negatively influenced by the level of ciprofloxacin present, 1/50th the empirical
ciprofloxacin therapeutic dose was supplemented into the drinking water and replaced
each day for 3-6 days. The urine titer of each mouse was monitored daily for changes as
described. At either three or six days, the dose was further increased to 1/25th the
empirical therapeutic dose for another 3-6 day period with urine titers again determined
daily. Lastly, the dose was increased further to 1/10th the empirical therapeutic dose for
three days to clear infection and ensure spontaneous development of ciprofloxacin
resistant mutants did not occur.

2.13.8 Human and murine tissue cytokine quantification
The influence of sub-therapeutic ciprofloxacin dosing on immune activation was assessed
during the early stages of infection. Prior to infection, mice were supplemented with
1/50th the empirical ciprofloxacin therapeutic dose for three days. Infections, as
described previously, were established by inoculation of 107 non-treated E. coli UTI89 or
control PBS (mock) into mice receiving sub-therapeutic ciprofloxacin or no antibiotic.
Infections were allowed to develop for 3.5 hours to permit activation of early immune
response elements. At this time, urines were extracted for later analysis, mice sacrificed,
and bladders and kidneys excised and snap frozen in liquid nitrogen for future analysis.
The cytokine expression profiles for murine bladders was conducted using a Luminex®
bead-based assay. Cytokines were liberated from tissues using homogenization, as
previously described, in extraction buffer containing 20 mM Tris-HCl (Sigma; pH 7.5),
150 mM NaCl (Sigma), 1 mM phenylmethylsulfonyl fluoride (PMSF; Sigma), 0.05%
Tween-20 (Sigma), and a protease inhibitor cocktail (100-fold dilution; Roche).
Conversely, supernatants from in vitro human T24 tissue cell line experiments were also
extracted and analysed. Extracts were maintained on ice, centrifuged at 14,000 rpm for
three minutes, and supernatants removed and stored at -80°C until use. Total protein
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levels were assess using a bicinchoninic acid (BCA) kit (Thermo Scientific) as per the
manufacturer's instructions and diluted when required.
Levels of cytokines IL-1β, IL-6, keratinocyte chemoattractant (KC - also referred to as
IL-8), granulocyte colony-stimulating growth factor (G-CSF), IL-17, IL-10, and tumor
necrosis factor alpha (TNFα) were measured using multiplexed immunoassay kits
according to manufacturers’ instructions (Bio-Rad Laboratories Inc., Hercules, CA). The
appropriate mouse or human kits were used for each sample. A Bio-Plex 200 readout
system was used (Bio-Rad), which utilizes Luminex® xMAP fluorescent bead-based
technology (Luminex Corporation, Austin, TX). Cytokine levels (pg/mL) were
automatically calculated from standard curves using Bio-Plex Manager software (v. 4.1.1,
Bio-Rad). Standard curves were generated in extraction buffer containing no protease
inhibitors.
Enzyme-linked immunosorbent assays (ELISA) were used to determine IL-8 expression
levels in human 5637 bladder cells. Infections were carried out as previously described
(In vitro tissue culture infection protocol), with the exceptions that lipopolysaccharide
(LPS; Sigma) was added at 5 µg/mL in place of S. saprophyticus 15305 as a cell-free
control, and ampicillin and gentamicin were also tested at 1/4MIC levels in addition to
ciprofloxacin. At four hours after incubation of the pathogen with the 5637 cells,
supernatants were removed, along with bacteria and cellular debris via centrifugation
(14,000xG for three minutes), and the resulting extracts placed in the wells of a 96-well
plate and frozen at -80°C until needed. Cytokines were quantified using the Human
CXCL8/IL-8 Quantikine ELISA Kit (R&D Systems, Minneapolis, MN) as per the
manufacturer's instructions.

2.13.9 Quantification of urine sediment polymorphonuclear
leukocyte infiltration
Urines collected at 3.5 hpi from mice receiving 1/50th the empirical ciprofloxacin
therapeutic dose were further analysed for their immune cell content. Urine sediments
were obtained by cytocentrifuging 80 µL of a 10-fold (PBS) diluted urine sample onto
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poly-L-lysine-coated glass slides using a CytoPro 7620 cytocentrifuge (Wescor, Logan,
UT). Samples were briefly heat fixed and stained with filter sterilized Protocol 3 Hema 3
stains (Wright-Giemsa method, Fisher Scientific). Stained urine sediments were
examined by light microscopy on an Olympus BX51 light microscope (Olympus
America), and the average number of polymorphonuclear leukocytes (PMN) per 400x
magnification field (high powered field) calculated from counting at least five fields. A
semi-quantitative scoring system was used for analysis and is described in Table 2.2.

2.13.10 Model of ciprofloxacin prophylaxis
In general, the proof-of-principle antibiotic dosing strategies used throughout this work
are not reflected in real-world therapeutic scenarios. However, low-dose, extended use
prophylactic strategies are often implemented for the management of recurrent UTI.
These aim to achieve sub-inhibitory levels throughout the daily dosing period. It is
possible that these transient, low-dose periods are sufficient to enhance E. coli UTI89
virulence. Therefore, a mock prophylaxis dosing scheme was applied to the current
murine infection model. C3H/HeN mice were abandoned for prophylaxis experiments as
they have a congenital anatomical defect which promotes vesicoureteral reflux and
subsequent kidney infection (Hung et al., 2009; Hopkins et al., 1995). Instead, C57BL/6
mice were utilized to avoid this issue. The model involved a 24 hour infection period as
described previously, followed by a three day regimen of normal co-trimoxazole therapy
as described by Schilling et al. (2002) (270 µg/mL replaced daily; Qualitest
Pharmaceuticals, Huntsvill, AL). Together these periods mimic an infection event,
symptom development, and subsequent initiation of antibiotic therapy. Following therapy
cessation, mice were provided a seven day rest period prior to initiation of ciprofloxacin
prophylaxis. They received either a typical prophylactic dose of ciprofloxacin (1/4th the
empirical therapeutic dose) or vehicle (dH20) daily via oral gavage for seven days. Oral
dosing was conducted by injecting 100 µL of 1 µg/mL ciprofloxacin directly into the
stomachs of mice. Following prophylactic therapy, animals were sacrificed, and kidneys
and bladders excised for bacterial titer, as described earlier. In some cases, murine
bladders were gentamicin treated for determination of the intracellular population. Urine
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was taken at least every two days throughout the course of the experiment to allow
tracking of infection.
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Table 2.2 PMN Categorical Scoring Scheme
Total PMNsa
0-4
5-24
25-49
50-99
100+
a

Score
0
1
2
3
4

Per 5x high-powered fields of views [hpf (40x objective)].
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2.14 TYPE I AND TYPE II PERSISTER CELL ASSAYS
Type I persisters were isolated by directly applying lethal concentrations of ciprofloxacin
(5 µg/mL), ampicillin (100 µg/mL), or gentamicin (10 µg/mL) to stationary phase (24
hour) cultures of E. coli UTI89, PAS0209, PAS0211, CFT073 or S. saprophyticus 15305
for three hours and enumerating the surviving fraction before and after treatment (Keren
et al., 2004). Conversely, overnight cultures were first seeded 1000-fold into fresh LB
and then grown for ~3 or ~7 hours (for UPEC and S. saprophyticus respectively) to
deplete the Type I persister population for Type II persister assays (until earlyexponential phase; turbidity of 0.5-0.6 for S. saprophyticus and E. coli at 600 nm). A
subsequent 1000-fold seed in fresh LB with 1/4MIC antibiotics lasting ~3-7 hours
(turbidity of 0.5-0.6 at 600 nm) was performed to enrich the Type II persister fraction.
Following this incubation period, cells were washed and percent survival was determined
through the enumeration of viable cells prior to and following treatment with lethal
antibiotics. Colonies were isolated by serially diluting cultures in PBS, spot-plating 10
µL drops on LB agar, and counting the resulting colonies. In cases where viability fell
below 1000 cfu/mL, 10 or 100 µL drops would be applied directly from cultures
reconstituted in PBS and spread over the entire surface of an LB plate. Survival due to
phenotypic tolerance and not spontaneous resistance was determined by sub-culturing the
surviving fraction in fresh LB and determining the MIC.

2.14.1 Persister resuscitation assays
The kinetics of persister resuscitation were determined for both E. coli CFT073 and S.
saprophyticus 15305 following Type II persister assays. After treating cultures with
relevant antibiotics at lethal levels, cultures were resuspended in fresh LB, serially diluted
into the wells of a 96-well plate containing LB, sealed and grown for 21 days at 37°C.
Wells were marked daily as positive when turbidity was observed.
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2.15 AUTOAGGREGATION ASSAY
It is well established that organisms in the confinement of adherent high-density biofilms
are much more refractory to antibiotic therapy then their planktonic counterparts.
Importantly, this trait is not due to the inability of antibiotics to penetrate the extracellular
matrix, as most agents readily diffuse to the cores of such films (Singh et al., 2010).
Therefore, persister cells have been labelled as the biofilm constituents which confer
high-grade MDT. In addition to surface-dependent biofilm formation, rapid planktonicphase aggregation has a positive influence on antibiotic tolerance and host immune cell
evasion while enhancing adherence properties (Boll et al., 2013; Haaber et al., 2012;
McNabe et al., 2011). However, it is unknown whether high-density growth is a
contributor or side-effect of high frequency persisters within biofilms. A contributing role
seems plausible as persisters comprise a significantly larger fraction of the overall
population as cultures reach stationary phase.
Autoaggregation was quantified in a number of ways. First, antibiotic effects on this
process were considered. The protocols used have been described, and involved
quantification via the microscope adherence assay protocol for S. saprophyticus 15305
aggregation, and negative staining and analysis by transmission electron microscopy
protocol for E. coli UTI89 aggregation. In both cases, aggregation was considered as the
number of associated organisms per individual aggregate. Visualization of individual E.
coli UTI89 in aggregates via light microscopy was not reliable, necessitating the TEM
approach which was used instead.
A third protocol was utilized to compare levels of stationary-phase, type 1 fimbriaedependent aggregation in the absence of antibiotics. This was accomplished using a
sedimentation assay, which measures the rate of settling over time as a function of
aggregate size. Type 1 fimbriae deficient E. coli UTI89 mutants ΔfimH (pili expressed
without adhesin) and ΔfimS (pili not expressed - bald phenotype) were utilized.
Organisms were grown to stationary phase as previously described. At this point, cells
were harvested via gentle centrifugation at 4500xG for 10 minutes. Pellets were
resuspended in PBS to an OD600 of 1.0. Cell suspensions were then vortexed for ~10
seconds and incubated at room temperature for five hours to permit sedimentation. Every
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hour, 0.1 mL of the upper suspension was gently removed and transferred to 0.9 mL of
PBS and the OD600 measured. The autoaggregation determined was expressed as 1(At/A0)x100, where At represents the absorbance at time t = 5 hours and A0 the
absorbance at t = 0.

2.16 TRANSCRIPTOMIC ANALYSES

2.16.1 Bacterial preparation, RNA extraction and enrichment
protocols
RNA sequencing was conducted in order to gain a better understanding of how
transcription is modulated in response to sub-inhibitory antibiotics, and to complement
the phenotypic changes already characterized. Both S. saprophyticus 15305 and E. coli
UTI89 were grown in the presence or absence 1/4MIC ciprofloxacin until an OD600 of 1.0
was achieved. An additional treatment group included the application of 1/4MIC
ciprofloxacin at OD600 of 1.0 for 30 minutes to determine the early effects of subinhibitory antibiotic on transcript expression. After these incubation periods, RNA protect
was directly added at a ratio of 2:1 RNA protect:sample for 10 minutes. Solutions were
centrifuged at 5,000xG for five minutes and pellets frozen at -80°C until required for
RNA extraction.
S. saprophyticus 15305 pellets were resuspended in 1 mL TE buffer containing 10 mM
Tris-HCl, 1 mM EDTA, 20 mg/mL lysozyme (Sigma), and 50 U/mL lysostaphin (Sigma)
at 37°C for 30 minutes, while E. coli UTI89 was incubated in the same buffer without
lysostaphin for the same period. Samples were then centrifuged at 5,000xG for five
minutes, supernatants discarded, and pellets resuspended in 1 mL TRIzol (Ambion,
Burlington, ON) reagent by vortexing followed by a 10 minute incubation period at room
temperature. 200 µL of chloroform was added to each sample then vortexed for 15
seconds and incubated at room temperature for 10 minutes followed by centrifugation at
16,000xG for 15 minutes. 500 µL of the upper aqueous phase was transferred to an
RNase-free tube and 500 µL of 100% ethanol was added then vortexed. Samples were
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then run through a PureLink RNA Mini Kit (Ambion) to purify the extracted RNA as per
the manufacturer's instructions. In all instances, RNA was eluted in 30 µL volumes using
RNase-free water. RNA quality and purity was determined at Robarts Research Institute,
London Regional Genomics Centre using an Agilent 2100 Bioanalyzer (Agilent
Technologies Inc., Palo Alto, CA) and the RNA 6000 Pico Kit (Caliper Life Sciences,
Mountain View, CA). Only samples containing high-quality RNA [RNA integrity
numbers (RINs) ≥ 9.0] were used for further analysis and sequencing. mRNA was
enriched prior to sequencing using the MICROBExpress kit (Ambion). A single
enrichment run was sufficient to deplete 16S and 23S ribosomal RNA from the S.
saprophyticus 15305 samples; however, E. coli UTI89 samples required two depletions
prior to sequencing.

The purity and quantity of the RNA was assessed prior to

enrichment using a Qubit 2.0 Fluorometer (Life Technologies, Burlington, ON) and RNA
BR Assay (Life Technologies). RNA was added to the MICROBExpress kit at a
concentration of 0.6 µg/mL in 15 µL total volume and extracted in RNase-free water
following ethanol precipitation. Effective ribosomal RNA depletion was confirmed using
a bioanalyzer.

2.16.2 RNA library preparation and sequencing
Purified and depleted RNA was barcoded using ScriptSeq Index PCR Primers 1-19
(Epicenter Biotechnologies, Madison, WI) and pooled into a library at Robarts Research
Institute, London Regional Genomics Centre using the ScriptSeq v2 RNA-Seq Library
Preparation Kit (Epicentre). Briefly, samples were fragmented, cDNA was synthesized,
tagged, cleaned-up and subjected to PCR with barcoded reverse primers to permit
equimolar pooling. In total, 50 ng of RNA was used for each library preparation. The
quality and quantity of the library preparation was confirmed via bioanalyzer (Agilent
High Sensitivity DNA chip) and qPCR Library Quant Kits (KAPA Biosystems,
Wilmington, MA), with primers specific to end library fragments. Samples were
clustered via cBOT (Illumina, Toronto, ON) and sequenced using the HiSeq 2000
platform (Illumina) at The Biodiversity Research Centre, NGS Facility (University of
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British Columbia). Samples were run on two lanes at 12 pM using 100 bp, paired-end
reads as per Illumina specifications and protocols.

2.16.3 Reference sequence library and mapping
E. coli UTI89 [accession NC_007946.1 (Chen et al., 2006)] and S. saprophyticus 15305
[accession NC_007350.1 (Kuroda et al., 2005)] were included for mapping. These
datasets included the predicted coding sequences extracted from the complete genomes
and plasmids available from the National Center for Biotechnology Information (NCBI)
database. Reads uniquely mapped to coding sequences using BOWTIE 2.2.1 (Langmead
and Salzberg, 2012) were included in the differential expression analysis (all other
unmapped reads were discarded). Reads were trimmed by 20 nt from the 5' end and 40 nt
from the 3' end, and a maximum of two mismatches were allowed. Reads with equal best
hits were mapped at random to one of the locations. Amino acid translations of predicted
coding sequences were compared using SEED Subsystems (Overbeek et al., 2005) and
assigned by blastp with an e-value cutoff of 1e-3. The KEGG Automatic Annotation
Server (KAAS) (Moriya et al., 2007) was used for annotation of enzyme functions
(KOs).

2.17 STATISTICAL ANALYSES
Statistical analyses were conducted using GraphPad Prism version 4.00 for Windows
(GraphPad Software, San Diego, CA). Significance was determined using one-way
ANOVA and Dunnett's multiple comparison test or Bonferroni's multiple comparison
test, Mann-Whitney test with Gaussian approximation, Logrank test, and two-tailed or
unpaired t-test. Each test used for respective experiments is detailed in its figure legend.
Statistical analyses for the differential expression of reads generated using RNA
sequencing were conducted using the ALDEx R package version 2.0.6 (Fernandes et al.,
2013; Fernandes et al., 2014 - awaiting publication). A log2 median effect size of at least
1.5 was required for genes to be considered differentially expressed. In addition, a less
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than 1% overlap in the distributions between the two conditions was permitted for
inclusion as described elsewhere (Fernandes et al., 2013; Macklaim et al., 2013).
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3

RESULTS

3.1 EXAMINING THE EFFECTS OF SUB-INHIBITORY
ANTIBIOTICS ON UROPATHOGEN VIRULENCE
The notion that sub-inhibitory antibiotics demonstrate signalling capacity in prokaryotes
is of clinical concern and certainly warrants investigation. This is especially true in
situations where antibiotics are applied at low-doses for prolonged periods of time such
as during prophylactic management of recurrent UTI. Thus far, the majority of studies
exploring phenomenon have utilized transcriptomics and reporter strains to illustrate
global changes in gene expression. However, there is a severe deficit in our
understanding of what exactly these changes accomplish on the phenotypic level, and
how they influence virulence and pathogenesis. An aim of the present study was to
investigate the capacity of sub-inhibitory antibiotics to influence various aspects of
uropathogen virulence in vitro.

3.1.1

Characterizing uropathogen strain sensitivity to various
antibiotics

Antibiotic dosing strategies were optimized against all uropathogens utilized before
undertaking this work. Initial susceptibility screening was carried out using the KirbyBauer method, which indicated that all strains demonstrated clinical susceptibility (Table
3.1). Minimal inhibitory concentration (MIC) cut-offs were generated using the broth
microdilution procedure as outlined by the Clinical and Laboratory Standards Institute
(CLSI; 2007) (Table 3.1). S. saprophyticus strains were comparatively more tolerant of
ciprofloxacin than E. coli isolates. Conversely, E. coli strains were much less sensitive to
ampicillin and gentamicin challenge.
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Table 3.1 Summary of strain MICs and antibiotic susceptibilities

Strain (type)
S. saprophyticus strains
15305
15305:C1
7108
E. coli strains
CFT073
TOP277 (SSR)
TOP263 (SSR)
TOP379 (SSR)
TOP344 (SSR)
TOP345 (SSR)
PUTS277 (AI)
PUTS278 (AI)
PUTS1127 (AI)
PUTS1236 (AI)
UTI89
UTI89 (ΔrecA)
UTI89 (lexAT355G)
a

MIC (µg/mL)
CIP
AMP

GEN

ZOI (mm [susceptibility])a
CIP
AMP

GEN

0.25
0.25
0.25

0.125
0.125
0.25

0.0625
0.0625
0.0625

26.5 (S)
26.5 (S)
26 (S)

28.25 (S)
28.25 (S)
28 (S)

20 (S)
20 (S)
21 (S)

0.0156
0.0125
0.0166
0.0208
0.0229
0.0146
0.0208
0.0166
0.0166
0.0166
0.0188
0.0009
0.0039

3
6
8
10
10
8.5
9
6
9.5
9
9
8
8

1
0.75
0.5625
0.6875
0.875
0.875
0.3125
0.375
1
0.75
1.25
1
1.25

25.5 (S)
22.75 (S)
23.5 (S)
23.25 (S)
21.75 (S)
26 (S)
26.25 (S)
25 (S)
28 (S)
23.5 (S)
26.5 (S)
43.75 (S)
35.5 (S)

17 (S)
19.75 (S)
16.25 (S)
14 (I)
14 (I)
19.75 (S)
17.5 (S)
17.25 (S)
17.75 (S)
17.25 (S)
16.75 (S)
25.75 (S)
22.75 (S)

17 (S)
16 (S)
16 (S)
15 (S)
15 (S)
16.25 (S)
17.25 (S)
17.75 (S)
16 (S)
16.5 (S)
15.75 (S)
25.25 (S)
21 (S)

ZOI, zone of inhibition; S, susceptible; I, intermediately susceptible; R, resistant (per
CLSI guidelines).
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Optimal sub-inhibitory antibiotic dosing strategies were evaluated to determine
concentrations which confer phenotypic effects without perturbing growth. Although a
range of concentrations were considered, 1/4MIC levels were the maximal dose that
organisms could tolerate without loss of fecundity (Figure 3.1). Therefore, this dose was
used throughout unless stated otherwise.

3.1.2

Evaluating the ability of sub-inhibitory antibiotics to induce
adherence of S. saprophyticus to abiotic surfaces

Colonization of surfaces represents one of the first critical steps in bacterial infection.
Therefore, the influence of antibiotic stress on this process was the first trait to be
evaluated in S. saprophyticus 15305. Initially, experiments were carried out using human
pooled urine (HPU) as a growth medium. Surfaces which come into contact with urine
are immediately coated with a conditioning film which is composed of various urine
metabolites and host proteins such as immunoglobulins, Tamm-Horsfall protein, histones,
and nuclear DNA-condensing proteins (Canales et al., 2009), and are important in
surface-pathogen adherence potential. To achieve a basic understanding of antibiotic
influence on adherence, trials were first carried out on glass microscope slide surfaces to
permit rapid visualization of experimental outcomes. Early-exponential phase S.
saprophyticus 15305 cultures were exposed to 1/4MIC antibiotics or control for one hour
prior to incubation on slide surfaces. This time point was selected to demonstrate the
rapid influence of antibiotics on colonization processes. Following a brief wash period to
remove non-irreversibly attached organisms, slides were stained with crystal violet and
imaged using a light microscope. Representative light-micrographs of all samples
revealed the presence of adherent S. saprophyticus as punctate purple spots, with
antibiotic-primed groups demonstrating visibly larger populations (Figure 3.2A).
Enumeration of randomly selected fields of view (FOV) for each treatment group, and
comparison with HPU control populations demonstrated that antibiotics are effective in
increasing the relative adherence in primed pathogens (Figure 3.2B). Specifically,
adherence was significantly increased with 1/4MIC ciprofloxacin and ampicillin
treatments (37%; P < 0.05), and 1/4MIC gentamicin treatments (50%; P < 0.01).
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Figure 3.1. Comparison of cfu/mL between subinhibitory antibiotic pre-treated and
untreated uropathogens immediately prior to lethal antibiotic challenge. Negligible
impact of antibiotic pre-treatment on uropathogen growth receiving either 1/4MIC
ciprofloxacin (A), 1/4MIC ampicillin (B) or 1/4MIC gentamicin (C) for three hours is
shown. Means are from at least three independent experiments. Significance determined
using paired t-test for each pair-wise combination (all combinations are non-significant;
P > 0.05).
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Figure 3.1
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Demonstrating that antibiotics can modulate bacterial adherence capacity to hydrophilic
glass warranted further exploration of this phenotypic change using hydrophobic
surfaces. Foley urethral catheters and InLay Optima® ureteral stents were selected as
target surfaces both for their hydrophobic properties and application as medical devices
for the management of urinary obstruction. These devices are widely used in urology, are
readily colonized by uropathogens, and are often placed in conjunction with single-dose
prophylactic antibiotics as per AUA best practice policies (Wolf et al., 2008). S.
saprophyticus 15305 was incubated in either the presence or absence of 1/4MIC
antibiotic and 1 cm sections of either stent or catheter in LB broth (HPU was
discontinued for adherence assays due to the reproducibility issues associated with batch
variations). Antibiotic-primed organisms demonstrated an increased capacity to adhere to
both stent and catheter surfaces (Figure 3.3), as was found on hydrophilic glass slides. S.
saprophyticus 15305 adhered more readily to catheters, with antibiotic-primed groups
demonstrating significantly larger adherent populations. Adherence increased by 5.9, 6.1,
and 6.2-fold on urethral catheters in the presence of 1/4MIC ciprofloxacin, ampicillin,
and gentamicin respectively (P < 0.05), and by 2.6, 2.6, and 2.7-fold on ureteral stents (P
< 0.05; P < 0.01).
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Figure 3.2. Representative images of S. saprophyticus 15305 adhering to glass
microscope slide surfaces in the presence or absence of 1/4MIC of various antibiotics (A)
and relative adherence (B). Attachment percent indicated as a function of the human
pooled urine (HPU) control. Means from at least three independent experiments are
shown with significance. Significance was determined using one-way ANOVA and
Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01).
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Figure 3.2
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Figure 3.3. Percent adherent S. saprophyticus 15305 of the total population (adherent and
non-adherent) to InLay Optima ureteral stent (A) or Foley urethral catheter (B) segments
in the presence or absence of 1/4MIC of various antibiotics. Means from at least three
independent experiments are shown with significance. Significance was determined using
one-way ANOVA and Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01).
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Figure 3.3
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3.1.3

Evaluating the ability of sub-inhibitory antibiotics to
modulate biofilm formation in S. saprophyticus and E. coli

Adhesion of uropathogens to surfaces represents the first steps in establishing acute
colonization during UTI. Since sub-inhibitory antibiotics were effective in increasing
initial bacterial adherence, it was postulated that they would also be able to enhance their
biofilm-forming capacity. This was explored by incubating S. saprophyticus 15305 in 96well plates for 24 and 48 hours in the presence or absence of sub-inhibitory antibiotic
concentrations. Ciprofloxacin, ampicillin, and gentamicin increased maximal biofilm
mass by 38.5%, 34%, and 27.8% respectively compared to untreated controls (P < 0.05;
P < 0.01) (Figure 3.4A). Although antibiotics also were able to enhance biofilm mass
after 48 hours, the effect was comparatively much less pronounced compared to 24 hours
(Figure 3.4B), with, ciprofloxacin, ampicillin, and gentamicin increasing maximal
biofilm amount by only 13.6%, 11.7%, and 12.8% respectively (P < 0.05). This plateau
in biofilm mass is likely due to saturation effects as S. saprophyticus 15305 biofilms
approach the maximal capacity supported within the well of the plate.
Compared to S. saprophyticus, E. coli is more commonly associated with biofilm-related
UTI, especially when indwelling urinary devices are present. Previous work has
demonstrated this organism can increase biofilm mass in response to aminoglycoside
antibiotics (Hoffman et al., 2005). The biofilm forming capacity of E. coli UTI89 was
also determined following sub-inhibitory antibiotic exposure. The experiments were
carried out as described for S. saprophyticus 15305, with the exception that only a 24
hour time-point was considered. Sub-inhibitory ciprofloxacin, ampicillin, and gentamicin
increased maximal biofilm amounts by 57.7%, 60.0%, and 57.9% respectively (P < 0.05;
P < 0.01) (Figure 3.5).
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Figure 3.4. S. saprophyticus 15305 biofilm formation in the presence of various
antibiotic concentrations at 24 (A) and 48 (B) hours. Means from at least three
independent experiments are shown with significance. Significance was determined using
one-way ANOVA and Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01).
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Figure 3.4
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Figure 3.5. Biofilm formation of wild-type E. coli UTI89 after 24 hours in the presence
of various antibiotic concentrations. Means from at least three independent experiments
are shown with significance. Significance was determined using one-way ANOVA and
Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01).
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Figure 3.5
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3.1.4

Assessing the contribution of the SOS response to
antibiotic-dependent biofilm formation

It is well known that the SOS response is activated following dosing with various
antibiotics (Miller et al., 2004; Mesak et al., 2008). However, it has more recently been
implicated in the regulation of various aspects of pathogenicity (Bisognano et al., 2000;
Kelley et al., 2006). Here, the involvement of the SOS response to antibiotic-dependent
biofilm formation is considered. SOS-deficient E. coli UTI89 strains PAS0209 and
PAS0211 demonstrated a modest suppression in biofilm formation, amassing only 69.6%
and 74.3% of the wild-type E. coli UTI89 levels respectively (P < 0.05) (Figure 3.6A).
Next, the contribution of SOS activation during antibiotic-dependent biofilm formation
was assessed. E. coli PAS0209 biofilm formation was not significantly influenced by
ciprofloxacin and gentamicin antibiotics (P > 0.05) (Figure 3.6B, D). However, similar to
wild-type E. coli UTI89, PAS0209 formed more robust biofilms following ampicillin
treatment (Figure 3.6C), increasing mass by 40.0% compared to untreated controls (P <
0.05). This result was also observed in E. coli PAS0211, with ampicillin treatment
increasing biofilm mass by 36.6% (P < 0.05) (Figure 3.6F). Although no appreciable
changes were noted following ciprofloxacin treatment, gentamicin was able to increase
biofilm mass by 29.0% (P < 0.05) (Figure 3.6E, G).

3.1.5

Antibiotics induce bacterial aggregation

Initial light micrograph images appeared to exhibit S. saprophyticus 15305 cultures that
would aggregate in the presence of sub-inhibitory antibiotics (Figure 3.2A). In order to
investigate whether this process is an important contributor to therapy failure, qualitative
aggregation in the presence or absence of sub-inhibitory ciprofloxacin was determined
via direct visualization using scanning electron microscopy (SEM) for S. saprophyticus
15305 (Figure 3.7A, B) and transmission electron microscopy (TEM) for E. coli UTI89
(Figure 3.7C, D). Representative images of control (Figure 3.7A, C) and 1/4MIC
ciprofloxacin treated (Figure 3.7B, D) organisms reveal extensive aggregation when
ciprofloxacin is present.
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Figure 3.6. Biofilm formation of E. coli UTI89 and SOS-deficient strains after 24 hours
(A). Biofilm formation of E. coli SOS-deficient strains ΔrecA (B-D) and lexAT355G (E-G)
after 24 hours in the presence of various antibiotics at subinhibitory concentrations.
Means from at least three independent experiments are shown with significance.
Significance was determined using one-way ANOVA and Dunnett's multiple comparison
test (*, P < 0.05; **, P < 0.01).
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Figure 3.6
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Figure 3.6 (continued)
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Figure 3.7. Representative images showing adherence and aggregation of S.
saprophyticus 15305 (A, B; SEM), and E. coli UTI89 (C, D; TEM), and the effect of
1/4MIC ciprofloxacin treatment (B, D) on these processes.
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Figure 3.7
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S. saprophyticus 15305 aggregation was assessed using the glass microscope slide
technique previously described. As expected from previous observations, antibioticpriming significantly increased planktonic aggregate size (Figure 3.8A). Ciprofloxacin,
ampicillin and gentamicin increased aggregate size from a control median of 6 to 9, 8,
and 8 organisms/aggregate respectively (P < 0.05; P < 0.01). Inability to distinguish
individual E. coli UTI89 organisms from one-another necessitated the use of TEM for
accurate aggregation quantification. Similar to S. saprophyticus 15305, E. coli UTI89
was treated with 1/4MIC antibiotics for one hour prior to fixation and enumeration.
Subsequent visualization demonstrated that like S. saprophyticus 15305, E. coli UTI89
aggregates in the presence of sub-inhibitory antibiotics (Figure 3.8B). Aggregate size
increased from a control median of 3 to 6 organisms/aggregate for ciprofloxacin,
ampicillin and gentamicin treatment groups (P < 0.01).

3.1.6

Evaluating the ability of antibiotics to induce S.
saprophyticus urothelial cell adherence and internalization

Having demonstrated that antibiotic-primed uropathogens more readily adhere to abiotic
surfaces, it was postulated that the same outcome would occur if urothelial cells were
used as the adhering substrate. Experiments were conducted to assess the ability of
antibiotics to improve S. saprophyticus 15305 adherence to both 5637 bladder and A498
kidney cell lines. These cell lines were selected for their similarity to normal urinary
epithelium tissue. All antibiotics induced increased adherence to both cell lines, with
ciprofloxacin, ampicillin and gentamicin improving adherence to 5637 bladder cells 12.8,
7.4, and 7.0-fold (Figure 3.9A), and 10.7, 11.4, and 9.7-fold in A498 kidney cells
respectively (P < 0.05; P < 0.01) (Figure 3.9C). Antibiotic-dependent modulation of
adherence also resulted in a larger intracellular reservoir for both cell types.
Ciprofloxacin, ampicillin and gentamicin increased the intracellular population in 5637
bladder cells by 5.6, 6.6, and 8.3-fold respectively (P < 0.01) (Figure 3.9B). Similarly,
ciprofloxacin and ampicillin both increased internalization 3.4-fold (P < 0.05), while
gentamicin resulted in a 4.4-fold increase in A498 kidney cells (P < 0.01) (Figure 3.9D).
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Figure 3.8. Average planktonic cluster size (bacteria/aggregate) of S. saprophyticus
15305 (A) and E. coli UTI89 (B) following exposure to either 1/4MIC ciprofloxacin,
ampicillin, gentamicin, or no antibiotic. Means from at least three independent
experiments are shown with significance. Significance was determined using one-way
ANOVA and Dunnett's multiple comparison test (*, P < 0.05; **, P < 0.01).
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Figure 3.8
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Figure 3.9. The effect of antibiotics on S. saprophyticus 15305 adherence (A, C) and
internalization (B, D) to 5637 bladder (A, B) and A498 kidney cells (C, D). Means from
at least three independent experiments are shown with significance. Significance was
determined using one-way ANOVA and Dunnett's multiple comparison test (*, P < 0.05;
**, P < 0.01).
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Figure 3.9
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3.1.7

Assessing the contribution of adhesin upregulation to
improved adhesion and internalization in antibiotic-primed
S. saprophyticus

Antibiotic-dependent changes in adherence were much more substantial when biotic
surfaces were used compared to abiotic urological device materials. This is likely not
solely attributable to changes in the surface chemistry of S. saprophyticus 15305 exposed
to antibiotic. Rather, the dramatic increase in relative adherence was postulated to be due
to the improved expression of adhesins on the S. saprophyticus 15305 surface. As UafA
is the most critical urothelial adhesion factor for this organism, its modulation was
investigated. Hemagglutination experiments suggested that UafA is in part responsible
for the increased adherence following ciprofloxacin therapy. The results demonstrate a
dose-dependent effect, with 1/16MIC ciprofloxacin levels inducing a 45.0% increased
level of hemagglutination (P < 0.05) (Figure 3.10A). The differences found between
hemagglutination by wild-type S. saprophyticus 15305 and the acapsular C1 strain,
demonstrate the blocking effect of the robust capsule. However, the greater
hemagglutination following ciprofloxacin-priming in the absence of capsule, suggests
that UafA surface expression was enhanced by antibiotics and not simply due to capsule
downregulation. This effect was also observed in S. saprophyticus 7108, suggesting
ciprofloxacin might have this affect across this species.
Adherence capacity to 5637 bladder cells following ciprofloxacin treatment was also
compared between wild-type and acapsular strains of S. saprophyticus. As predicted,
ciprofloxacin increased adhesion in both strains. These results further demonstrated that
increased adhesion is likely due to UafA upregulation, not capsule suppression. Total
wild-type adherence was increased from 0.7% to 5.2% for control and ciprofloxacin
treatment groups respectively (P < 0.05), while adherence increased from 18.4% to
83.7% in the acapsular strain (P < 0.001) (Figure 3.10B). Internalization was also found
to significantly increase in the absence of capsule, but in the presence of sub-inhibitory
ciprofloxacin. Total wild-type internalization was improved from 0.057% to 0.294% for
control and ciprofloxacin treatment groups respectively (P < 0.05), while internalization
was increased from 0.323% to 1.188% in the acapsular strain (P < 0.001) (Figure 3.10C).
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Figure 3.10. UafA-dependent hemagglutination of S. saprophyticus 15305, 7108, and the
acapsular C1 strain following exposure to various concentrations of ciprofloxacin (A),
and effect on 5637 bladder cell adherence (B) and internalization (C). Means from at
least three independent experiments are shown with significance. Significance was
determined using one-way ANOVA and Bonferroni's multiple comparison test (*, P <
0.05; **, P < 0.01; ***, P < 0.001).
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Figure 3.10
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3.1.8

Evaluating the capacity of sub-inhibitory antibiotics to
induce adhesin expression in E. coli

The results obtained for S. saprophyticus entertained the idea that E. coli might also
increase biofilm forming capacity following antibiotic-priming by upregulating critical
surface adhesins. As type 1 fimbriae have been demonstrated to be critical in urothelial
colonization, invasion, and UTI pathogenesis, antibiotic-dependent modulation of this
adhesin was postulated to contribute to biofilm formation. Type 1 fimbriae-dependent
hemagglutination was assessed over 24 hours and the results showed that expression
increased over time and in response to 1/4MIC and 1/16MIC ciprofloxacin (P < 0.05; P <
0.01; P < 0.001) (Figure 3.11A).
Previous results suggest that the SOS response might partially contribute to E. coli UTI89
biofilm formation when antibiotics are applied. Thus, it was reasonable to postulate an
SOS-dependent role in type 1 fimbriae regulation in E. coli UTI89. This was explored
using SOS-deficient E. coli UTI89 strains PAS0209 and PAS0211. Baseline type 1
fimbriae expression levels were not significantly changed in the SOS-deficient strains
(Figure 3.11B). Only wild-type E. coli UTI89 significantly increased hemagglutination
following exposure to 1/4MIC ciprofloxacin, ampicillin, and gentamicin (P < 0.05),
leaving SOS-deficient strains unaffected by antibiotic treatment.

3.1.9

Assessing the influence of sub-inhibitory antibiotics on E.
coli phase variation as a mechanism of type 1 fimbriae
expression

The mechanisms by which antibiotics improve adhesin expression in E. coli and S.
saprophyticus are unclear. However regulation of type 1 fimbriae is phase variable, and
the proportion of E. coli in phase ON or OFF orientation can be measured using PCR of
the fim-switch, with restriction digestion of amplicons yielding 489 and 359 base-pair
products for phase ON and OFF respectively (Figure 3.12A). Combined with
densitometric analysis, these bands can accurately elucidate the relative gene expression
of type 1 fimbriae in different conditions.
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Figure 3.11. Type I fimbriae-dependent hemagglutination of E. coli UTI89 exposed to
various subinhibitory concentrations of ciprofloxacin over time (A). Effect of 1/4MIC of
various antibiotics on hemagglutination of wild-type and SOS-deficient E. coli strains
(B). Means from at least three independent experiments are shown with significance.
Significance was determined using one-way ANOVA and Bonferroni's multiple
comparison test (ns = not significant; *, P < 0.05; **, P < 0.01; ***, P < 0.001).

92

Figure 3.11

93

Figure 3.12. Time-course indicating Type I fimbriae gene ON/OFF phase changes in
shaking or static cultures of E. coli UTI89 following exposure to various subinhibitory
concentrations of ciprofloxacin (A). Densitometric gel analysis indicates the percentage
of E. coli UTI89 with Type I fimbriae in the phase ON orientation during shaking (B) and
static (C) growth. Means from at least four independent experiments are shown with
significance. Significance was determined using one-way ANOVA and Bonferroni's
multiple comparison test (ns = not significant).
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Surprisingly, no significant changes were observed in OFF-ON phase variation in either
shaking (Figure 3.12B) or static (Figure 3.12C) cultures at any time point with any subinhibitory ciprofloxacin treatment. At this time it is unclear how antibiotics regulate the
expression of type 1 fimbriae in E. coli UTI89.

3.1.10 Evaluating the effect of sub-inhibitory antibiotics on
flagellar activity in E. coli
Sub-inhibitory antibiotics appear to signal uropathogens to upregulate factors important
to adherence and subsequently biofilm formation. Importantly, confounding factors
which promote motility would ideally be suppressed in order to achieve a fully sedentary,
adherent state. Thus, it is reasonable to postulate that flagellar activity would be
suppressed following the application of sub-inhibitory antibiotics. E. coli UTI89 and
SOS-deficient variants PAS0209 and PAS0211 were spot plated on soft-agar plates in the
presence or absence of sub-inhibitory antibiotics (Figure 3.13A). These strains were also
pre-treated with sub-inhibitory antibiotics prior to loading on untreated soft-agar plates to
assess antibiotic changes to flagella regulation during planktonic phase growth (Figure
3.13B). Interestingly, SOS-deficient strains demonstrated less motility compared to wildtype E. coli UTI89 in both conditions. In general, sub-inhibitory antibiotics suppressed
motility in all strains tested, with the exception of ciprofloxacin which significantly
upregulated swarming in the lexAT355G E. coli PAS0211 strain (Figure 3.13A). This
finding was recapitulated in antibiotic-primed organisms, with wild-type E. coli UTI89
demonstrating a greater swarming deficiency following ciprofloxacin treatment than its
SOS-deficient counterparts (Figure 3.13B).
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Figure 3.13. Swarming motility of wild-type and SOS-deficient strains of E. coli UTI89
in the presence of sub-inhibitory antibiotics. Strains were either plated directly onto softagar containing antibiotic (A), or pre-treated with antibiotics for 4 hours prior to plating
on unloaded soft-agar (B). Means from at least three independent experiments are shown
with significance. Significance was determined using one-way ANOVA and Bonferroni's
multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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3.1.11 Assessing sub-inhibitory antibiotic-depended changes in
gene expression in both E. coli UTI89 and S.
saprophyticus 15305
RNA sequencing was performed in order to better understand the pathways involved in
antibiotic tolerance and signalling, and to corroborate data generated using phenotypic
assays. Reads mapped to genomic coding regions were grouped by their annotated
function in order to evaluate the differences between control (no antibiotic), and short (30
minute) or long (4-6 hour) 1/4MIC antibiotic treatment groups for both E. coli UTI89 and
S. saprophyticus 15305. SEED Subsystem annotations were used to estimate expression
differences for subsystem 4 functions using ALDEx and expressed in the form of strip
plots where subsys4 functions were plotted by absolute fold-change between conditions.
Analysis of differential expression of E. coli UTI89 genes (Figure 3.14A, B) at the
broadest functional level (SEED subsystem 1) revealed high variation in responses
between 30 minutes (Figure 3.14A) and 4 hours (Figure 3.14B) of sub-inhibitory
ciprofloxacin exposure. Early responses in E. coli UTI89 are dominated by increased
relative abundance of transcripts related to DNA metabolism. Long-term exposure
revealed similar changes in DNA metabolism-related genes, in addition to increases in
the relative abundance of transcripts related to virulence and phage-components.
Transcripts related to stress, respiration, carbohydrate and amino acid metabolism were
generally found at a lower relative abundance following long-term ciprofloxacin
exposure.
The responses of S. saprophyticus 15305 to sub-inhibitory ciprofloxacin were markedly
different compared to those of E. coli UTI89 (Figure 3.14C, D). Early (30 minutes)
responses were dominated by increases in the relative abundance of transcripts related to
protein, DNA, and carbohydrate metabolism (Figure 3.14C). After prolonged
ciprofloxacin exposure (6 hours), stress response transcripts are abundant, in addition to
those related to respiration, and protein and carbohydrate metabolism (Figure 3.14D).
Despite ciprofloxacin's ability to induce DNA-related stress, there were few changes in
elements related to DNA maintenance in S. saprophyticus 15305 compared to E. coli
UTI89. In addition, overall changes in transcripts related to cellular activity (respiration
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Figure 3.14. Subsystem 1 categories indicating enriched subsystem 4 functions for E.
coli UTI89 (A, B) and S. saprophyticus 15305 (C, D) exposed to sub-inhibitory
ciprofloxacin for either 30 minutes (A, C), 4 hours (B), or 6 hours (D). Each point
represents a specific subsystem 4 function, and the magnitude in change is plotted on the
x-axis relative to ciprofloxacin treatment conditions. Points are coloured cyan (relative
transcript abundance decreased following treatment) or red (relative transcript abundance
increased following treatment) if significantly different between conditions, while grey
points are non-significant changes. A log2 median effect size of at least 1.5 was required
for genes to be considered differentially expressed. In addition, a less than 1% overlap in
the distributions between the two conditions was permitted for inclusion.
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Figure 3.14
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Figure 3.14 (continued)
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and metabolism) were increased in S. saprophyticus 15305 following ciprofloxacin
treatment while they were decreased in E. coli UTI89.
Assessing the changes in relative abundance of specific transcripts indicated several
genes that might contribute to adherence, invasion, and biofilm formation in both
uropathogens. The majority of early E. coli UTI89 responses were dominated by stressinducible elements including damage-inducible (din) genes (dinG, dinF, dinP, dinD),
nucleotide excision repair (NER) factors (uvrB, uvrD), and SOS regulon-associated
components sulA, lexA, and recN (Table 3.2). Late responses in this uropathogen were
comparatively more diverse, and included increased relative abundance in the
aforementioned transcripts, in addition to several phage components (kil2, erf, ninE2,
ninB2, ninB1, ral, cro, etc) (Table 3.3). Conversely, transcripts related to cell division
(minE, minD, minC), and metabolism regulatory elements (yjdE, lacY, nuoM, sdhA,
nuoF, nuoJ) were relatively decreased. Transcripts of the fimbrial repressor element focX,
and the luxR homolog sdiA were significantly decreased 1.48 and 4.37-fold following 4
hours of sub-inhibitory ciprofloxacin treatment. Conversely, putative fimbrial FimH
(fmlD) and hek [also known as heat resistant agglutinin-1 (Hra1)] adhesin transcripts
were significantly more abundant 4.84 and 2.47-fold in the ciprofloxacin treatment group
compared to control.
Early responses of S. saprophyticus 15305 to sub-inhibitory ciprofloxacin are
characterized by decreased relative abundance of transcripts related to cell wall
remodelling (SSP0843, SSP0988, SSP1294), and increases in transcripts related to
protein stabilization and folding (groEL, SSP0296), cell division inhibition (SSP1593),
metabolism (SSP0750, SSP2178, SSP1416, SSP0333, SSP1618, etc), exopolysaccharide
synthesis (capH, capL), and general stress responses (SSP1024) (Table 3.4). In addition,
an increased relative abundance of recA transcripts is indicative of DNA damage;
however, late responses demonstrate that S. saprophyticus 15305 does not commit to a
full-fledged SOS response during sub-inhibitory ciprofloxacin treatment as SOS regulon
transcripts (lexA, NER components, error-prone polymerases, etc) are absent (Table 3.5).
Rather, elements related to energy production and utilization (SSP1520, SSP1819,
SSP2178, SSP1814, SSP1358, SSP0776, SSP1068, etc), protein stabilization (SSP0296,
SSP1800, SSP1178, SSP1176, dnaK), and exopolysaccharide synthesis (SSP0769, capH)
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are present at greater relative abundance. In addition to exopolysaccharide, increased
presence of other virulence-related transcripts of unknown function included putative
virulence factor B and hemolysin III homolog. Together, the divergent responses detailed
by these transcriptomic data indicate that E. coli UTI89 and S. saprophyticus 15305
utilize distinct mechanisms to tolerant sub-inhibitory ciprofloxacin-dependent stress.
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Table 3.2 Significant changes in differentially expressed transcripts - E. coli UTI89
control versus 1/4MIC ciprofloxacin (short-term exposure)
Gene
Fold Change (log2)
Median Effect Size
Functional Annotation
UTI89_C1489
-0.724
-2.506
putative phage protein
cspE
-0.692
-2.523
cold shock protein
tqsA
-0.657
-2.375
pheromone autoinducer 2 transporter
UTI89_C4928
-0.593
-1.923
unknown
UTI89_C5141
-0.473
-1.83
unknown
ydfZ
-0.395
-1.765
putative selenium-binding protein
lysU
0.183
2.229
lysyl-tRNA synthetase
ydeN
0.2
2.107
sulfatase
selD
0.23
1.858
selenophosphate synthetase
ftsK
0.272
1.626
DNA translocase FtsK
manX
0.273
1.539
PTS system mannose-specific transporter
UTI89_C0964
0.286
1.873
putative phage regulator Cox
UTI89_C2924
0.287
1.555
unknown
pgk
0.318
1.741
phosphoglycerate kinase
selA
0.319
2.761
selenocysteine synthase
tatB
0.349
2.477
sec-independent translocase
int
0.421
2.904
integrase
uvrB
0.45
1.719
excinuclease ABC subunit B
uvrD
0.629
2.117
DNA-dependent helicase II
ruvB
0.645
2.529
Holliday junction DNA helicase
dinG
0.72
3.94
ATP-dependent DNA helicase
polB
0.724
5.097
DNA polymerase II
umuC
0.763
3.12
DNA polymerase V subunit
UTI89_C5142
0.764
4.032
unknown
ydjQ
0.783
2.352
nucleotide excision repair endonuclease
ruvA
0.791
3.18
Holliday junction DNA helicase
dinP
0.892
4.023
DNA polymerase IV
sulA
0.998
2.459
SOS cell division inhibitor
yebG
1.156
2.754
DNA damage-inducible protein
dinD
1.159
2.447
DNA-damage-inducible protein
recA
1.184
2.78
DNA repair, SOS induction
UTI89_C4473
1.221
3.011
putative lipase
dinF
1.3
7.118
DNA-damage-inducible SOS response protein
lexA
1.334
2.877
repressor of LexA
UTI89_C1922
1.371
2.442
contains a metal-dependent hydrolase
umuD
1.58
3.75
DNA polymerase V subunit
UTI89_C5143
2.021
5.049
putative DinI
recN
2.255
7.558
recombination and repair protein
Genes indicated in bold are putative SOS regulon-associated elements.
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Table 3.3 Significant changes in differentially expressed transcripts - E. coli UTI89
control versus 1/4MIC ciprofloxacin (long-term exposure)
Gene
adiA
UTI89_C1489
UTI89_C5141
UTI89_C0936
UTI89_C0914
UTI89_C0938
yjdE
UTI89_C0915
lacY
UTI89_C1011
UTI89_C5140
nuoM
ycdB
sdhA
ycgE
UTI89_C3113
UTI89_C2270
UTI89_C1363
focX
minE
nuoF
nuoJ
minD
UTI89_C2959
minC
nuoN
UTI89_C2766
msrB
dadA
ldcA
sdhB
UTI89_C0728
UTI89_C0965
sdiA
cyoB
cydB
ynjC
pntA
ycdW
ompA
UTI89_C1090
UTI89_C1960
UTI89_P009
znuA
UTI89_C0750
UTI89_C1017
accB

Fold Change (log2)
-1.442
-1.363
-0.966
-0.953
-0.88
-0.852
-0.816
-0.69
-0.683
-0.675
-0.675
-0.674
-0.657
-0.652
-0.635
-0.625
-0.598
-0.595
-0.562
-0.556
-0.551
-0.538
-0.517
-0.507
-0.499
-0.49
-0.49
-0.486
-0.485
-0.484
-0.478
-0.476
-0.453
-0.45
-0.45
-0.446
-0.442
-0.43
-0.422
-0.395
-0.389
-0.386
-0.378
-0.375
-0.374
-0.374
-0.373

Median Effect Size
-1.986
-3.627
-3.129
-2.399
-2.183
-3.202
-1.872
-2.872
-2.556
-2.931
-2.452
-1.896
-2.834
-1.764
-2.305
-2.276
-2.1
-2.616
-2.156
-3.683
-1.595
-2.15
-2.349
-3.758
-2.276
-6.227
-1.517
-2.088
-2.048
-2.924
-1.822
-1.858
-2.388
-2.255
-1.926
-1.943
-2.437
-1.864
-2.437
-2.505
-3.108
-2.637
-3.015
-2.107
-2.939
-1.866
-3.511

Functional Annotation
biodegradative arginine decarboxylase
putative phage protein
unknown
small terminase subunit of phage
phage tail sheath protein
phage capsid scaffolding protein
arginine:agmatin antiporter
phage tube protein FII
lactose permease
putative iron-sulfur protein, 2Fe-2S clusters
unknown
NADH dehydrogenase subunit M
unknown
succinate dehydrogenase flavoprotein subunit
HTH-transcriptional repressor
putative lipoprotein NlpD
putative phospholipase
putative prophage protein
repressor of S fimbrial adhesin
cell division topological specificity factor
NADH dehydrogenase I subunit F
NADH dehydrogenase subunit J
cell division inhibitor
putative prophage protein
septum formation inhibitor
NADH dehydrogenase subunit N
putative acetyltransferase
methionine sulfoxide reductase B
D-amino acid dehydrogenase small subunit
L,D-carboxypeptidase A
succinate dehydrogenase iron-sulfur subunit
putative cytochrome d ubiquinol oxidase
bacteriophage WPhi phage protein C
putative quorum sensing homolog of LuxR
cytochrome o ubiquinol oxidase subunit I
cytochrome d terminal oxidase polypeptide
ABC transporter solute-binding protein
NAD(P) transhydrogenase subunit alpha
glyoxylate/hydroxypyruvate reductase A
outer membrane protein A
unknown
putative NAD(P)H nitroreductase
ubiquinone
high-affinity periplasmic zinc transporter
homeobox protein
unknown
acetyl-CoA carboxylase biotin carboxyl carrier
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Table 3.3 (continued)
Gene
ybbM
gdhA
dhaK
ydiA
fumA
cspD
uspC
cstA
mukE
narX
yecA
gltP
UTI89_C0891
metH
UTI89_C0833
folX
ybbL
yjeQ
mfd
artP
ompC
UTI89_C1133
hlpA
pflB
UTI89_C2496
ydhO
asnC
UTI89_C1472
cld
yfhM
UTI89_C3005
sfcA
ftsK
selA
osmB
UTI89_C1937
spy
uvrB
int
ibpA
endA
yebF
UTI89_C2389
yfdQ2
ydeP
uvrD
UTI89_C2643

Fold Change (log2)
-0.372
-0.369
-0.363
-0.361
-0.359
-0.333
-0.329
-0.326
-0.323
-0.301
-0.3
-0.29
-0.288
-0.286
-0.28
-0.276
-0.272
-0.272
-0.268
-0.268
-0.256
-0.251
-0.247
-0.244
-0.242
-0.234
-0.234
-0.226
-0.224
-0.202
-0.189
-0.158
0.304
0.306
0.383
0.395
0.432
0.483
0.518
0.534
0.553
0.623
0.624
0.703
0.772
0.812
0.814

Median Effect Size
-1.949
-1.895
-2.752
-1.797
-2.513
-1.691
-2.774
-2.034
-1.946
-2.111
-1.9
-2.84
-2.945
-1.919
-2.111
-2.138
-1.997
-1.994
-1.821
-1.656
-1.746
-3.115
-1.799
-1.563
-1.872
-1.742
-1.707
-1.859
-1.839
-1.85
-2.077
-2.021
1.962
2.218
2.223
1.826
1.99
3.317
2.698
1.501
1.934
1.933
1.999
1.94
2.381
2.591
2.455

Functional Annotation
metal resistance protein
glutamate dehydrogenase
dihydroxyacetone kinase subunit
unknown
class I fumarase
stationary phase/starvation regulator
universal stress protein
carbon starvation protein A
condensin subunit E
nitrate/nitrite sensor protein
unknown
glutamate/aspartate:proton symporter
CRISPR helicase Cas3/CRISPR protein Cas1
B12-dependent methionine synthase
hemin-binding lipoprotein
pterin biosynthesis
ABC transporter ATP-binding protein
ribosome-associated GTPase
transcription-repair coupling factor
arginine transporter ATP-binding subunit
porin
putative HcpC beta-lactamase precursor
periplasmic chaperone
putative formate acetyltransferase 1
putative outer membrane protein
putative lipoprotein
asparaginyl-tRNA synthetase
unknown
length regulator of LPS O-antigen chains
putative lipoprotein
unknown
malate dehydrogenase
DNA translocase FtsK
selenocysteine synthase
lipoprotein
unknown
spheroplast protein Y
excinuclease ABC subunit B
integrase
heat shock protein
endonuclease I
unknown
putative molybdate metabolism regulator
unknown
oxidoreductase
DNA-dependent helicase II
gene 16-like, phage DNA transfer protein
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Table 3.3 (continued)
Gene
uvrA
ruvB
UTI89_C4650
ruvA
polB
rmuC
UTI89_C1713
UTI89_C1753
ibpB
yfdQ1
dinG
UTI89_C1023
UTI89_C5093
ydjQ
UTI89_C0582
UTI89_C2644
hek
asnA
umuC
UTI89_P101
dinD
UTI89_C2690
dinP
UTI89_C2653
UTI89_P099
sulA
UTI89_C5142
UTI89_C2647
hkaH
UTI89_C4473
UTI89_P091
UTI89_C2675
UTI89_C2648
UTI89_C5096
UTI89_C2649
recA
UTI89_C2646
UTI89_C5091
UTI89_C0801
UTI89_C2654
UTI89_C2657
cro
UTI89_C2651
UTI89_C2660
UTI89_C2672
dinF
yahM

Fold Change (log2)
0.919
0.949
0.964
0.985
1.149
1.151
1.151
1.158
1.171
1.177
1.221
1.229
1.256
1.257
1.276
1.302
1.304
1.306
1.318
1.335
1.365
1.369
1.407
1.447
1.468
1.499
1.585
1.593
1.598
1.611
1.64
1.653
1.681
1.735
1.744
1.751
1.787
1.792
1.808
1.865
1.871
1.93
1.932
1.95
1.97
1.988
1.996

Median Effect Size
1.976
4.379
1.74
7.498
4.389
1.688
3.164
2.055
2.118
2.653
6.389
2.915
2.315
2.289
1.653
3.853
3.475
2.394
6.519
5.005
4.762
1.966
3.789
2.66
2.501
4.158
6.784
2.296
1.913
3.933
2.56
1.992
3.111
2.274
2.331
3.75
2.712
1.892
2.066
2.878
2.54
2.69
2.896
3.036
2.46
5.541
2.198

Functional Annotation
excinuclease ABC subunit A
Holliday junction DNA helicase
putative SoxR
Holliday junction DNA helicase
DNA polymerase II
DNA recombination protein
HTH/AraC transcriptional regulator
maltoporin-like protein
heat shock chaperone
unknown
ATP-dependent DNA helicase
unknown
unknown
nucleotide excision repair endonuclease
unknown
gene 20-like, phage DNA transfer protein
Hek adhesin/virulence factor
asparagine synthetase AsnA
DNA polymerase V subunit
unknown
DNA-damage-inducible protein
putative phage protein
DNA polymerase IV
gene 1-like, phage portal protein
unknown
SOS cell division inhibitor
unknown
gene 26-like, phage head assembly protein
unknown
putative lipase
unknown
CII, involved in the initiation of lysogeny
gene 10-like bacteriophage DNA stabilizer
regulatory phage protein
putative P22 tail-4 accessory factor
DNA repair, SOS induction
gene 14-like, putative phage protein
putative phage protein
unknown
gene 2-like, putative phage terminase
putative phage regulatory protein Rha
phage Cro protein
putative phage capsid/coat protein
gene R-like, bacteriophage lysozyme
bacteriophage Nil2 gene P DnaB analogue
DNA-damage-inducible SOS response protein
unknown
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Table 3.3 (continued)
Gene
Fold Change (log2)
Median Effect Size
Functional Annotation
UTI89_C1922
2
6.13
contains a metal-dependent hydrolase
lexA
2.03
5.635
repressor of LexA
yebG
2.081
5.7
DNA damage-inducible protein
UTI89_C2655
2.091
2.899
putative phage terminase
hkbD
2.094
2.575
unknown
UTI89_C2678
2.121
2.269
regulatory phage protein
ral
2.145
2.189
bacteriophage lambda restriction inhibitor
UTI89_C2692
2.147
1.688
putative prophage protein
UTI89_C2691
2.151
1.632
putative phage protein
UTI89_C2656
2.157
1.743
putative phage protein
yfdr1
2.191
2.945
unknown
UTI89_C2674
2.191
3.653
unknown
roi
2.2
2.988
DNA-binding protein
UTI89_C2681
2.236
2.501
unknown
UTI89_C4883
2.239
4.363
unknown
UTI89_C2663
2.246
1.846
bacteriophage ST64T anti-terminator gp23
UTI89_C2652
2.263
1.947
gene 8-like phage scaffold protein
fmlD
2.275
1.891
fimbrial fimH mannose-binding
ninB1
2.279
2.981
NinB protein encoded within prophage
UTI89_C2673
2.301
2.895
bacteriophage replication protein O
umuD
2.307
5.395
DNA polymerase V subunit
UTI89_C2679
2.309
2.898
phage regulatory protein N
UTI89_C2645
2.322
2.858
gene 7-like, putative phage protein
UTI89_C2650
2.342
3.263
unknown
UTI89_C1186
2.347
4.136
DinI
UTI89_C1282
2.366
2.066
lambda ant-restriction protein
UTI89_C2661
2.397
2.792
gene S-like, putative phage holin
kil2
2.403
2.021
kil protein of bacteriophage HK97
UTI89_C2685
2.456
1.98
putative phage protein
UTI89_C2693
2.474
2.163
unknown
ninB2
2.491
2.862
putative phage NinB protein
rus
2.53
2.868
Holliday-junction resolvase
hkaJ
2.546
2.29
anti-RecBCD 2, putative phage protein
UTI89_C2682
2.546
2.385
putative lambda CIII
ninH
2.563
2.663
putative phage NinH protein
ninE2
2.575
2.36
bacteriophage lambda nin 60-like protein
UTI89_C2687
2.579
2.085
bacteriophage HK97 gp40
UTI89_C2668,
2.594
3.964
unknown
erf
2.631
2.258
bacteriophage HK97 gp40
UTI89_C5143
2.786
7.032
putative DinI
UTI89_C2684
2.888
2.267
bacteriophage kil protein
recN
2.949
15.096
recombination and repair protein
Genes indicated in bold are putative SOS regulon-associated elements.
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Table 3.4 Significant changes in differentially expressed transcripts - S.
saprophyticus 15305 control versus 1/4MIC ciprofloxacin (short-term exposure)
Gene
SSP0843
SSP1254
SSP2255
SSP0308
SSP0988
SSP0831
SSP2065
SSP1669
SSP2275
rho
trmD
SSP1294
SSP1850
SSP1520
groEL
SSP2237
SSP1797
SSP1024
SSP0325
SSP1233
gmk
SSP1618
SSP1782
SSP2198
SSP1593
SSP0336
SSP0333
aspS
SSP0052
SSP0499
SSP1470
SSPP216
capH
rplW
SSPP115
rplF
SSP1466
SSP0960
SSP1059
SSP2075
rplE
SSP1180
SSP0717
rpmD
SSP2208
SSP1416
valS

Fold Change (log2)
-0.47
-0.431
-0.369
-0.349
-0.309
-0.29
-0.231
-0.222
-0.205
-0.171
-0.167
-0.161
-0.134
0.141
0.192
0.192
0.21
0.215
0.225
0.229
0.235
0.252
0.266
0.271
0.278
0.28
0.282
0.286
0.293
0.297
0.31
0.31
0.311
0.316
0.323
0.334
0.352
0.353
0.362
0.363
0.375
0.377
0.399
0.404
0.427
0.445
0.461

Median Effect Size
-1.969
-2.204
-3.692
-1.977
-2.205
-1.76
-1.626
-1.684
-3.166
-1.582
-2.157
-3.773
-2.178
1.59
1.795
1.873
2.094
1.861
2.619
1.692
2.473
2.29
2.265
2.2
4.602
2.475
1.929
2.449
5.154
2.823
3.996
2.033
4.685
2.015
2.099
1.903
1.72
1.835
1.586
1.663
1.787
3.269
1.812
7.223
1.508
1.516
1.702

Functional Annotation
amidohydrolase
Fur-family transcriptional regulator
50S ribosomal protein L25 Ctc
unknown
mannosyl-protein endo-beta-N-acetylglucosamidase
putative mutS DNA mismatch repair protein
lipase
unknown
Orn Lys Arg decarboxylase
transcription termination factor Rho
tRNA (guanine-N(1)-)-methyltransferase
penicillin-binding protein 2
lipoyl synthase
succinyl-CoA synthetase subunit alpha
chaperonin
pyridoxal biosynthesis lyase PdxS
3-oxoacyl-[acyl-carrier-protein] synthase II
putative general stress protein
acetyl-CoA acetyltransferase
geranylgeranyl pyrophosphate synthase
guanylate kinase
6-phospho-3-hexuloisomerase domain, PHI
hemoglobin-like protein
3-hydroxybutyrate dehydrogenase
cell division inhibitor protein MraZ
glucose-specific PTS transporter IIABC
pyruvate oxidase
aspartyl-tRNA synthetase
restriction endonuclease S subunit
formate nitrite family transporter
unknown
putative cadmium resistance transporter
glycosyl transferase
50S ribosomal protein L23
arsenic efflux pump protein
50S ribosomal protein L6
thiamine-precursor transporter protein
putative gas vesicle protein
Xaa-Pro dipeptidase
nucleoside transporter
50S ribosomal protein L5
16S ribosomal RNA methyltransferase RsmE
putative hemolysin III homolog
50S ribosomal protein L30
elongation factor G
transketolase
valyl-tRNA synthetase
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Table 3.4 (continued)
Gene
Fold Change (log2)
Median Effect Size
Functional Annotation
capL
0.467
1.874
capsular polysaccharide synthesis protein
SSP1124
0.488
2.209
adenine phosphoribosyltransferase
SSP0532
0.503
1.554
major facilitator superfamily permease
SSP0508
0.506
1.844
proton sodium-glutamate symport protein
SSP1005
0.513
2.051
major facilitator superfamily permease
SSP2277
0.527
2.023
unknown
SSP2178
0.535
2.218
ribulokinase
SSP2259
0.543
2.785
translation initiation inhibitor
SSP2346
0.609
3.203
unknown
SSP0197
0.689
4.328
unknown
SSP0296
0.696
2.437
copper chaperone
SSP0750
0.753
2.207
putative phosphopentomutase
recA
0.765
1.82
recombinase A
SSP2138
0.92
1.997
unknown
Genes indicated in bold are putative SOS regulon-associated elements.
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Table 3.5 Significant changes in differentially expressed transcripts - S.
saprophyticus 15305 control versus 1/4MIC ciprofloxacin (long-term exposure)
Gene
SSP0584
SSP1390
SSP0895
SSP1043
SSP2255
SSP0485
SSPP138
SSP0021
SSP1267
clpX
SSP2206
SSP1850
SSP2074
capB
SSP0052
mutL
SSP0623
SSP1520
SSP1819
prfC
SSP1300
SSP1360
rpmD
capH
SSP1618
SSP1953
SSP0834
gatB
aroB
SSP1593
SSP0499
SSP0336
SSP1064
SSP0948
dnaK
SSP1175
SSP0025
SSP2232
SSP1068
SSP0845
SSP1466
SSP0762
SSP0269
SSP0851
SSP2242
rpsM
SSP0776

Fold Change (log2)
-0.501
-0.48
-0.467
-0.432
-0.349
-0.337
-0.315
-0.277
-0.22
-0.163
-0.162
-0.15
-0.148
-0.123
0.156
0.165
0.17
0.188
0.191
0.192
0.195
0.243
0.246
0.248
0.271
0.282
0.283
0.293
0.3
0.301
0.304
0.308
0.308
0.315
0.316
0.329
0.33
0.34
0.348
0.351
0.361
0.368
0.375
0.375
0.39
0.394
0.402

Median Effect Size
-1.777
-1.647
-1.839
-1.935
-9.872
-1.968
-2.058
-2.125
-2.108
-2.868
-2.167
-2.705
-2.187
-1.645
2.334
1.641
1.525
5.695
3.238
1.992
2.844
1.556
1.901
2.519
4.58
1.919
2.595
1.579
2.241
2.943
2.53
2.463
3.309
2
1.829
3.893
3.233
2.819
2.358
3.597
3.088
1.506
2.264
2.294
2.591
3.536
2.505

Functional Annotation
unknown
methionine sulfoxide reductase regulator MsrR
unknown
spermidine acetyltransferase
50S ribosomal protein L25 Ctc
major facilitator superfamily permease
IS431 transposase
two component response regulator OmpR-like protein
thioredoxin reductase
ATP-dependent protease ATP-binding subunit ClpX
peptidase
lipoyl synthase
unknown
polysaccharide synthesis length determinator
restriction endonuclease S subunit
DNA mismatch repair protein
iron-siderophore ABC transporter periplasmic protein
succinyl-CoA synthetase subunit alpha
NADH:flavin oxidoreductase
peptide chain release factor 3
permease
putative virulence factor B
50S ribosomal protein L30
glycosyl transferase
6-phospho-3-hexuloisomerase domain, PHI
thioredoxin reductase
sulfur transporter
aspartyl/glutamyl-tRNA amidotransferase subunit B
3-dehydroquinate synthase
cell division inhibitor protein MraZ
formate nitrite family transporter
glucose-specific PTS transporter IIABC
DNA polymerase III alpha chain
proton glutamate symporter
molecular chaperone heat shock protein 70
heat-inducible transcriptional repressor
beta-lactamase metal-dependent hydrolase
ATP:guanido phosphotransferase
6-phosphofructokinase
unknown
putative thiamine-precursor transporter protein
aldehyde dehydrogenase
oligopeptide-peptide ABC transporter permease
acetyltransferase
dihydropteroate synthase
30S ribosomal protein S13
ATP synthase F0F1 subunit C
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Table 3.5 (continued)
Gene
Fold Change (log2)
Median Effect Size
Functional Annotation
SSP1358
0.416
2.286
aldo keto reductase
SSP1814
0.418
2.248
argininosuccinate synthase
SSP1176
0.421
1.576
heat shock protein GrpE
SSP0767
0.429
1.836
rRNA or tRNA methylase
SSP1005
0.43
2.005
major facilitator superfamily permease
SSP1729
0.457
1.58
putative bacterial Ig-like 3-domain protein
SSP1627
0.468
1.989
short-chain alcohol dehydrogenase
SSP0208
0.471
4.741
nitroreductase
SSP0960
0.473
2.961
putative gas vesicle protein
SSPP218
0.532
3.139
cadmium efflux system accessory protein
SSP1178
0.538
2.667
chaperone protein DnaJ
SSP0178
0.561
1.559
glycerate kinase
SSP2233
0.593
3.447
McsA modulator of heat shock repressor CtsR
SSP2178
0.662
3.863
ribulokinase
SSP0197
0.676
2.829
unknown
gidB
0.691
2.35
glucose inhibited division protein B
SSP1800
0.77
2.841
putative ATP-depended chaperone ClpB
SSP2138
0.795
1.633
unknown
SSP0296
0.85
3.989
copper chaperone
SSP0769
1.084
1.816
exopolysaccharide-associated tyrosine-phosphatase
Genes indicated in bold are putative SOS regulon-associated elements.
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3.2 DEMONSTRATING THE INFLUENCE OF SUBINHIBITORY CIPROFLOXACIN ON
UROPATHOGENENESIS IN A MURINE MODEL OF
UTI
Having demonstrated antibiotic-dependent changes in vitro, the next logical step was to
establish the potential clinical relevance and therapeutic implications in vivo. This work
used a well defined murine model of UTI and was conducted in the laboratory of Dr.
Scott Hultgren (Washington University School of Medicine in St Louis, MO) over four
months, with funding by a Canadian Institutes of Health Research - Michael Smith
Foreign Study Supplement.

3.2.1

Evaluating the pathogenic potential of ciprofloxacinprimed S. saprophyticus and E. coli during acute phase
infection

The outcome of UTI is generally accepted to be determined within the first 24 hours of
inoculation, with underlying host and pathogen factors contributing to either resolution,
or establishment of chronic infection. Generally, these trends are observed at this time as
a bimodal distribution of bacterial load, with ~50% of C3H/HeN mice revealing signs of
resolution, and the remainder sustaining high titers. The bacterial load after initial
infection with untreated or ciprofloxacin-primed uropathogens was assessed to determine
the effect of sub-inhibitory antibiotics on colonization after 24 hpi. A typical bimodal
distribution of bacterial loads was observed at this time point, with ciprofloxacin-priming
prior to infection resulting in higher overall bladder and kidney titers for both S.
saprophyticus 15305 and E. coli UTI89 after 24 hours (Figure. 3.15). Almost 100% of
murine kidneys showed no signs of infection clearance at this time point for both
organisms primed with ciprofloxacin.
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Figure 3.15. S. saprophyticus 15305 and E. coli UTI89 titers in C3H/HeN mouse
bladders and kidneys following 24 hour infections. Starter cultures were reconstituted in
fresh media supplemented with 1/4MIC ciprofloxacin for 4 hours prior to infection.
Dotted line indicates limit of detection. Means from at least three independent
experiments shown with significance. Significance was determined using Mann-Whitney
test (Gaussian approximation) (*, P < 0.05).
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Figure 3.15

116

3.2.2

Establishing the effect of ciprofloxacin priming on chronic
UTI risk in S. saprophyticus and E. coli infected mice

In order to determine the frequency of chronic cystitis and pyelonephritis in antibioticprimed versus control pathogens, infection periods were extended to 14 days postinoculation (dpi). C3H/HeN mice were either inoculated with untreated or ciprofloxacinprimed S. saprophyticus 15305 and E. coli UTI89 as described. Following sacrifice,
bladders and kidneys were plated, and uropathogens enumerated to determine bacterial
load. In addition to increasing bacterial load 24 hpi, ciprofloxacin-priming resulted in
significantly worse infections 14 dpi (P < 0.05) (Figure 3.16). The clinical threshold for
assessing lifetime chronic infection risk is the presence of E. coli UTI89 loads of >104
cfu/mL at 14 dpi (such data does not exist for S. saprophyticus) (Hannan et al., 2010).
Control animals infected with E. coli UTI89 demonstrated expected bimodal results, with
40% of mice spontaneously resolving their infections after 14 days. Conversely,
ciprofloxacin-priming resulted in 100% of mice developing chronic E. coli UTI89
infections. Similarly, 50% of control mice showed signs of kidney clearance while only
20% showed similar results for ciprofloxacin-primed groups. Although there are no
established clinically significant S. saprophyticus 15305 infection thresholds for this
model, it is interesting that 100% of mice resolved cystitis in the control group while 50%
maintained bladder titers with ciprofloxacin-priming. In addition, 100% of primed S.
saprophyticus 15305 treated mice maintained at least some infectious kidney titer, while
only 60% exhibited the same result in control groups.

3.2.3

Evaluating ciprofloxacin modulation of pathogenic
mechanisms which contribute to chronic infection

Changes in intracellular bladder populations during the early stages of infection were
assessed using gentamicin-protection assays (3.5 hpi) for S. saprophyticus 15305, and
microscopy (6 hpi) for E. coli UTI89. Analysis parameters varied as both E. coli UTI89
and S. saprophyticus 15305 exploit distinct pathogenic mechanisms to establish chronic
infection. E. coli IBC formation was detected by staining for lacZ expression using XGal. IBCs are visible as punctate blue stains under examination using a dissecting
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Figure 3.16. S. saprophyticus 15305 and E. coli UTI89 titers in C3H/HeN mouse
bladders and kidneys following 14 day infections. Starter cultures were reconstituted in
fresh media supplemented with 1/4MIC ciprofloxacin for 4 hours prior to infection.
Dotted line indicates limit of detection. Means from at least three independent
experiments shown with significance. Significance was determined using Mann-Whitney
test (Gaussian approximation) (*, P <0.05).

118

Figure 3.16
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microscope (Figure 3.17A). This technique indicated significantly more IBCs in
ciprofloxacin-primed groups versus control (P < 0.01) (Figure 3.17B). Ex vivo
gentamicin protection assays of murine bladders revealed a similar trend, with categorical
increases in intracellular S. saprophyticus 15305 populations observed in ciprofloxacinprimed organisms (P = 0.0019) (Figure 3.17C). Although total invasion events were rare
in S. saprophyticus 15305, intracellular reservoirs were comparatively much lower in the
untreated group, with only 30% of mice demonstrating pathogen presence compared to
100% in treated groups.

3.2.4

Investigating IBC and cellular morphology in ciprofloxacinprimed E. coli

In addition to being more numerous, IBCs also appeared larger under light microscopy
following antibiotic exposure. This observation was further explored using a green
fluorescent protein (GFP) expressing E. coli UTI89 strain and confocal microscopy.
Murine bladders were removed and prepared as previously described, but fixed and
stained with fluorescent wheat germ agglutinin (WGA) and SYTO9 for cell surface and
nuclei detection respectively. Appearance of control E. coli UTI89 was unremarkable as
IBCs demonstrated characteristic tight, globular clustering (Figure 3.18A). Examination
of ciprofloxacin-primed E. coli UTI89 revealed larger, diffuse IBCs with atypical
morphology (Figure 3.18B). Early filamentation was noted in several of the IBCs
belonging to the ciprofloxacin treated E. coli UTI89 group (Figure 3.18C). Volumetric
analysis of the IBCs confirmed that ciprofloxacin-priming significantly increased overall
size 2.0-fold (P = 0.0007).
The ability for ciprofloxacin to induce filamentation was investigated further as this
process might contribute to observed early IBC evacuation. Cultures of E. coli UTI89
were treated with sub-inhibitory ciprofloxacin and imaged using TEM. Control E. coli
UTI89 were unremarkable, appearing ~1-2 µm in length (Figure 3.19A). Most organisms
in the ciprofloxacin treatment group appeared similar in nature; however, ~10% of the
overall population presented with the observed filamenting phenotype, sometimes
increasing to >10 µm in length (Figure 3.19B).
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Figure 3.17. E. coli UTI89 IBC detection using lacZ staining in C3H/HeN mouse
bladders (A) and quantification (B) following 6 hour infections. Number of intracellular
S. saprophyticus 15305 isolated from murine bladders following a gentamicin protection
assay (C). Whole bladders were plated and S. saprophyticus colonies identified using
lacZ staining. Means from at least two independent experiments are shown with
significance. Significance determined using Mann-Whitney test (B) with Gaussian
approximation (C) (**, P < 0.01; ***, P = 0.0019).
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Figure 3.17

122

Figure 3.18. Representative confocal images of control (A) and antibiotic pre-treated (B)
E. coli UTI89 IBCs in C3H/HeN mouse bladders following 6 hour infections (red =
GFP/UTI89; blue = SYTO9/nuclei; green = WGA/cell). Early pathogen evacuation from
an IBC via filamentation in a ciprofloxacin pre-treated sample is shown (indicated with
arrows - C). Volumetric analysis of confocal images is depicted for both control and
antibiotic pre-treated IBCs (D). Means from at least two independent experiments are
shown with significance. Significance was determined using a Mann-Whitney test (***,
P = 0.0007).
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Figure 3.18

124

Figure 3.19. Representative TEM images of non-treated (A) and 1/4MIC ciprofloxacin
treated (B) E. coli UTI89 filamentation. The first panel depicts individual and clustered
rod and coccoidal E. coli while the second panel reveals filamenting and non-filamenting
organisms. Magnification for each micrograph is indicated.
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Figure 3.19
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3.2.5

Assessing the effect of sub-therapeutic ciprofloxacin on
recurrence risk in 'resolved' mice and infection severity
chronically infected mice

Thus far, experimental models have only made use of ciprofloxacin-primed
uropathogens, with mice receiving no antibiotic exposure. To overcome this, a new
model of infection was established whereby mice were supplemented with subtherapeutic ciprofloxacin in their drinking water daily. Sub-therapeutic antibioticdependent changes in bacterial urine titers of mice who were previously inoculated with
E. coli UTI89 but had spontaneously resolved (<104 cfu/mL bacterial urine load) their
infection were initially considered. Urine titers were tracked for three days in the absence
of antibiotic to determine baseline cfu/mL. Over this period no mice presented with
clinically significant infection (>104 cfu/mL) (Figure 3.20A). Antibiotics at 1/50th the
empirical therapeutic concentration were then supplemented into the drinking water and
changes in bacterial urine load were tracked. This dose significantly increased the
frequency of mice with clinically significant infection from 0% to 80% occurrence (P =
0.0131) (Figure 3.20A). The dose was further increased to 1/25th the empirical
therapeutic dose with no changes observed in the remaining mice (Figure 3.20A).
Increasing the dose to 1/10th the empirical therapeutic dose resulted in retraction of
bacterial urine loads to the limit of detection, suggesting that observed antibioticdependent increases were not due to the appearance of resistant mutants (data not shown).
Although it can be concluded that ciprofloxacin initiated infection recurrence, it is
unclear whether this was due to re-infection with a new strain or recalcitrance of the
previously inoculated pathogen.
The effect of inadequate dosing was also assessed in mice with chronic infection (>104
cfu/mL for ≥ 14 dpi). This experiment was undertaken to test if antibiotics would worsen
an already established infection, such as might occur during low-dose, extended use
prophylaxis. Chronically infected mice were supplemented with 1/50th the empirical
therapeutic dose for three days, with urine titers measured after this period. This
significantly increased E. coli UTI89 urine load by an order of magnitude of 1.7 (P <
0.001) (Figure 3.20B). Again, treatment with 1/10th of the therapeutic dose was sufficient
to decrease cfu/mL to the limit of detection indicating spontaneous resistant mutants did
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Figure 3.20. Fraction of 'resolved' C3H/HeN mice presenting with clinically significant
(>104 cfu/mL) bacterial urine titers following sub-therapeutic ciprofloxacin dosing over
time (N = 10 mice; A). Antibiotic dosing period is indicated in the upper x-axis as
fractions of the therapeutic dose. Urine titers of chronically infected mice receiving either
no antibiotic or sub-therapeutic ciprofloxacin for three days (B). Means from at least two
independent experiments are shown with significance. Significance was determined using
a Logrank (A; P = 0.0131) or one-way ANOVA and Bonferroni's multiple comparison
test (B) (***, P < 0.001).
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not contribute to increased titers during dosing (Figure 3.20B). The application of
ciprofloxacin resulted in more significant infections than when organisms were primed
prior to inoculation. This observation suggests that additional factors unrelated to the
pathogens themselves are potentially enhancing virulence.

3.2.6

Evaluating the capacity of ciprofloxacin to modulate
urothelial immune responses

It was postulated that the changes in infection frequency and severity observed in mice
could in part be attributed to the immunomodulatory capacity of ciprofloxacin on the
host. This was first tested in a controlled in vitro experiment using bladder cell lines.
Cytokines interleukin (IL)-6 and IL-8 were analyzed for their role in recruiting
neutrophils to urothelial infection sites using a Luminex® bead-based assay. Baseline
expression was compared to infection groups in the absence of antibiotics and results
showed a typical spike in cytokine secretion for both molecules (P < 0.001) (Figure
3.21A, B). All sub-inhibitory ciprofloxacin concentrations reduced IL-6 and IL-8
secretion to below baseline levels (P < 0.05; P < 0.01; P < 0.001). The finding that even
low ciprofloxacin doses induced suppression of cytokine release was reflective of the
drug's potency at physiologically relevant concentrations.
The findings observed in the T24 bladder cell lines were recapitulated in 5637 bladder
cells. Ampicillin and gentamicin were also tested at 1/4MIC levels to assess the
specificity of immune suppression. S. saprophyticus 15305 infections were carried out as
described, and supernatants were analyzed for IL-8 expression using an enzyme linked
immunosorbent assay (ELISA). While ciprofloxacin treatment reduced IL-8 secretion to
below baseline levels (P < 0.05) (Figure 3.21D), ampicillin and gentamicin did not
induce this effect. An additional experimental group containing LPS was applied as a
cell-free control to ensure S. saprophyticus 15305 was not influencing the release of
cytokine. LPS in the absence of antibiotic caused a predicted spike in IL-8 (P < 0.001)
(Figure 3.21C), however, ciprofloxacin depressed IL-8 secretion (P < 0.01). Although
ampicillin did not influence IL-8 secretion, gentamicin did demonstrate slight but not
significant immunomodulatory activity.
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Figure 3.21. IL-6 (A) and IL-8 (B) cytokine expression profiles for T24 bladder cells
infected with S. saprophyticus 15305 exposed to various subinhibitory levels of
ciprofloxacin. Release of IL-8 from 5637 bladder cells following treatment with either
LPS (C) or S. saprophyticus 15305 (D) in the presence of 1/4MIC of either ciprofloxacin
(C), ampicillin (A), or gentamicin (G) as indicated. Significance was determined using
one-way ANOVA and Dunnett's (A,B) or Bonferroni's (C,D) multiple comparison tests
(*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns = not significant).
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Figure 3.21
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3.2.7

Evaluating the immunomodulatory effects of subtherapeutic ciprofloxacin during early stages of UTI in vivo

It was hypothesized that the immunomodulatory effects of ciprofloxacin in vitro would
suppress the secretion of pro-inflammatory mediators and decrease immune cell infiltrate
in vivo. Both E. coli UTI89 and mock (PBS) infected mice receiving sub-therapeutic
ciprofloxacin were found to have significantly fewer PMNs in urine sediments compared
to controls (P < 0.05; P < 0.001) (Figure 3.22). The results for the mock infected,
ciprofloxacin treated group were especially noteworthy, with no measurable PMN score
being achieved.
The cause of the reduced immune cell infiltrate in ciprofloxacin treated mice was
postulated to be related to modulation of cytokine secretion. This was assessed using a
Luminex® bead-based multiplex assay of bladder tissue homogenates. A total of seven
urinary-relevant cytokines were assessed and included IL-1β, IL-6, KC (IL-8), G-CSF,
IL-17, IL-10, and TNFα. All produced reliable profiles with the exception of TNFα (data
not shown). Changes in IL-17 secretion were unremarkable in either control or
ciprofloxacin treatment groups (Figure 3.23). Similarly, KC was not significantly
impacted by ciprofloxacin, although there was a trend of reduced secretion when
antibiotic was present (Figure 3.23). All other cytokines were significantly affected by
the presence of ciprofloxacin. The pro-inflammatory mediators IL-1β and IL-6 were
suppressed while secretion of the anti-inflammatory cytokine IL-10 was increased (P <
0.05; P < 0.01; P < 0.001) (Figure 3.23). These cytokine alterations could reasonably
account for the observed decrease in immune cell infiltrate in urine sediments. In
contrast, the pro-inflammatory cytokine G-CSF was significantly increased in the
presence of ciprofloxacin and E. coli UTI89 infection (P < 0.05) (Figure 3.23). Of note,
E. coli have previously been reported to increase the expression of this cytokine. It
remains unclear how ciprofloxacin influences this process.
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Figure 3.22. PMN counts collected from urine sediments of either E. coli UTI89 or mock
(PBS) infected mice treated with or without 1/50 sub-therapeutic ciprofloxacin
supplemented drinking water (3 day exposure). Means from at least two independent
experiments are shown with significance. Significance was determined using one-way
ANOVA and Bonferroni's multiple comparison test (*, P < 0.05; ***, P < 0.001).
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Figure 3.23. Murine bladder cytokine secretion following 3.5 hour E. coli UTI89 or
mock (PBS) infection in the presence or absence of 1/50 sub-therapeutic ciprofloxacin
supplemented drinking water (3 day exposure). Means from at least two independent
experiments are shown with significance. Significance was determined using one-way
ANOVA and Bonferroni's multiple comparison test (*, P < 0.05; **, P < 0.01; ***, P <
0.001).
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Figure 3.23
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3.2.8

Assessing the influence of sub-therapeutic ciprofloxacin
on host and pathogen responses in vivo

As ciprofloxacin modulates the immune response, it was hypothesized that mice
receiving sub-therapeutic ciprofloxacin would develop less severe inflammation and
decreased risk of developing chronic infection than control mice. Sub-therapeutic
ciprofloxacin treatment did not significantly affect bacterial urine loads compared to
untreated controls (Figure 3.24). Still, mice presented with lower infection titers at 14 dpi
when they received ciprofloxacin supplemented drinking water (Figure 3.24D, E). Early
kidney infection titers were slightly higher in the mice receiving antibiotic, compared to
controls (Figure 3.24B). In addition to decreased titer, bladders from ciprofloxacin treated
mice weighed significantly less than those from the control group, suggestive of
decreased immune infiltration (P < 0.05) (Figure 3.24C).

3.2.9

Evaluation of infection severity in a murine ciprofloxacin
prophylaxis model of recurrent UTI

The possibility that low-dose prophylaxis promotes virulence and enhances pathogenesis
was investigated. Changes in bacterial urine load were assessed at least every two days to
track the course of infection using a prophylaxis therapy model. As expected, bacterial
urine loads decreased with the application of co-trimoxazole, with the exception of two
mice in experiment 2 (Figure 3.25). The following 7 day rest period revealed dynamic
changes in E. coli UTI89 urine titer, with frequent recurrences observed. In general,
prophylactic therapy did not appear to improve the frequency of infection resolution over
the 7 day treatment period compared to non-treated controls. Indeed, 10% of mice in the
prophylactic group presented with clinically significant infection while 15% did so in the
control group at the study's end (Figure 3.25).
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Figure 3.24. Bladder and kidney titers of E. coli UTI89 inoculated mice receiving 1/50th
sub-therapeutic ciprofloxacin supplemented drinking water or control. Mice were
sacrificed at either 24 hpi (A, B) or 14 dpi (D, E) to determine infection severity. Bladder
weight was also measured at 24 hpi (C). Means from at least two independent
experiments are shown with significance. Significance was determined using MannWhitney test (Gaussian approximation) (*, P <0.05).
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Figure 3.25. Two experimental replicates follow E. coli UTI89 urine titers in C57BL/6
mice treated prophylactically with ciprofloxacin (red) or vehicle (water - black) via daily
gavage. Each line represents the bacterial urine load for an individual mouse. Axis labels
indicate the start of co-trimoxazole (TMP/SMX) therapy and period of prophylaxis
dosing. Dotted line indicates the cut off for clinically significant (>104 cfu/mL) infection.
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The unremarkable urine results from the prophylaxis experiments necessitated further
investigation. Therefore, upon sacrifice both bladders and kidneys were evaluated to
assess E. coli UTI89 colonization. Although both organs demonstrated greater bacterial
loads in the prophylaxis group, this difference was not significant (Figure 3.26A, B).
However, comparison of E. coli UTI89 intracellular bladder reservoirs revealed
prophylaxis significantly increased the frequency of urothelial invasion (P < 0.05). The
inability of prophylaxis to eradicate infection is worthy of further investigation.
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Figure 3.26. E. coli UTI89 titers in C57BL/6 mouse bladders (A) and kidneys (B)
following a 1 week prophylactic treatment regimen with either ciprofloxacin or vehicle
(water). Gentamicin protection assays indicate the presence of intracellular E. coli
reservoirs (C). Dotted line indicates limit of detection. Means from at least two
independent experiments are shown with significance. Significance was determined using
an unpaired, two-tailed t-test. (ns = not significant; *, P = 0.0148).
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3.3 UNDERSTANDING THE ABILITY OF
UROPATHOGENS TO PERSIST DESPITE ADEQUATE
ANTIBIOTIC INTERVENTION DURING INFECTION
The inability of antibiotics to eradicate bacteria during chronic diseases such as recurrent
UTI is attributed to the presence of MDT persister cells. Yet, despite the susceptibility of
E. coli UTI89 to ciprofloxacin, titers were unchanged by prophylaxis, and actually
increased slightly in some cases (Figure 3.25A, B). As persister cells are known to form
in response to environmental stress, it was hypothesized that antibiotics are capable of
promoting onset of this MDT state. In designing studies to address this hypothesis, it was
deemed important to characterize the nature of uropathogen persisters in order to evaluate
novel therapeutic modalities.
Persister cells are believed to benefit from MDT through complete, global metabolic
dormancy. Therefore, two hypotheses were considered to evaluate the contribution of
dormancy towards persistence: i) dormancy is necessary and sufficient to convey MDT
such that persisters will respond to different antibiotics with the same levels of survival;
and ii) different antibiotics will induce global dormancy such that surviving persisters
will demonstrate tolerance to both lethal levels of the same and different agents (crosstolerance). This work challenges the notion that persister cells represent truly dormant
variants of the overall population.

3.3.1

Different classes of antibiotics induce persister cell
formation in both S. saprophyticus and E. coli

The ubiquity of antibiotic-dependent persister induction was assessed using
ciprofloxacin, ampicillin, and gentamicin against both Gram-negative (E. coli CFT073)
and Gram-positive (S. saprophyticus 15305) organisms. The persister traits of E. coli
CFT073 are better characterized than those of E. coli UTI89, justifying its initial use for
these experiments. Importantly, growth phase has a significant impact on persister levels,
requiring growth rate characterization of all strains utilized prior to investigation. In
general, all strains of E. coli used throughout this study demonstrated similar growth
rates, while S. saprophyticus 15305 was comparatively distinct, warranting adjustment of
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experimental protocols to permit accurate enumeration of the persister fraction (Figure
3.27).
Exposing bacteria to a lethal antibiotic dose followed by enumeration of survivors
permits rapid characterization of the persister fraction. This approach was undertaken to
assess the ability of antibiotics to modulate persister formation in uropathogens. Both E.
coli CFT073 and S. saprophyticus 15305 showed significant (P < 0.05; P < 0.01
respectively) increases in percent survival following ciprofloxacin, ampicillin, and
gentamicin pre-treatment and challenge (Figure 3.28). Analysis of strains from these
surviving fractions did not reveal any significant changes in MIC compared to the
original starting culture, indicating that spontaneous resistance which developed during
sub-inhibitory antibiotic challenge did not contribute to survival (data not shown).
Resuscitation of persisters following therapy cessation presumably plays a critical role in
antibiotic therapy failure. Therefore, the recalcitrance rate of persisters was evaluated in
the presence or absence of antibiotic priming. This was accomplished by reconstituting
presumed 'killed' cultures in fresh media and observing persister re-emergence via
turbidity. There was a significant difference in persister resuscitation time for E. coli
CFT073 compared to S. saprophyticus 15305, with the former emerging rapidly
(exclusively within 24 hours) across treatment groups while the latter required ~24-72
hours depending on the antibiotic (Figure 3.29). The antibiotic priming influenced
resuscitation rates in S. saprophyticus 15305 but not E. coli CFT073, with ciprofloxacin
and gentamicin pre-treatments prolonging reactivation. In some cases, persister cells
could spontaneously emerge up to 14 days following initial challenge in S. saprophyticus
15305 but not E. coli CFT073 cultures.
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Figure 3.27. Comparison of growth kinetics for all uropathogens tested. Means are from
at least two independent experiments. Significance was determined using unpaired t-test
(all E. coli strains are non-significant for growth variation over a 24 hour period; P >
0.05).
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Figure 3.28. Persister induction following a 1/4MIC pre-treatment with either
ciprofloxacin, ampicillin, or gentamicin for 3 hours. Percent surviving fractions represent
the persister sub-population following 3 hour lethal treatment with either ciprofloxacin
(A, D), ampicillin (B, E), or gentamicin (C, F) in E. coli CFT073 (A-C) or S.
saprophyticus 15305 (D-F). Means from at least three independent experiments shown
with significance. Significance determined using unpaired t-test (*, P < 0.05; **, P <
0.01; ***, P < 0.001).
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Figure 3.29. Average number of days till persister resuscitation following lethal
antibiotic challenge. Pre-treated (1/4MIC) and non-treated cultures were considered for
both E. coli CFT073 and S. saprophyticus 15305. Means from at least four independent
experiments shown with significance. Significance was determined using one-way
ANOVA and Bonferroni's multiple comparison test (*, P < 0.05; ***, P < 0.001).
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3.3.2

Evaluating antibiotic susceptibility patterns in Type I and II
persister cells

The efficacy of ciprofloxacin, ampicillin, and gentamicin was surveyed against stationary
phase (predominantly Type I persister) cultures. S. saprophyticus 15305 demonstrated
significantly greater antibiotic tolerance during stationary phase with percent survival
increasing 443.2, 90,263.0 and 14,682.4-fold compared to exponential phase cultures for
ciprofloxacin, ampicillin, and gentamicin respectively (P < 0.001) (Figure 3.30B).
Similarly, E. coli CFT073 survival increased 676.2, 5,325.0, and 7,782.1-fold following
lethal ciprofloxacin, ampicillin, and gentamicin challenge (P < 0.001) (Figure 3.30A).
Heterogeneity in percent survival was observed across bacterial genera and antibiotic
class. S. saprophyticus 15305 was significantly more susceptible to gentamicin (33.5%
survival) than ciprofloxacin (80.9%) or ampicillin (80.7%) (P < 0.001). Conversely, E.
coli CFT073 demonstrated greater survival against ampicillin (76.8% survival) and
gentamicin (56.6%), while remaining significantly susceptible to ciprofloxacin (3.6%) (P
< 0.001).

3.3.3

Characterizing the nature of antibiotic-induced persisters
by challenging with lethal doses of the same and different
agents

The large variations observed in persister fraction size between antibiotic treatment
groups suggests heterogeneity in persister sensitivity to antibiotics. This finding
discredits the null hypothesis that dormancy is both necessary and sufficient to convey
MDT, such that persisters will respond to different antibiotics with the same levels of
survival. It was therefore hypothesized that antibiotic-induced persisters would
demonstrate similar heterogeneity, implying that dormancy is not a significant
contributing factor of MDT.
The nature of the antibiotic-induced persister fraction was explored by challenging with
the same agent that induced tolerance in addition to those with different cellular targets.
Cross-tolerance was detected for some antibiotic classes but varied with organism genus.
Ciprofloxacin and gentamicin pre-treatments most effectively enhanced survival of
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Figure 3.30. Fraction sizes of Type I and Type II persisters of exponential and stationary
phase cultures. Percent survival was determined following 3 hour challenge with lethal
ciprofloxacin, ampicillin, or gentamicin for both E. coli CFT073 (A) and S. saprophyticus
15305 (B). Means from at least three independent experiments are shown with
significance. Significance was determined using one-way ANOVA and Bonferroni's
multiple comparison test (***, P < 0.001).
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E. coli CFT073 (Figure 3.31A, C), while ampicillin pre-treatment was favourable in S.
saprophyticus 15305 (Figure 3.31). Sub-inhibitory ciprofloxacin significantly enhanced
survival 5.2-fold and 3.2-fold following lethal treatment with ampicillin and gentamicin
in E. coli CFT073, while sub-inhibitory ampicillin significantly increased survival 4.1fold and 34.9-fold following lethal ciprofloxacin and gentamicin challenge in S.
saprophyticus 15305 (P < 0.05; P < 0.01). The variability of surviving fraction sizes
between sub-inhibitory antibiotic pre-treatment groups further recapitulates the
hypothesis that dormancy does not solely account for MDT. However, the relative
contribution of uropathogen persister cells to UTI recurrence risk, and their capacity to
form in the presence of sub-inhibitory antibiotic doses, are not well documented and
warrant investigation.

3.3.4

Characterizing the persister fraction of E. coli strains
isolated from same-strain recurrent and acute infections

A direct correlation between persister fraction size and recurrence risk has never been
explored. However, the MDT characteristics of persister cells potentiates their role in
recurrent UTI. Although MDT is acquired through physiological changes, the persister
fraction of an organism is genetically ordained, suggesting that these traits are subject to
selective pressure during antibiotic therapy. This property was explored by assessing the
persister forming capacity of E. coli strains isolated from patients suffering from either
typical acute infection (AI) or same-strain recurrence (SSR).
As growth phase influences the persister fraction, we first confirmed that all UPEC
strains demonstrated similar rates of growth (Figure 3.27). Thus, any change in the
persister fraction is due solely to variations in the organism's capacity to form persisters.
Stationary phase cultures were considered for Type I persister frequency. Standard
antibiotic susceptibility testing revealed all strains to be similarly susceptible to the
antibiotics tested, with the exception of SSR organisms TOP379 and TOP344 which
demonstrated intermediate susceptibility to ampicillin (Table 3.1). Similar to E. coli
CFT073, all isolates within the Type I stationary fraction tolerated ampicillin and
gentamicin while succumbing to ciprofloxacin treatment (Figure 3.32). Unexpectedly,
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Figure 3.31. Cross-tolerance susceptibility patterns of Type II persisters induced with
various antibiotic pre-treatments. Percent surviving fractions represent the persister subpopulation following 3 hour lethal treatment with either ciprofloxacin (A, D), ampicillin
(B, E), or gentamicin (C, F) for both E. coli CFT073 (A-C) and S. saprophyticus 15305
(D-F). Means from at least three independent experiments are shown with significance.
Significance was determined using one-way ANOVA and Bonferroni's multiple
comparison test (*, P < 0.05; **, P < 0.01).
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some SSR organisms revealed slight growth during lethal treatment. Although antibiotics
were already provided at therapeutic levels, we observed the same result upon
challenging with 10x the previous lethal dose (data not shown). Viability of all AI strains
declined as expected. When grouped, AI strains had significantly lower survival for
ampicillin (69.15%) and gentamicin (77.93%) treatment compared to SSR organisms
(118.0% and 151.2% respectively), which had a higher persister fraction (P < 0.01).
Surviving organisms did not display any changes in MIC following the experiments,
suggesting spontaneous acquisition of resistance elements did not occur (data not shown).
Cross-tolerance assays were also conducted to determine sub-inhibitory antibiotic effects
on Type II persister formation during exponential phase growth and to permit assessment
of their susceptibility. Ciprofloxacin and gentamicin pre-treatments induced persister
states at the highest frequency in SSR organisms (P < 0.05; P < 0.01; P < 0.001) (Figure
3.33A), while most AI strains failed to respond to antibiotics (Figure 3.33B). However,
gentamicin pre-treatment significantly (P < 0.01) increased the persister fraction in E.
coli AI strain PUTS1236. In almost all cases, pre-treatment with ampicillin significantly
(P < 0.05) improved the efficacy of gentamicin in both SSR and AI organisms. Some
antibiotic/SSR-organism combinations again demonstrated slight growth in lethal
antibiotic concentrations. This effect was amplified in strains TOP379 and TOP344
which are intermediately susceptible to ampicillin, with growth observed following lethal
treatment with ampicillin and gentamicin irrespective of pre-treatment compared to nontreated controls. Taken together, these results indicate that organisms with large persister
fractions either initiate recurrent UTI, or that persister traits are selected for during
repeated bouts of antibiotic therapy.

3.3.5

SOS-deficient E. coli persister cells are not tolerant to
ciprofloxacin

The involvement of SOS response systems and virulence enhancement has been a
recurring theme of this work. SOS responses have been intrinsically linked with the
formation of persister cells following fluoroquinolone therapy, which is a potent DNA
damaging agent and therefore stimulator of this system. These observations permit

160

Figure 3.32. Percent survival of same strain recurrent (SSR) and acute infection (AI) E.
coli isolates challenged with lethal ciprofloxacin (A), ampicillin (B), or gentamicin (C)
during stationary phase growth. Dashed lines indicate average SSR or AI grouped
survival to the respective antibiotics. Means from at least four independent experiments
are shown with significance. Significance between SSR and AI groups was determined
by comparing average survival using an unpaired t-test (ns = not significant; **, P <
0.01).
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Figure 3.33. Cross-tolerance susceptibility patterns of SSR (A) and AI (B) E. coli
persisters induced with various antibiotic pre-treatments. Percent survival was determined
after challenge with a lethal dose of either ciprofloxacin, ampicillin, or gentamicin.
Means from at least four independent experiments are shown with significance.
Significance was determined using one-way ANOVA and Bonferroni's multiple
comparison test (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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further evaluation of the role dormancy plays in MDT. It was hypothesized that if
complete metabolic dormancy is both necessary and sufficient for MDT then established
persisters should be refractory to antibiotics regardless of the functionality of their SOS
system. Investigation of the SOS system's contribution to persister onset with other
antibiotics was also warranted.
E. coli UTI89 strains deficient in RecA production (ΔrecA - PAS0209) and LexA
autoproteolysis (lexAT355G - PAS0211) were considered in order to compare the effects of
insufficient double-strand break repair and SOS-induction on persister cell maintenance
and onset. E. coli UTI89 strains PAS0209 and PAS0211 were significantly (P < 0.001)
sensitized to ciprofloxacin challenge, thus 1/4MIC pre-treatment values were adjusted
accordingly (Table 3.1). Ciprofloxacin and gentamicin priming significantly induced
persister cell production in wild-type E. coli UTI89 as anticipated (P < 0.01; P < 0.001)
(Figure 3.34A-C). This effect was completely abrogated in both SOS-deficient strains
regardless of pre-treatment and subsequent lethal dose applied (Figure 3.34A-C).
Although less proficient in antibiotic-dependent persister induction, SOS-deficient E. coli
strains PAS0209 and PAS0211 did produce Type II persister levels that were comparable
to those of wild-type E. coli UTI89.
The contribution of active double-strand break repair and SOS response to antibiotic
tolerance was investigated using the Type I, stationary phase persister fraction. The
surviving fractions of the SOS-deficient E. coli UTI89 strain PAS0211 was significantly
reduced 29.7-fold following ciprofloxacin challenge (P < 0.001) (Figure 3.35). In
addition, E. coli UTI89 strain PAS0209 which is devoid of RecA activity, was
completely eradicated (to the limit of detection) following ciprofloxacin challenge (P <
0.001). However, persister levels were unchanged following incubation with ampicillin
and gentamicin compared to wild-type E. coli UTI89 indicating PAS0209 and PAS0211
strains were not deficient in persister cell development. These finding suggest that
topoisomerases II and IV are not only active within persisters, but corruptible with
ciprofloxacin treatment. Furthermore, the observed eradication of recA knock-out strains
indicates that active double-strand DNA break repair is required for tolerance. It is
reasonable to conclude with this data that persister cells do not constitute completely
metabolically inactive variants.
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Figure 3.34. Cross-tolerance assays comparing persister induction capacity of wild-type
or SOS-deficient E. coli UTI89 strains following subinhibitory antibiotic therapy. Percent
survival was determined after challenge with a lethal dose of either ciprofloxacin (A),
ampicillin (B), or gentamicin (C). Means from at least five independent experiments are
shown with significance. Significance was determined using one-way ANOVA and
Bonferroni's multiple comparison test (ns = not significant; *, P < 0.05; **, P < 0.01;
***, P < 0.001).
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Figure 3.35. Sensitivity of Type I E. coli persisters deficient in SOS to various
antibiotics. Fraction size was determined following 3 hour challenge of stationary phase
cultures with lethal ciprofloxacin, ampicillin, or gentamicin and enumerating the
surviving population. Means from at least four independent experiments are shown with
significance. Significance was determined using one-way ANOVA and Bonferroni's
multiple comparison test (***, P < 0.001).
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3.3.6

Assessing the contribution of high-density growth to
persister cell onset

As sub-inhibitory antibiotics promote aggregation (Figure 3.8) and persister formation
(Figures 3.28, 3.31, 3.33), it was hypothesized that there may be a link between these two
processes and MDT onset. This was tested using stationary phase cultures of E. coli
UTI89 deficient in aggregation which is conferred through atypical type 1 fimbriae
formation. Aggregation was assessed using a sediment assay which measures the rate of
settling over time as a function of aggregate size. Type 1 fimbriae deficient strains ΔfimH
(fimbriae expressed without adhesin) and ΔfimS (fimbriae not expressed - bald
phenotype) were utilized. As expected, wild-type and hyper-fimbriated (Locked ON) E.
coli UTI89 strains demonstrated significant aggregation while aggregation-deficient
strains did not (P < 0.01) (Figure 3.36A). Stationary phase killing assays were then
carried out and revealed that aggregation-deficient strains were also significantly
deficient in persister formation, demonstrating ~10-fold fewer survivors than wild-type E.
coli UTI89 (P < 0.01) (Figure 3.36B). Although direct cause-and-effect relationships
cannot be confirmed from these results, the data presented throughout this work is
compelling evidence that high-density growth may be a trigger for the induction of
persister states.
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Figure 3.36. Percent aggregation of stationary phase, wild-type, Locked ON, ΔfimH, and
ΔfimS E. coli UTI89 strains (A), and the subsequent persister fractions of each strain
following exposure to lethal ciprofloxacin for 3 hours. Means from at least three
independent experiments are shown with significance. Significance was determined using
one-way ANOVA and Bonferroni's multiple comparison test (**, P < 0.01; ***, P <
0.001).
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4

DISCUSSION

4.1 THE IMPORTANCE OF UNDERSTANDING THE
INFLUENCE OF ANTIBIOTICS ON THE HOST AND
PATHOGEN
Antibiotics have been used successfully in treating bacterial infections for over 60 years.
In this time, humanity has seen their canonization from modest beginnings as soil-derived
signalling agents to clinically available cures, saving countless lives. However, the 'post
antibiotic era' is already quickly becoming a reality, in part driven by indiscriminate,
inappropriate and promiscuous use. Well-respected researchers have drawn attention to
some of these issues in recent years (Levy and Marshall, 2004), calling for the global
banning of antibiotic use for animal weight-gain, over-the-counter sales in developing
countries, and demanding stricter prescribing policies for physicians and dentists (Angulo
et al., 2005; Kay, 2012; Ali et al., 2006). Models suggest that even a 1% reduction in the
usefulness of existing antibiotics, driven by inappropriate use, corresponds with costs of
$600 billion to $3 trillion in lost human health (Hollis and Ahmed, 2013). Aspects of
human nature are probably reflected in this antibiotic story. When something is so
effective at a particular job, in this case killing pathogenic bacteria, humans have a
tendency to rapidly, exhaustively and broadly apply the discovery often without
completely understanding the consequences of such promiscuous use. Thus, antibiotics
are still administered for the common cold, despite it being caused by a virus (Pechère,
2001); they are prescribed prophylactically for patients undergoing many surgical and
dental procedures when risk of infection is low and antibiotic efficacy weak (Enzler et
al., 2011); they are utilized in children repeatedly and often for long periods of time, in
part because diagnostic tools are limited or poor, or physicians are guided by ‘instinct’
rather than evidence-based findings (Conway et al., 2007).
It is now coming to light that issues associated with antibiotics extend far beyond those
related to drug resistance. Only within the last decade have scientists began to understand
the natural role of antibiotics in the environment (Linares et al., 2006; Romero et al.,
2011; Yim et al., 2007). Newly discovered inter-species signalling properties may
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potentiate the augmentation of bacterial virulence when applied therapeutically. To
complicate matters, some antibiotic classes are also known to directly influence the host,
necessitating even further characterization to optimize treatment strategies (Dalhoff and
Shalit, 2003; Čulić et al., 2001). These findings raise several important questions
regarding contemporary antibiotic use in the clinic. Firstly, are antibiotics being applied
unnecessarily to certain patient cohorts? If so, does their application negatively affect
treatment outcome? Secondly, can the signalling properties of antibiotics on the host and
pathogen be capitalized on to enhance therapeutic efficacy? Thirdly, do different
antibiotic classes confer different phenotypic properties in different pathogens? The
studies conducted here aim to answer these questions in the context of antibiotic therapy
for the treatment of recurrent UTI. This disease milieu presents an ideal platform for the
study of antibiotic management strategies, as there is growing debate over the necessity
of its application and associated methodologies (Garin et al., 2006; Nickavar and
Sotoudeh, 2011). In this thesis, the effects associated with inadequate antibiotic therapy
are demonstrated, and reveal that multiple aspects of bacterial virulence are modulated
affecting disease outcome. Ultimately, understanding the influence of antibiotics on the
host, pathogen, and infection outcomes will provide physicians with new strategies for
therapeutic optimization, and knowledge that helps them avoid the use of antibiotics
when they are not effective or even detrimental to the patient.

4.2 THE INFLUENCE OF SUB-INHIBITORY ANTIBIOTICS
ON UROPATHOGEN VIRULENCE
Studies characterizing the wider effects of sub-inhibitory antibiotics on soil organisms
and human pathogens are still in their infancy. Thus far, techniques have focused
primarily on the use of transcriptomic approaches, both for their high-throughput
potential and ready application to a wide variety of organisms (Linares et al., 2006;
Fajardo and Martínez, 2008). Although these studies have provided the first links
between off-target antibiotics effects on bacteria and their potential contribution to
disease, they are not ideal for the study of pathogenesis as changes in gene transcription
do not often reflect changes in translation, protein folding or extracellular localization
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(Straub, 2011). Therefore, one of the aims of this thesis was to characterize changes in
virulence expression of uropathogens at the phenotypic level.

4.2.1

Effect of sub-inhibitory antibiotics on uropathogen adhesin
expression and adherence to surfaces

The capacity for antibiotics to affect bacterial adherence to abiotic and biotic surfaces
were characterized. This was initially done by assessing the ability of S. saprophyticus
15305 to adhere to the surface of glass microscope slides in the presence and absence of
antibiotics. Human pooled urine (HPU) was used as a growth substrate over routine
culture media for its capacity to form conditioning films on contact with foreign surfaces
(Santin et al., 1999; Canales et al., 2009). Although more relevant to the urinary tract, the
use of HPU posed several problems, the foremost of which was poor inter-experimental
reproducibility due to batch variation. This was despite steps being taken to avoid such
issues, which included strict collection schedules and extraction from the same donors.
However, the metabolic and protein profiles of urine are known to change over the course
of a day, month, and year (Connor et al., 2004). In addition, diet, medication, and
hormone levels heavily influence urinary composition and could not be controlled in this
study. For these reasons, the use of this medium was thereafter discontinued.
Experiments investigating the adherence of S. saprophyticus 15305 to glass microscope
slides demonstrated that sub-inhibitory antibiotic exposure influenced this process.
Ciprofloxacin, ampicillin, and gentamicin were all capable of increasing bacterial
adherence to similar degrees despite targeting different cellular machinery. Although not
conclusive, this finding suggests that observed induction of adherence is mediated
through general stress response systems. Activation of the Sigma B transcription factor
by fluoroquinolones has been demonstrated to increase adhesion in quinolone-resistant
strains of S. aureus, but other antibiotics and response systems have not been explored in
non-resistant strains (Li et al., 2005a).
As glass exhibits hydrophilic surface chemistry not reflective of materials or tissues
routinely found in the urinary tract, hydrophobic medical devices utilized in this
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environment were subsequently investigated. This is an important consideration, as
hydrophilic surfaces are poorly colonized by most bacteria due to the repulsive
interaction of negatively charged elements (Boks et al., 2008). In addition to their
experimentally desirable surface properties, stents and catheters are also widely used in
urological applications and are usually readily colonized (Habash and Reid, 1999; Siddiq
and Darouiche, 2012). Together these materials represent the greatest cause for
nosocomial infection, and are associated with increased morbidity, hospital cost, and
length of stay, further warranting their use in this model (Saint, 2000; Platt et al., 1982;
Givens and Wenzel, 1980; Tambyah et al., 2002). Antibiotic priming of S. saprophyticus
15305 resulted in greater adherence to both stent and catheter material. The change in
adherence was more substantial than found with glass microscope slides, supporting the
adhesion promoting properties of these devices. The hydrophobic surface chemistry of
urological devices is often masked using hydrophilic, hydro-gel coatings for this reason
(Beiko et al., 2004). Catheter colonization was higher than stent colonization, likely due
to the different polymers used between these materials. The proprietary polymer utilized
in the InLay stent prohibits inquiries into its anti-infective properties. However, the latex
polymer surfaces used in Foley catheters are more irregular, and readily colonized
compared to silicone material which support the findings presented (Nickel and
Costerton, 1992; Stickler et al., 2003).
The capacity for different antibiotic classes to promote urological device colonization is
concerning. Single dose antibiotics are usually applied prophylactically during device
placement as per American Urological Association guidelines, a practice which may not
be warranted (2008), and might actually promote adhesion. In addition, the modification
of urological materials through coating, matrix loading, and immersion in antimicrobial
agents has become a widespread practice (Siddiq and Darouiche, 2012). Many coatings
have become available, and incorporate bactericidal silver ions and nanoparticles,
enzyme inhibitors, antibiotics and sometimes even bacteriophages (Saint et al., 1998;
Furno et al., 2004; Morris and Stickler, 1998; Burton et al., 2006; Carson et al., 2010;
Mendez-Probst et al., 2012). The aim of these enhancements are to discourage pathogen
growth once they have been driven into the urinary environment during device
placement. However, the efficacy of modified devices has shown no benefit over

178
untreated instruments, questioning the merit of their application (Srinivasan et al., 2006;
Cadieux et al., 2009). This is especially true considering the capacity of antibiotics to
improve bacterial device colonization, a process which could occur during long-term
device placement once bio-active agents have been leached to sub-inhibitory levels.
Antibiotic-induced changes in S. saprophyticus 15305 adherence frequency to abiotic
surfaces warranted further investigation into downstream processes such as modulation of
biofilm formation. Biofilm-associated organisms are common during UTI, and play an
important role in the contribution to recurrences, especially when urinary devices are
present (Choong and Whitfield, 2000; Hatt and Rather, 2008; Reid et al., 1992).
Organisms growing in the sessile environment of the biofilm matrix contribute to the
aetiology, pathogenesis and continued persistence of bacteria in the urinary tract through
antibiotic tolerance mechanisms and subversion of host defences including shear stress
mediated detachment during voiding and anti-phagocytic properties (Nickel et al., 1994;
Donlan, 2002). In addition, biofilms continuously seed planktonic organisms into the
urinary lumen contributing to disease propagation and spread to new environments
(Costerton et al., 1999).
The capacity for aminoglycosides to promote biofilm formation has been described, and
is dependent on the Arr signalling pathway found in some Enterobacteriaciae (Hoffman
et al., 2005). Similar processes were explored in S. saprophyticus 15305 and E. coli
UTI89 uropathogens in this thesis. All antibiotics tested induced biofilm formation for
both uropathogens. E. coli UTI89 demonstrated greater biofilm accumulation compared
to S. saprophyticus 15305, which may have been accounted for in part by aminoglycoside
induction of the Arr signalling pathway. However, a search for this or other homologous
genes in either organism using the Basic Local Alignment Search Tool (BLAST;
http://blast.ncbi.nlm.nih.gov/Blast.cgi) did not yield any results. The absence of this
signalling system in E. coli UTI89 might be due to it being a human pathogen, and loss of
this environmental response element through genome reduction via negative selection.
Such processes have been demonstrated to increase fitness in site-specific, steady-state
niches such as the human host, over those that are dynamically changing such as the soil
environment (Koskiniemi et al., 2012). Moreover, Arr was characterized in the soil
bacterium and opportunistic pathogen P. aeruginosa PA01, supporting this system's
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importance in environmental but not host niches (Hoffman et al., 2005; Stover et al.,
2000). Antibiotic-dependent biofilm formation in these uropathogens could reasonably be
driven through an alternative pathway, potentially governed by the activity of general
stress response elements. Indeed, non-targeted stressors including nutrient deprivation,
ethanol, and extremes in pH and salinity have all been implicated in driving biofilm
formation (Fux et al., 2005, Gotoh et al., 2010; Davey and O'toole, 2000; Knobloch et
al., 2002; Lapaglia and Hartzell, 1997). An organism's commitment to sessile growth
states in response to stress makes sense in the light of the reduced metabolic requirements
and added matrix-associated protection imparted by biofilms (Kim et al., 2009).
However, the activity of specific antibiotic signalling systems cannot be ruled out at this
time, especially from environmentally derived ampicillin and gentamicin. Although
fluoroquinolones are fully synthetic compounds, they demonstrate quorum-sensing-like
properties, which may influence biofilm development (Diggle et al., 2003; Heeb et al.,
2010).
The contribution of a general stress response system in antibiotic-dependent biofilm
formation was tested using SOS-deficient strains derived from E. coli UTI89. Although
there are several stress response systems in E. coli, SOS was considered because of its
activation when exposed to several types of antibiotics (Miller et al., 2004; Mesak et al.,
2008). In addition, SOS has been implicated previously in the modulation of other
virulence determinants (Kelley, 2006; Bisognano et al., 2000). Even without the
application of antibiotics, both the ΔrecA and lexAT355G strains tested had reduced biofilm
forming capacity compared to wild-type E. coli UTI89, suggesting a role for SOS in
normal biofilm formation, confirming previous studies (Gotoh et al., 2010). These results
were recapitulated with antibiotic treatment, whereby antibiotic-dependent biofilm
formation was severely depressed or non-existent in both SOS-deficient strains.
Gentamicin was capable of inducing biofilm formation in the lexAT355G but not ΔrecA
strain, suggesting downstream signalling via activated RecA, or its interaction with other
cellular components might be involved. In addition, all strains were influenced by
ampicillin regardless of the activity of their SOS response systems. These observations
recapitulate findings which demonstrated low-dose β-lactam antibiotics enhance eDNA
release in methicillin resistant and sensitive strains of S. aureus, resulting in the

180
production of more robust biofilms (Kaplan et al., 2012). It was thought that autolysin
activity was important in this process; however, such observations are absent in E. coli so
their contribution to biofilm formation in this organism is speculative. Alternatively,
ampicillin's activity at the cell surface might activate the Cpx two-component signal
transduction pathway, which responds to disturbances in the cell envelope, in turn
activating regulation of adhesion genes (Otto et al., 2002).
In addition to enhancing biofilm formation, antibiotics were able to induce rapid
planktonic aggregation of both E. coli UTI89 and S. saprophyticus 15305. As with
adherent biofilms, all antibiotic classes demonstrated similar capacity to induce
aggregation. This phenotype may represent an alternative to biofilm formation when
surfaces are not readily available. In this manner, uropathogen aggregates can benefit
from the immuno-protective and antibiotic tolerance effects of sessile growth without
committing to host cell adherence (Haaber et al., 2012; Rakita et al., 1999). The
mechanism of aggregation is likely conveyed through upregulation of polysaccharide
intercellular adhesin (PIA) in S. saprophyticus 15305, which has been suggested through
the use of a congo red agar plate assay (data not shown), and is an important mediator of
biofilm formation in this species (Mack et al., 1994). Expression of this adhesin has been
shown to be induced following antibiotic therapy and exposure to other stressors (Haaber
et al., 2012; Rachid et al., 2000). Conversely, increased expression of type 1 fimbriae and
other fimbrial-like surface components are likely constituents of aggregation in E. coli
UTI89, and have been previously associated with adhesive, biofilm, and aggregative
properties (Rodrigues and Elimelech, 2009; Schembri et al., 2001). A semi-quantitative
approach using TEM for enumerating fimbrial expression on E. coli UTI89 surface was
attempted but did not yield any meaningful findings (data not shown).
Since uropathogen adherence to abiotic surfaces and biofilm formation were significantly
upregulated in response to diverse classes of antibiotics, their capacity to induce adhesion
to urothelial surfaces was also investigated. This was accomplished using the transitional
epithelial carcinoma cell lines 5637 and A498, which were originally isolated from
human bladders and kidneys, respectively. The use of these tissues was justified for their
characteristics, extraction site, and previous in vitro UTI studies (Svensson et al., 2001;
Mulvey et al, 2001). Antibiotic incubation with S. saprophyticus 15305 resulted in
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enhanced adhesion and internalization in both bladder and kidney cell lines. The capacity
for S. saprophyticus 15305 to invade bladder cells has been previously documented, but
the ability of antibiotics to modulate this process has never been explored (Szabados et
al., 2008). In addition, this work is the first to demonstrate the S. saprophyticus 15305 is
capable of invading kidney cells and may represent an important mechanism in urothelial
persistence. This is especially relevant in this pathogen, which is suggested to
preferentially colonize the kidneys (Kline et al., 2010). Other groups which have assessed
the ability of sub-inhibitory antibiotics to enhance S. aureus invasiveness found no
significant changes (Rasigade et al., 2011). This is despite increases in fibronectinbinding protein expression which improved adherence (Bisognano et al., 2000). The
discrepancies between these studies may reflect differences in proposed mechanisms that
S. saprophyticus 15305 utilizes to invade host cells (Szabados et al., 2008). In the case of
S. aureus, they primarily rely on their regimen of fibronectin-binding proteins to trigger
α5β1 integrin-mediated internalization of non-phagocytic cells (Agerer et al., 2005; Sinha
et al., 1999). Although some strains of S. saprophyticus express fibronectin and collagenbinding proteins, S. saprophyticus 15305 does not (Kuroda et al., 2005). However,
staphylococcal autolysins have been implicated as invasins (Hirschhausen et al., 2010),
and thus may account for urothelial invasion in S. saprophyticus 15305.
Antibiotic treatments had the greatest effect on S. saprophyticus 15305 adhesion when
urothelial cell surfaces were compared to abiotic surfaces. This led to the speculation that
specific adhesin-urothelial interactions were involved and were likely driven by
antibiotic-induced expression of adhesion factors. Hemagglutination assays were utilized
to determine changes in the relative surface presence of UafA, and suggested
ciprofloxacin induced their expression. Bacterial capsules block the interaction of UafA
with adhesins (Kuroda et al., 2005), but enhanced hemagglutination in the acapsular S.
saprophyticus C1 strain recapitulated the previous findings. However, differential
regulation of capsule cannot be ruled out as antibiotic-dependent modulation in capsular
expression has been demonstrated previously in E. coli (Lu et al., 2008; Fowler et al.,
2009). The influence of ciprofloxacin-induced UafA expression on adherence was
confirmed in 5637 bladder cells. Again, ciprofloxacin resulted in enhanced adhesion in
the absence of capsule suggesting UafA significantly contributes to this process. In
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addition, increased internalization in the acapsular strain treated with ciprofloxacin
suggests UafA plays a potential role in S. saprophyticus 15305 urothelial invasion.
However, this is conjecture and requires further analysis with UafA knock-out strains for
confirmation.
Antibiotics were found to also increase the expression of type 1 fimbriae in E. coli UTI89
using hemagglutination assays. This adhesin contributes to aggregation and biofilm
formation in this organism (Rodrigues and Elimelech, 2009; Schembri et al., 2001). It is
interesting that antibiotics from diverse classes should have such a profound impact on
adhesin expression, biofilm formation, and aggregation in unrelated Gram-negative and
positive uropathogens. As the SOS response has been implicated previously in antibioticdependent E. coli UTI89 biofilm formation, it was reasonable to postulate a similar role
in type 1 fimbrial expression. These experiments revealed that antibiotics were incapable
of increasing hemagglutination in the SOS-deficient E. coli UTI89 strains, suggesting an
important role of this response in type 1 fimbriae regulation during stress. This is
supported by previous studies, which have demonstrated involvement of the SOS
response in adhesin regulation in S. aureus, but not for E. coli (Bisognano et al., 2000).
As the SOS regulon controls the expression of dozens of genes in almost all bacteria, it
was thought that antibiotic-dependent changes in type 1 fimbriae occurred at the
transcriptional level. Type 1 fimbriae regulation is phase variable, and regulated by the
fim switch element within its operon (Gally et al., 1996). However, the analysis of
ciprofloxacin exposure on changes in this regulatory element was not revealing. This is
not to say that transcriptional modulation does not play a role in antibiotic-dependent
type 1 fimbriae expression, but that involvement of the fim switch is unlikely. This is
especially perplexing considering that mannose-resistant (type 1 fimbriae-independent)
hemagglutination was not observed (data not shown), indicating that other fimbrial
adhesins, such as P fimbriae, were not expressed following antibiotic treatment (van den
Bosch et al., 1980; Hull et al., 1981).
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4.2.2

Antibiotics concomitantly downregulate motility and
upregulate factors critical for adherence

Both S. saprophyticus 15305 and E. coli UTI89 appear to respond to antibiotic therapy by
increasing adhesin expression, adhering to surfaces, and adopting a sessile lifestyle.
Reduced metabolic activity imparted by this strategy would certainly benefit both
uropathogens to endure times of stress. Adoption of an adherent, inactive lifestyle would
require the transition from motile, planktonic states. Demonstrating the suppression of
flagellar-mediated motility in E. coli UTI89 in response to antibiotics supported this
hypothesis. Furthermore, flagella regulation was also assessed in SOS-deficient strains,
revealing that activation of this system has a negative influence on motility. This finding
agrees with a recent observation of P. aeruginosa motility, suggesting SOS is involved in
adhesion and biofilm formation in several organisms (Chellappa et al., 2013).
Ciprofloxacin, a DNA targeting drug and potent SOS activator, was particularly
efficacious in inhibiting wild-type E. coli UTI89 swarming, a phenotype which was
depressed in the SOS-deficient strains. These findings support the hypothesis that
ciprofloxacin concomitantly upregulates adhesin expression and downregulates motility
to promote surface adherence. Unexpectedly, bacterial swarming motility in the presence
of ciprofloxacin was increased in the E. coli UTI89 lexAT355G strain but suppressed in the
ΔrecA. This suggests RecA positively regulates flagellar activity, a finding that has been
observed in other strains of E. coli (Gómez-Gómez et al., 2007). Although not fully
characterized, the mechanism appears to depend on RecA interacting with CheW, a
component which governs mechanical control of the chemotaxis system during swarming
motility. This finding is further supported, as ciprofloxacin pre-treatment of cells prior to
swarming had no effect on flagellar activity.
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4.2.3

Transcriptomic analysis provides insight into virulence
modulation and antibiotic tolerance mechanisms utilized
by Gram-negative and positive uropathogens

The similar phenotypic responses of S. saprophyticus 15305 and E. coli UTI89 to subinhibitory ciprofloxacin was suggestive of a common underlying mechanism explaining
changes in virulence trait expression. RNA-sequencing provided a useful high-throughput
tool to characterize the global responses during treatment conditions for these
uropathogens. Although changes in virulence gene expression were observed for both
organisms, the regulatory networks affected by sub-inhibitory ciprofloxacin stress appear
to be divergent, despite similar doses relative to the MIC being provided. Specifically, E.
coli UTI89 committed to the activation of a full-fledged SOS response while S.
saprophyticus 15305 appeared to rely upon general stress response elements. The nature
of cell surface components, including peptidoglycan matrix thickness, membrane
abundance/composition and the availability of porins, influences ciprofloxacin
penetration and intracellular availability, and might explain different tolerance
mechanisms. It is generally accepted that ciprofloxacin is better able to access the
intracellular compartment of Gram-negative organisms compared to Gram-positives,
enhancing its efficacy in these pathogens (Drlica and Zhao, 1997). Here, E. coli UTI89
effectively blocked this route of access by decreasing the availability of various porin
transcripts. Interestingly, Berlanga et al. (2004) suggested that Gram-positive tolerance to
ciprofloxacin may be instead related to the interaction of the drug with its target enzymes
rather than diminished permeability. In addition, the decreased replication and
transcription rates of S. saprophyticus 15305 compared to E. coli UTI89 may be
conducive to its survival against DNA gyrase and topoisomerase-acting antibiotics while
negating SOS activation.
The activation of RecA is associated with phage commitment to the lytic cycle, and
evacuation of host cells (Wagner and Waldor, 2002). Both E. coli UTI89 and S.
saprophyticus 15305 initially responded to ciprofloxacin challenge by increasing the
abundance of this important DNA repair transcript, but only E. coli UTI89 went on to
express a number of phage-related SOS response elements. Importantly, the E. coli
UTI89 genome contains a much larger proportion of phage-coding regions compared to
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S. saprophyticus 15305 (as inferred from SEED strip-plots; Figure 3.15). It is possible
that activation of RecA in E. coli UTI89 triggered the activation of a phage lysis cascade,
which in turn contributed to further SOS response commitment in a self-propagating
feed-back loop. The Kil-family of proteins translated from phage transcripts observed
during ciprofloxacin treatment have been shown to induce the SOS response in S.
enterica the past (Campoy et al., 2006), supporting this novel hypothesis. Counterintuitively, the phage transition into lytic cycles may enhance the virulence of E. coli by
permitting the expression of phage-encoded virulence traits during ciprofloxacin therapy.
This process has been demonstrated before in Enterococcus faecalis and is evolutionarily
mutually beneficial to both the host cell and infecting phage (Matos et al., 2013). Further
analysis using strains cured of their phages may provide insight into the cause-and-effect
relationship between onset of the phage lytic cycle and SOS induction.
Sub-inhibitory ciprofloxacin resulted in global suppression of transcripts related to
metabolism including amino acid, cofactor, iron, fatty acid, cell division, and
carbohydrates in E. coli UTI89 after four hours of exposure. This response seems
beneficial, as limiting cellular activity decreases the need for transcription and
replication, in turn limiting the effect that ciprofloxacin can have on these processes.
Remarkably, transcripts related to metabolism and nutrient uptake were found at a higher
abundance in S. saprophyticus 15305. Specifically, transcripts of enzymes important to
glycolysis and the TCA cycle were present at increased quantities following 6 hours of
ciprofloxacin exposure. Although the purpose of this change is unknown, TCA induction
has been shown to be associated with virulence, survival, and persistence of
staphylococci and other pathogens (Begun et al., 2005; Sadykov et al., 2010). These
findings corroborate another transcriptomic-based study which characterized S. aureus
expression changes in response to inhibitory-doses of ciprofloxacin (Cirz et al., 2007).
Although a full S. aureus SOS response was activated in the study, the authors' results
reflect those of this thesis, concluding that an active SOS response is more critical in
ameliorating damage caused by DNA-active antibiotics in Gram-negative organisms.
Interestingly, these authors did not observe changes in the recruitment of transcripts
related to general stress responses. This might suggest that these systems only contribute
to the tolerance of DNA stress at levels which are insufficient to induce SOS.
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A number of transcripts related to virulence were found to be significantly upregulated in
both uropathogens following sub-inhibitory ciprofloxacin exposure. In E. coli UTI89,
hemagglutination assays suggested that FimH-surface expression might be enhanced by
sub-inhibitory antibiotics. The results of the RNA-sequencing analysis confirmed that a
putative fimH-like element was differentially expressed following ciprofloxacin
treatment, indicating antibiotic-dependent hemagglutination is regulated at the
transcriptional level. As FimH is critical in the adherence and invasion strategies of
UPEC, this finding might indicate a mechanism by which sub-inhibitory antibiotics
enhance pathogenesis during UTI. The fimbrial repressor focX was also downregulated in
response to ciprofloxacin, further highlighting this agent's capacity to mediate fimbrial
adhesion. Importantly, expression and cross-talk of the putative focX-regulated fimbrialoperon may preclude the transcription of other fimbriae (including type 1), as UPEC
generally only express one type at any given time (Simms and Mobley, 2008). This might
account for ciprofloxacin's inability to induce type 1 phase switching. Characterization of
the ORFs governed by the focX regulatory element would provide insight into the
mechanisms with which ciprofloxacin induces hemagglutination and biofilm formation in
UPEC.
In addition to changes in fimbrial transcripts, the autoaggregative adhesin and invasin hek
was found to be expressed in the presence of sub-inhibitory ciprofloxacin. This virulence
factor has been associated with severe infections including neonatal meningitis and sepsis
(Fagan and Smith, 2007; Fagan et al., 2008). The hek gene is also present in 55% of
UPEC isolates (Srinivasan et al., 2003), and binds to cells with greater affinity under
shear stress suggesting a potential role in urothelial adherence (Fagan and Smith, 2007).
Therefore, in addition to FimH, increased expression of this adhesin likely accounts for
the ciprofloxacin-dependent aggregation that was observed using TEM. Similarly, the
expression of sulA during ciprofloxacin treatment is sufficient to account for the
filamentation observed using TEM. Transient SulA-mediated filamentation during the
IBC phase of pathogenesis is essential for UPEC virulence and QIR formation in murine
models of cystitis (Justice et al., 2006).
The genome of S. saprophyticus 15305 is much less well characterized compared to E.
coli UTI89, introducing problems in assigning functions to genes that were differentially
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regulated in response to sub-inhibitory ciprofloxacin. However, increased surface
expression of UafA was posited based on phenotypic assays which revealed a
ciprofloxacin-dependent changes in hemagglutination capacity. Unfortunately, RNAsequencing did not reveal significant changes in the relative abundance of this transcript,
suggesting one of the many uncharacterized transcripts upregulated might instead
contribute to this observation. Efforts to produce a UafA knock-out strain were not
fruitful, but would be essential in ruling out other sheep erythrocyte ligands which could
account for UafA-independent hemagglutination. Interestingly, one transcript upregulated
by ciprofloxacin encoded a putative bacterial immunoglobulin-like 3-domain (BIG III)
protein. Proteins encoding domains belonging to the immunoglobulin-like superfamily
are often found in bacterial adhesins (Hamburger et al., 1999). However, similar
structures also have calcium-binding potential (Raman et al., 2010). Regardless, these
findings provide merit in further characterizing this differentially expressed element in S.
saprophyticus 15305.
Transcripts encoding enzymes related to exopolysaccharide production and export were
among those most highly abundant following ciprofloxacin treatment. Generally, it is
thought exopolysaccharide interferes with UafA ligand interactions, a hypothesis which
is supported in this work as acapsular strains demonstrate greater adherence to urothelial
cells. However, hemagglutination was enhanced in the acapsular strain, suggesting that
ciprofloxacin has an effect on either the expression of an uncharacterized adhesin (for
example, the upregulated BIG III-containing protein), or that bacterial aggregation caused
by this antibiotic influences the appearance of hemagglutination as observed elsewhere
(Orndorff et al., 2004). Regardless, exopolysaccharide production is important in
resisting opsonophagocytosis (Peterson et al., 1978), mediating mucosal surface
adherence, aggregation, and biofilm formation (Stephens et al., 1993; Sutherland, 2001,
Li et al., 2005b), contributing to persistence during staphylococcal infection (O'Riordan
and Lee, 2004), and tolerating antibiotic exposure (Fernebro et al., 2004). Therefore, the
increased expression of this virulence factor by ciprofloxacin could certainly enhance the
pathogenicity of this uropathogen. In addition, the availability of TCA cycle
intermediates are critical for exopolysaccharide production, supporting a purpose for
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increasing the activity of this metabolic hub during ciprofloxacin treatment (Sadykov et
al., 2010).

189

4.3 SUB-INHIBITORY CIPROFLOXACIN AFFECTS
PATHOGENESIS IN A MURINE MODEL OF UTI
Ciprofloxacin-dependent modulation of pathogenesis S. saprophyticus 15305 and E. coli
UTI89 was assessed in a murine model of UTI, developed by Dr. Scott Hultgren's group
(Hung et al., 2009). Ciprofloxacin was solely utilized in these studies for its widespread
administration in urology to treat acute and complicated infections (Krcméry and Naber,
1999), in addition to its capacity to modulate uropathogen virulence. The resistance
observed in other antibiotics, such as co-trimoxazole, further warrants investigation of
this next-line therapeutic (Eliopoulos and Huovinen, 2001; Talan et al., 2000). The
murine studies presented within this thesis are the first to demonstrate that antibioticdependent in vitro augmentation of virulence directly influences in vivo pathogenesis.

4.3.1

Ciprofloxacin priming predisposes mice to chronic UTI

Previous results demonstrated that antibiotics are capable of 'priming' organisms for
downstream colonization, primarily through the upregulation of adhesins. This approach
was utilized for the characterization of both E. coli UTI89 and S. saprophyticus 15305
pathogenesis in C3H/HeN mice as it removed the parameter of antibiotic-host
interactions. However, long-lasting epigenetic effects could also potentially influence
downstream virulence in this model (Davidson and Surette, 2008). Type 1 fimbriae phase
variation is one such example, but it was not altered by antibiotic therapy here. Infections
of C3H/HeN mice with 107 cfu of E. coli UTI89 resulted in a bimodal infection outcome
at 24 hpi, with mice showing signs of either bacterial clearance or maintaining high titers
(Hannan et al., 2010). This distribution was observed in both control and ciprofloxacinprimed infection groups. However, ciprofloxacin treatment prior to infection shifted the
equilibrium towards infection persistence in bladders and kidneys. This effect was most
dramatic in the kidneys, with both uropathogens showing no signs of clearance. The
different colonization patterns are likely attributable to differences in defence strategies,
the foremost of which is superficial umbrella cell exfoliation, a major contributor of
pathogen clearance in the bladder (Mulvey et al., 2000; Zasloff, 2007).
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This finding highlights the shortcomings of this UTI model, with C3H mice
demonstrating severe vesicoureteral reflux (VUR) and significant pathogen kidney
deposition upon inoculation (Murawski et al., 2010; Hung et al., 2009). However, there is
still merit in using this model for characterization of 'worst-case-scenario' patients, who
demonstrate high grade VUR. The results demonstrate that infection severity could be
worsened by the application of ciprofloxacin prophylactically, a practice that is widely
conducted (Garnica et al., 2013; Garin et al., 2006; Mattoo, 2009). In addition, S.
saprophyticus 15305 poorly colonizes the bladder tissues of mice but showed similar
infective capacity as E. coli UTI89 in the kidneys. The absence of UafA ligand in mice
likely accounts for this (King et al., 2011; Matsuoka et al., 2011; Kline et al., 2010). It is
noteworthy that despite this, ciprofloxacin-priming significantly increased bladder titers,
suggesting that other factors might contribute towards virulence. The autolysin Aas has
been implicated in fibronectin-binding and thus could contribute to increased adhesive
capacity (Hell et al., 1998; von Eiff et al., 2002).
It is established that C3H/HeN mice inoculated with 107 cfu of E. coli UTI89 presenting
with >104 cfu/mL at 14 days post-inoculation (dpi) are at very high risk of chronic UTI
(Hannan et al., 2010). The increased titers observed following ciprofloxacin priming
alluded that these organisms were better equipped to colonize the host compared to
untreated counterparts. The host-pathogen interactions during the first 24 hours postinoculation (hpi) are thought to play a significant role in infection establishment or
resolution, suggesting increased titers at this time have some predictive value in
determining the severity of UTI (Hannan et al., 2012). The data obtained at 14 dpi with
E. coli UTI89 validated this hypothesis, with ciprofloxacin-priming prior to inoculation
sufficient to increase frequency of chronic cystitis to 100% compared to 60% in untreated
groups. While no such data exists describing the infection thresholds of S. saprophyticus
15305, it is noteworthy that 100% of mice resolved infection when inoculated with
untreated S. saprophyticus 15305, while 50% of ciprofloxacin-primed inoculated mice
maintained low-grade bladder colonization. Furthermore, bacterial kidney titers were
consistently higher in both organisms when primed. The presence of pyelonephritis in the
absence of cystitis in this model supports the hypothesis that chronic cystitis and chronic
pyelonephritis represent mutually exclusive disease outcomes, governed by different
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underlying host-pathogen checkpoints in each organ (Hannan et al., 2010; Hopkins et al.,
2009).
Though upregulation of adhesins likely contribute to persistence, immune activation is
also an important factor in uropathogenesis, with early severe inflammatory responses
increasing risk of chronic infection during UPEC UTI (Hannan et al., 2010).
Overstimulation and infiltration of immune response elements are thought to promote
destruction of the protective urothelium (Ragnarstóttir et al., 2010). This might be driven
directly by type 1 fimbriae which are known to interact with TLR4 and promote
neutrophil infiltration (Mossman et al., 2008; Ashkar et al., 2008), but it is also possible
that upregulation of secreted factors which disrupt the host urothelium contribute
significantly to enhanced virulence potential. The potential for antibiotics to promote
toxin production in S. aureus and E. coli has been demonstrated several times, and is
associated with increased immunogenicity (Serna IV et al., 2008; Dumitrescu et al.,
2011; Otto et al., 2013). However, primed organisms are washed prior to inoculation,
presumably removing any secreted factors from the inoculum and requiring continued
expression in the mouse urinary tract without antibiotics. In addition, no such toxins exist
in S. saprophyticus 15305, suggesting this mechanism does not contribute to persistence
during bladder infection with ciprofloxacin-primed organisms (Kuroda et al., 2005).
Rather, it is postulated that exposure of additional surface adhesins, such as UafA and
Aas, enhance colonization and internalization efficiency resulting in persistent cystitis.
This is supported by ex vivo gentamicin protection experiments, which demonstrated the
increased invasive capacity of ciprofloxacin-primed S. saprophyticus 15305.

4.3.2

Ciprofloxacin priming promotes rapid urothelial invasion
and IBC formation

The capacity for ciprofloxacin to promote E. coli UTI89 chronic infections is likely
dependent on its ability to induce type 1 fimbriae-dependent invasion of urothelial cells.
Type 1 fimbriae are critical in internalization and intracellular bacterial community (IBC)
formation (Martinez et al., 2000; Hadjifrangiskou et al., 2012; Wright et al., 2007); their
expression in response to ciprofloxacin and subsequent chronic infection development is
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likely paramount. Increased numbers of IBCs are associated with an increased risk of
chronic cystitis and the establishment of quiescent bladder reservoirs, which precede
recurrent UTI (Schwartz et al., 2011). The enhanced IBC-forming capacity observed in
ciprofloxacin-primed E. coli UTI89 indicates that establishment of an intracellular niche
is an important step in developing chronic infection in this model. Ciprofloxacin also
altered the morphology of IBCs, resulting in a dispersed phenotype compared to
untreated controls. The characteristics of these IBCs are reminiscent of those observed
during later stages of infection (Justice et al., 2004), suggesting ciprofloxacin-priming
triggered the upregulation of type 1 fimbriae and early invasion of urothelial tissues. The
dynamics of E. coli fimbriation are tightly regulated, and production might not otherwise
occur immediately upon inoculation into the urinary environment (Schwan, 2011), giving
primed organisms an advantage over those left untreated.
Ciprofloxacin-triggered filamentation could potentially contribute to increased urothelial
adherence, immune evasion and invasion potential (Justice et al., 2006; Justice et al.,
2008). Filamentation is an important step in E. coli flux from IBCs and transfer to
neighbouring cells (Rosen et al., 2007). Ciprofloxacin-induced changes in E. coli UTI89
might hasten the spread to distal tissues before exfoliation can occur, promoting the
establishment of quiescent reservoirs in the bladder (Mysorekar and Hultgren, 2006).
Observed filamentation at early time-points in ciprofloxacin-treated, but not control
IBCs, supports this hypothesis. These processes might further help uropathogens subvert
aspects of early host immunity by rapidly gaining access to the intracellular environment
and at a higher frequency. Combined, alterations in these pathogenic mechanisms are
likely responsible for driving the dynamics of host-pathogen equilibrium in favor of the
pathogen and establishment of chronic infection.

4.3.3

Sub-therapeutic ciprofloxacin augments infection severity
and recurrence risk in chronically infected and resolved
mice

Experiments were carried out to investigate the influence of sub-therapeutic ciprofloxacin
on infection severity and recurrence risk. Including this parameter in the experimental
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system was critical, as antibiotics including fluoroquinolones are known to modulate
aspects of host immunity (Dalhoff and Shalit, 2003). Although the dosing regimens
utilized in these experiments are not necessarily reflective of real-world therapeutic
approaches, they are useful in studying concomitant changes in both the host and
pathogen and therefore contribute to our understanding of antibiotic influence on UPEC
pathogenesis in vivo.
Two experimental groups were considered to evaluate the influence of ciprofloxacin on:
i) the worsening of prognosis in chronically infected mice; and ii) predisposing
previously inoculated but 'resolved' mice to clinically significant recurrences. In both
cases, sub-therapeutic ciprofloxacin was associated with increased E. coli UTI89 urine
titers. The effect was compounded over time, suggesting that periods of sub-therapeutic
dosing have a cumulative effect on infection severity. Retrospective studies in humans
have revealed that repeated exposure to antibiotics are associated with recurrent C.
difficile infection risk, and found that the response was cumulative over time as observed
in this study (Stevens et al., 2011). C. difficile infection severity with antibiotics could be
due to clearance of commensal organisms from the gastrointestinal tract, decreasing
competitive inhibition in this niche (Parkes et al., 2009). Although endogenous, nonculturable bacteria have been noted in the urinary tract of healthy females, their role in
mucosal defence against infection is not established (Wolfe et al., 2012). In addition,
spontaneous development of antibiotic resistance could reasonably explain increased
urine load with antibiotics, but no changes in susceptibility were noted over the course of
the experiment.
The effects that underlie changes in E. coli titer with sub-therapeutic ciprofloxacin dosing
were concluded to be driven by suppressed host immune capability. Decreased immune
potential in mice could reasonably account for E. coli UTI89 urine loads increasing in
chronically infected subjects. However, the ability of ciprofloxacin to trigger clinically
significant recurrences in resolved mice was unexpected, and might occur through several
mechanisms. Firstly, the thresholds designating clinically significant infection do not
preclude the presence of UPEC. In fact, several mice in these treatment groups did
present with bacteriuria, but were considered colonized rather than infected as per clinical
standards (Hannan et al., 2010; Schwartz et al., 2011). Thus, increased titer in these mice
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receiving sub-therapeutic ciprofloxacin could be due to a similar phenomenon as
observed in chronically infected mice. However, some mice that experienced recurrences
had no visible signs of bacteriuria prior to treatment. It is possible that ciprofloxacin
triggered re-emergence of E. coli from quiescent reservoirs in these apparently sterile
mice. The filamentation induction observed in other experiments might cause organisms
to flux out from tissues resulting in new infection. However, cross-infection from another
mouse within the same cage cannot be ruled out. Interestingly, there were mice that never
experienced recurrences with ciprofloxacin therapy, indicating urinary clearance and
providing an argument against cross-infection. Regardless, these findings are the first to
directly associate inadequate antibiotic therapy with increased infection risk in vivo.

4.3.4

Ciprofloxacin modulates aspects of host immunity and is
protective against chronic UTI

Ciprofloxacin was found to have an immunomodulatory effect in urothelial tissues, which
might account for the changes in bacterial urine titers observed in mice during treatment.
The effect was noted in both human bladder cell lines in addition to murine tissues
extracted following infection. Low doses of ciprofloxacin were sufficient to depress the
release of IL-6 and IL-8 in T24 bladder cells, suggesting that residual levels left over
following therapy might predispose to infection later on. The effects were found to be
host-cell dependent in 5637 cells, as results in a cell-free system using LPS as an
immune-stimulant recapitulated those from the S. saprophyticus 15305 infections.
Furthermore, the baseline release of cytokines from unstimulated cells did not change
with ciprofloxacin addition, rather, the antibiotic appeared to function by preventing
secretion when LPS or S. saprophyticus 15305 was present. These finding corroborate
those of others (Dalfhoff and Shalit, 2003).
IL-6 and IL-8 are both important pro-inflammatory mediators for host cell immunity
during UTI. IL-6 is a pleiotropic cytokine whose function includes amplifying signals
involved in neutrophil recruitment (Romano et al., 1997), while IL-8 is a member of the
CXC chemokine family and potent neutrophil chemotactic molecule (Murphy, 1997).
Suppression of either cytokine has important implications on neutrophil chemotaxis to
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sites of infection (Hedges et al., 1994; Hang et al., 1999). This was confirmed in mice,
which showed significantly depressed PMN infiltrate in urine sediments when treated
with sub-therapeutic ciprofloxacin. In addition to IL-6 and IL-8 suppression in vivo, the
release of several other cytokines during early infection were affected by this antibiotic.
The pro-inflammatory mediator IL-1β, produced by activated macrophages, is an
important early response element to UPEC infection and was suppressed with
ciprofloxacin treatment. Alternatively, the anti-inflammatory cytokine IL-10 was
upregulated with infection and ciprofloxacin presence. IL-10 is involved in
downregulating co-stimulatory molecules on macrophages, and might be associated with
IL-1β suppression (Mosser, 2003; de Waal Malefyt el al., 1991). Furthermore, this
cytokine is upregulated during UTI and is associated with urothelial protection during
acute cystitis (Duell et al., 2011). The capacity for ciprofloxacin to induce one cytokine
and suppress another while having no effect in some is perplexing. It might depend on the
augmentation of immune populations and their activity within the bladder during
infection. Unfortunately, cytological profiles were not assessed, so immune population
changes in response to ciprofloxacin are unknown.
A surprising outcome of these studies was the finding that ciprofloxacin dramatically
increased the expression of G-CSF. This cytokine increases neutrophil migration from the
bone-marrow, and UPEC are known to trigger its upregulation during UTI (Ingersoll et
al., 2008). G-CSF presence would be effective in increasing levels of circulating
neutrophils, however, the local suppression of chemotactic cytokines in the bladder
would diminish the effect at sites of infection. It was not possible to collect sera from
these mice and as such ciprofloxacin augmentation of systemic responses are unknown.
In addition, G-CSF has immunomodulatory effects on macrophages and attenuates IL-1β
production leading to less efficient bacterial clearance which further corroborates our
findings (Boneberg and Hartung, 2002; Kim et al., 2006).
The immunomodulatory and urothelial-protective effects of ciprofloxacin were further
confirmed using infection models. In this case, decreased neutrophil infiltration and
related reduction in urothelial damage is likely, and has been demonstrated in other
studies (Ingersoll et al., 2008). Reduction in bladder mass in antibiotic-treated mice is
further indicative of suppressed immune cell tissue infiltration.

Although certain
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cytokine profiles might result in increased infection risk, those associated with
ciprofloxacin appear to favour the host. Further studies should explore how these
treatments modulate urothelial exfoliation, as cytokines are known to be involved in this
process (Mulvey et al., 2001; Bower et al., 2005).
Application of sub-therapeutic ciprofloxacin prior to E. coli UTI89 inoculation was
sufficient in abrogating the risk of chronic infection. Although no significant changes
were observed in organ titer, ciprofloxacin treatment was associated with decreased
UPEC abundance. The cytokine profiles generated in this work corroborate other studies
which have demonstrated that super-induction of IL-6, IL-8, IL-1β, and G-CSF, result in
more severe infection and risk of chronic disease (Ragnarsdóttir et al., 2010). Treatment
with the anti-inflammatory compound dexamethasone suppresses the release of cytokines
during early stages of UPEC infection and provided protection from chronic infection in
a similar manner as ciprofloxacin (Sharifian et al., 2008; Hannan et al., 2010). These
findings suggest that application of antibiotics with immune modulating activities might
have an overall protective benefit on the host. However, care should be taken as the risk
of developing a resistant infection is significant, and these findings require confirmation
in larger population cohorts. Furthermore, although ciprofloxacin is protective in the
short-term, the effect on humoral responses has not been characterized. It is possible that
the cytokine profiles generated with antibiotics might increase recurrence risk by
depressing future adaptive response. Overall, the cytokine profiles detailed in this study
demonstrate the dynamic interplay between host defences, which attempt controlled
immune recruitment, and E. coli pathogenic mechanisms, which aim to super-induce this
response.

4.3.5

Ciprofloxacin prophylaxis is not associated with improved
outcome and increases the intracellular bladder reservoir
in mice

An attempt to demonstrate the effects of ciprofloxacin therapy on UPEC pathogenesis in
a therapeutically relevant scenario was accomplished using a murine model of
prophylaxis. This model was developed for the purposes of this thesis and had not been
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attempted previously. Together, it consisted of an infection event, antibiotic therapy and
rest periods, followed by prophylaxis initiation and sacrifice. As mentioned previously,
female C57BL/6 mice replaced C3H/HeN mice, which are susceptible to pyelonephritis
through VUR. However, the characteristic responses of these mice to UPEC infection are
comparable (Hung et al., 2009).
Urine titers of mice were tracked over the course of the study. Co-trimoxazole therapy
was successful in clearing the bacteriuria in all but two mice, who went on to suffer from
chronic infection. During the seven-day rest period, urine titers further demonstrated
dynamic changes in bacterial load consistent with clinically significant recurrences.
Similar observations have been made by other groups and demonstrate the inadequacy of
short-course antibiotic therapy to clear UTI in this model (Blango and Mulvey, 2010;
Schilling et al., 2002). Admittedly, human patients experiencing such recurrences would
restart normal therapy until bacteria were absent from the urine prior to prophylaxis
initiation (Dason et al., 2011; Kodner et al., 2010). However, the timelines permitted in
with this work did not permit such measures to be taken. As such, mice began receiving
prophylaxis despite previous recurrences, and in some cases with positive urine cultures.
The effect on prophylaxis on bacterial urine loads was found to be negligible. This was
even true in the mice that had not cleared their infection with co-trimoxazole. These
results reflect human clinical findings, which inevitably question the effectiveness of this
management approach (Garin et al., 2006; Conway et al., 2007; Enzler et al., 2011).
Mice were sacrificed and further assessed for augmentation in bladder and kidney E. coli
UTI89 loads. Although there were no significant changes associated with prophylaxis or
vehicle treatment, there was trend towards higher titers when ciprofloxacin was provided.
In some cases, these changes might have clinical significance. For example, the bladders
from all animals receiving prophylaxis maintained some bacterial load, while those in the
control group showed signs of resolution. Only one animal in the control group
maintained kidney titers while six in the prophylaxis remained colonized. The most
important finding from these studies was in revealing the propensity for prophylaxis to
enhance UPEC tissue invasion in bladders. These results mirror clinical observations, in
that while prophylaxis might assist in decreasing UTI symptoms, they inexorably do not
alter the long-term risk of recurrence, and may in fact promote future episodes by

198
establishing intracellular reservoirs. The presence of intracellular UPEC has been
associated with recurrence risk both in humans (Garofalo et al., 2007) and mice
(Schwartz et al., 2011) in the past. Together, the data presented in this thesis provide
compelling evidence that low-dose antibiotics are capable of enhancing virulence and
pathogenesis during UTI.
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4.4 PERSISTER CELLS CONTRIBUTE TO RECURRENT
UTI BY IMPROVING SURVIVAL DURING ANTIBIOTIC
THERAPY
The results from the prophylaxis model demonstrate that antibiotics, even when applied
at therapeutic levels, are incapable of sterilizing the urinary tracts of mice. These findings
have been noted in several other studies, using a wide variety of agents and different
pathogens (Blango and Mulvey, 2010). Although the presence of organisms in protective
intracellular niches could account for these findings, the observation of organisms in the
urine and lumen of mice during prophylaxis suggest other mechanisms must also
contribute. Antibiotic tolerant persister cells were thought to play an important role in
survival, and were characterized in this thesis in the context of recurrent UTI.

4.4.1

The nature of persistence and MDT in uropathogens

Two population-based approaches were used to characterize the persister fractions of
representative uropathogens. The observation of variations in persister fraction sizes
between Type I stationary and Type II exponential sub-populations indicate that global
dormancy cannot solely account for MDT. Rather, it is proposed that persisters can be
classified based on the metabolic activity of distinct cellular processes such as
peptidoglycan cross-linking, transcription and translation, with each demonstrating
various degrees of activity and influencing a persister's susceptibility to antibiotics. In
this way, MDT is a function of whole populations, but not individual persisters, which
are heterogeneous in regards to their antibiotic sensitivity and tolerance. Furthermore,
antibiotic-induced tolerance is not dependent on onset of global dormancy, as crosstolerance results suggest that an individual persister's susceptibility to different agents is
contingent on its mechanism of onset. These results reflect other phenotypic
observations, such as filamentation, which occur in only a subset of the overall
populations. An organism's commitment to certain phenotypes may be stochastic in
nature, perhaps due to antibiotic-dependent changes to noise propagation in gene
networks, or augmentation in organelle and molecule partitioning during cell division
(Pedraza and Oudenaarden, 2005; Huh and Paulsson, 2011).

200
Generally, most antibiotics appear to primarily influence their cognate target, increasing
tolerance against further challenge with the same agent rather than resulting in global
down-regulation of overall cellular activity as hypothesized (Grønlund and Gerdes,
1999). However, there are notable exceptions, including that ampicillin pre-treatment
results in heightened MDT against all agents in S. saprophyticus 15305. The ability of
this drug to halt replication in an SOS-dependent manner and induce β-lactam tolerance
has been demonstrated in E. coli, but is perhaps more significant in Gram-positive
bacteria (Maisonneuve et al., 2011, Miller et al., 2004). Agents affecting transcription
and translation may impart more broad-spectrum tolerance by influencing downstream
processes and therefore the activity of other potential drug targets in a similar manner.
SOS-deficient UPEC strains were deficient in antibiotic-induced persister formation
against all agents tested. Surprisingly, gentamicin induction was also affected despite its
reported inability to induce SOS responses in E. coli (Baharoglu et al., 2013). This might
reflect a novel SOS-dependent mechanism of persister induction. Considering the
heterogeneity in Gram-negative and Gram-positive responses, various antibiotics may
demonstrate different persister-inducing potentials against different organisms. If true,
this hypothesis may have predictive clinical value in the prescribing of antibiotics, which
effectively ameliorate disease without unnecessarily enriching persister fractions.

The activation of SOS systems and release of Lon protease mediates antitoxin
degradation resulting in intracellular toxin build-up from numerous TA modules and
persister formation (Maisonneuve et al., 2011). These modules also appear to play a role
in dormancy maintenance, with sequestration of the toxin by its constitutively expressed
cognate antitoxin occurring to release cells from persistence (Hansen et al., 2008). As
antibiotics can influence SOS activity, their effect on persister stability and the dynamics
of resuscitation were investigated. Although antibiotic pre-treatments influence the
expression of these genes and result in dormancy onset, their presence does not seem to
alter the general kinetics of resuscitation. However, the dichotomy in resuscitation rates
between E. coli CFT073 and S. saprophyticus 15305 further suggests that mechanisms of
persister maintenance can vary between organisms. The potential application to chronic
infections is unclear and requires further exploration, as characterization of these traits
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might have the potential to enhance treatment strategies by outlining periods of
vulnerability during infection (Gefen et al., 2008).

Enumeration of the Type I and Type II persister fractions of UPEC isolates revealed
heterogeneity in both sub-populations' responses to antibiotics. Ciprofloxacin
significantly reduced survival in stationary phase cultures compared to ampicillin and
gentamicin treatments which were largely ineffective against both SSR and AI isolates,
as demonstrated in other strains tested. The comparatively enhanced efficacy observed
for the DNA gyrase inhibitor ciprofloxacin suggests significant activity in persisters. This
may indicate that transcription and replication actively occur in persisters and that they
are sensitive to changes affecting these processes (Ramage et al., 2009). This hypothesis
is further confirmed through the observation that SOS-deficient mutants are severely
inhibited when challenged with ciprofloxacin, while remaining refractory to ampicillin
and gentamicin, agents that do not directly damage DNA. In addition to revealing DNA
gyrase activity in persisters, this result also suggests that an active SOS response is
required to abrogate ciprofloxacin-induced DNA damage (especially with respect to
RecA-dependent double-strand break repair), which may be critical for fluoroquinolone
tolerance in UPEC. The concurrent inhibition of the SOS response (such as with the
application of RecA inhibitor N6-(1-Napthyl)-ADP) along with the application of
fluoroquinolone antibiotics may be an effective means to clear persister-dependent
chronic infections (Lee et al., 2005).

4.4.2

UPEC isolated from patients with same-strain recurrences
have larger persister fractions than those pathogens
cleared with normal therapy

Type II persisters were induced by antibiotics at a high frequency in SSR compared to AI
isolates, suggesting these traits may be subject to selection and enriched over the course
of recurrent UTI and prophylaxis. Selection of genes influencing persistence has been
previously demonstrated, where overproduction of the persister-inducing molecule indole
corresponded with increased antibiotic levels over time and subsequent MDT (Vega et
al., 2012). In addition, Lewis' group observed that P. aeruginosa persister fractions
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increased over a 96 month period in an individual suffering with cystic fibrosis and
undergoing antibiotic therapy (Mulcahy et al., 2010). These results are intriguing as
antibiotics often increase the incidence of mutation within organisms, thereby increasing
the frequency with which organisms gain persister traits during long-term prophylactic
therapy (Kohanski et al., 2010). This observation may have severe clinical ramifications
in suggesting that a patient's history of antibiotic use may increase their risk of going on
to suffer from recurrent infections. In some cases, SSR organisms not only survived
lethal antibiotic dosing, but actually continued replicating in the presence of the agents
despite their susceptibility. This resistance-like phenotype has been observed previously
in susceptible Type II persister fractions but is often unreported. Notably, Balaban's
group (2004) demonstrated that E. coli persisters with mutations in the TA hipQ gene
could continue limited growth when exposed to lethal ampicillin, corroborating our
results. Other groups have noted periods of slight replication following lethal antibiotic
dosing (Keren et al., 2011, Wiuff et al., 2005). Wiuff et al. (2005) concluded this could
not be explained by degeneration of the antibiotic in the growth media over time alone.
Maisonneuve et al. (2013) recently showed that slow growing variants within an
exponentially growing E. coli population demonstrate MDT in a (p)ppGpp-dependent
manner. Admittedly, it is possible that the observed limited replication of persisters is a
result of the categorical susceptibility cut-offs provided by the Kirby-Bauer method of
testing. Although strains appeared as susceptible during this routine test, they were often
highly tolerant with low ZOIs (nearly intermediately to resistant susceptibility). This is of
clinical concern as antibiograms may inaccurately designate intermediately susceptible
organisms as fully susceptible. However, the observed growth of persisters in this and
other studies is supportive that these cells maintain at least some metabolic activity.

Further analysis and comparisons using cross-tolerance illustrated that SSR isolates have
a greater capacity to form persisters following antibiotic pre-treatment than AI strains.
However, ampicillin often failed to induce persistence in clinical isolates tested, with pretreatment resulting in greater susceptibility especially following gentamicin challenge.
This finding supports the notion that persister cells demonstrate limited replication, as
ampicillin was capable of corrupting the still moderately active transpeptidase enzyme.
The resulting leakiness likely improved the uptake of gentamicin, which in turn enhanced
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its efficacy against the still active ribosome once available intracellularly (Maisonneuve
et al., 2011). This is supported by Collins' group who demonstrated that increasing
gentamicin uptake resulted in aminoglycoside sensitivity in E. coli (Allison et al., 2011).
The observation that persister cells do not demonstrate global metabolic dormancy
suggests that some combinatorial antibiotic therapies may be effective in treating
persister-related chronic infections. Larger, high-throughput screens are recommended to
validate this hypothesis.

In summary, persisters are differentially induced at sub-inhibitory levels by ampicillin
and gentamicin in addition to ciprofloxacin in both Gram-negative and Gram-positive
bacteria. Type I persister fraction analysis indicates that global metabolic dormancy is not
solely responsible for MDT. Rather, the metabolic activity of individual targets dictates
overall bacterial responses to agents applied, with some antibiotics imparting a greater
inhibitive effect on multiple cellular targets than others. This is supported in SOSdeficient strains, which are unable to specifically tolerate ciprofloxacin. Persister traits
are enriched in organisms derived from patients with a history of antibiotic therapy. As
low-dose suppressive antibiotic therapy and antibiotic prophylaxis are commonly utilized
regimens in clinical medicine, they may in fact be playing a role in the development of
MDT. The findings in this thesis raise concern that the incidence of chronic and recurrent
bacterial infections may increase with the use of antibiotics for prophylaxis,
corroborating a recent theory that modern recurrent UTI frequency correlates with the
widespread use of antibiotics (Nickel, 2005). A greater understanding of these unique
bacterial physiological states will be essential to improve management of these common
debilitating infections. Specifically, treatment should focus not on the 'waking' of
persisters, but rather on the characterization of cellular targets that are active and thus
susceptible to antibiotic corruption. On a broader scale, the fact that antibiotics can
induce persister states emphasizes the need to avoid where possible, exposure to lowdose concentrations of these agents, either as prophylactic agents or through
environmental contamination.
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4.5 RE-EVALUATING ANTIBIOTIC APPROACHES IN THE
CLINICAL SETTING
Having delineated the off-target effects of some antibiotics we can now begin to
approach therapy with novel strategies aimed at improving patient recovery while
reducing the risk of complication. Simply changing the manner in which antibiotics are
delivered may be a quick and viable approach to this problem (Craig, 1998). This is no
easy task as organism responses can be mixed, with certain factors induced and others
suppressed depending on the agent applied and strain challenged (Davies et al., 2006).
Combinatorial, suppressive therapies may be the best approach to ensure lethal antibiotic
delivery is achieved at sites of infection. Indeed, some antibiotic combinations have been
proven to synergistically inhibit the expression of toxin genes (Subrt et al., 2011) and
prevent resistance development (Zhanel et al., 2006; Berti et al., 2012). However,
effectiveness is questionable as organisms not cleared during initial treatment phases can
go on to develop multidrug resistance much quicker than had the therapy been single
regimen (Pena-Miller et al., 2013). Similarly, hospital-wide antibiotic cycling strategies
are currently not recommended as they promote the rapid accumulation of resistance
traits to multiple drug classes (Masterton et al., 2010). Rather, antibiotic rotation at the
patient level (referred to as heterogeneity mixing or Periodic Antibiotic Monitoring and
Supervision) is a more structured and specific approach to preventing resistance
development and spread, but more validation is needed (Masterton et al., 2010).

A simpler approach to curtail resistance may be to adjust the timing of dosing such that a
'mutation prevention concentration' is achieved (Cantón and Morosini, 2011). This
involves minimizing the 'mutant selection window' by ensuring sub-inhibitory levels are
avoided throughout the course of therapy. Thus, antibiotics which are delivered to
therapeutic sites at high concentrations and then rapidly cleared would be optimal to limit
onset of resistance and virulence gene expression (Krasniqi et al., 2012). In some cases,
antibiotic therapy may be avoided all together. For example, it is well known that some
infections can self-resolve or more quickly resolve with augmentation of probiotics (Reid
et al., 2010). One of the largest contributors to antibiotic prescriptions worldwide is
attributed to UTI, which also represents a major reservoir for resistance (Foxman, 2010).
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Bleidorn et al. (2010) demonstrated that ibuprofen was just as effective as the antibiotic
ciprofloxacin in ameliorating symptoms associated with uncomplicated UTI. This finding
suggests that some infections may be readily cleared by host immune responses, while
physicians can assist in minimizing patient symptoms in a 'watchful-waiting' approach,
providing antibiotics only when it is absolutely required. Some temporary medical
devices, such as ureteral stents that leach immune-modulating components may help
reduce symptoms and the need for additional medication (Mendez-Probst et al., 2012).
These approaches are worthy of more rigorous pursuit, as antibiotics should be reserved
for when they are absolutely required. The increasing frequency of non-reverting resistant
strains which do not demonstrate any measurable fitness cost support this (Sundqvist et
al., 2010). Once established these strains are here to stay and hamper current
antimicrobial stewardship programs, which are designed to curtail resistance through
negative selection after it has arisen.

Employing novel agents which prevent the activation of general stress response elements,
specifically those targeting the SOS system may prove efficacious in curtailing
hypervirulence, resistance and mutator phenotypes. RecA, a protein important to
activation of SOS, has shown to be a promising therapeutic target when suppressed with
inhibiting agents given in conjunction with antibiotics (Lee et al., 2005; Sexton et al.,
2010; Wigle et al., 2009; Do Thi et al., 2011). An array of RecA inhibitors have already
demonstrated effectiveness in curtailing the rate of spontaneous resistant mutants. In
addition, these agents may also be useful in limiting the antibiotic-dependent production
of persister cells and virulence determinants which occur in an SOS response dependent
manner. Similarly, SOS suppression by a novel, engineered bacteriophage served as an
adjuvant to enhance killing by quinolone antibiotics (Lu and Collins, 2009). This
approach was effective in vivo, successfully killing resistant organisms, persister cells,
and biofilm associated cells. Avoiding activation of stress responses altogether may be
another appealing alternative for managing infection. Compounds like mannosides,
pilicides and curlicides may accomplish this and function by interfering with pathogenhost binding. Promise in preventing and treating UTI has already been demonstrated
(Guiton et al., 2012; Cegelski et al., 2009). High-throughput screening methods to find
other 'non-antibiotic drugs' capable of potentiating the activity of widely used antibiotics
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have been successful to some degree (Ejim et al., 2011). The advantage of this approach
is that co-therapies are more selective than standard therapies in preferentially targeting
pathogenic species while limiting destruction of the host microbiota.

Effective treatment strategies will also need to eliminate or reduce persister fractions,
although it seems unlikely that any single antibiotic therapy could accomplish this
(Allison et al., 2011). Thus, novel treatment strategies must be conceived to control
chronic, persister-dependent infections. One such strategy involves activating a surface
protease using acyldepsipeptide (ADEP4), which leads to self-digestion and death of
pathogens when used in combination with antibiotics (Conlon et al., 2013). Another
method used mannitol to induce activation of various metabolic pathways in E. coli and
S. aureus persisters, potentiating the uptake of gentamicin and promoting ribosome
corruption (Allison et al., 2011). The issue will now be to develop such products, given
the challenges, costs and longevity of the drug development process. However, if these
strategies can be applied clinically they will have a great impact on not only eliminating
chronic infections, but also in decreasing the development and spread of resistance.
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4.6 CONCLUSIONS
Several conclusions can be drawn from the findings presented within this thesis, which
should be considered in the wider context for their potential implications for prophylactic
and therapeutic antibiotic use:

1) Sub-inhibitory antibiotics from a broad range of classes are capable of modulating the
virulence potential of various uropathogens. This finding is suggestive of the ubiquitous
nature of the responses observed, with regard to antibiotics applied, and organisms
challenged. Although a number of phenotypes may be induced with antibiotics, the onset
of a sessile lifestyle due to suppressed motility and increased adhesin and
exopolysaccharide expression is prominent.

2) Induction of the SOS response is in part responsible for the phenotypic changes
incurred as a result of sub-inhibitory antibiotic treatment. The changes following
antibiotic dosing were abolished in the SOS-deficient E. coli UTI89 strains challenged.
Although the influence of SOS was not explored in S. saprophyticus 15305, other groups
have found this system to impart phenotypic changes in other staphylococci with
antibiotic exposure. However, transcriptomic analysis reveals that general stress
responses are also involved in sub-inhibitory antibiotic tolerance in this uropathogen.

3) Sub-inhibitory antibiotic-induced changes of virulence gene expression in vitro reflect
pathogenic changes in vivo using a murine model of UTI. Ciprofloxacin-priming was
sufficient to promote the establishment of chronic reservoirs in the bladders and kidney
of mice infected, in both S. saprophyticus 15305 and E. coli UTI89. These changes likely
depended on the rapid invasion of urothelial tissues in the first 24 hours following
inoculation, and shifts in host-pathogen checkpoint equilibrium in favour of the pathogen
and establishment of chronic infection.
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4) Ciprofloxacin exhibits immunomodulatory effects in both mice and human tissues, and
is protective against the establishment of chronic UPEC infection. These changes likely
depend on cytokine profile augmentation in urothelial tissues, which suppress neutrophil
recruitment and inflammation at sites of infection.

5) Ciprofloxacin prophylaxis is not recommended for recurrent infections. Mice receiving
prophylaxis were not associated with significant changes in UPEC urine titer compared to
those receiving vehicle. Furthermore, animals receiving prophylaxis presented with
greater intracellular bladder reservoirs than the control group, which might predispose to
future recurrences.

6) The persistence of bacteria in the urinary tracts of patients suffering from recurrent
infections is likely due to the presence of MDT persister cells. Antibiotics are capable of
triggering this tolerant state, and might select for organisms with larger persister fractions
during prolonged therapy. Furthermore, persister cells do not exhibit the properties
required for complete metabolic dormancy, suggesting that anti-persister drug
development should focus not on the 'waking' of these variants, but on potentiating the
activity of currently available antibiotics, such as through the use of RecA inhibitors.
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 National Award ($6,000)
 Funding for international research, Laboratory of Dr. Scott
Hultgren, Washington University School of Medicine, St Louis,
MO, USA

2012-2013

Ontario Graduate Scholarship
 Ontario Government Award ($15,000)
 Award Declined - Accepted Canadian Institutes of Health
Research Frederick Banting and Charles Best Canada
Graduate Scholarship

2012-2013

Teaching Assistant Award Nominee

2012-2013

Western Graduate Research Scholarship
 University of Western Ontario Internal Award - Tuition
Scholarship ($7,816)
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SCHOLARSHIPS, AWARDS AND HONOURS (CONTINUED)
11/2012

Cedar Lane and Novus Biologicals Oral Presentation Award
 Infection and Immunity Research Forum - Best Oral
Presentation ($500)

2011-2013

Teaching Assistant Award Nominee

2011-2012

Queen Elizabeth II Graduate Scholarship in
Science/Technology
 Ontario Government Award ($15,000)

2011

Endourology Fellowship Manuscript Award (Basic Science
Division)
 International Endourological Society - Third Prize ($750) (Coauthor)

2011-2012

Western Graduate Research Scholarship
 University of Western Ontario Internal Award - Tuition
Scholarship ($8,508)

2010-2011

Lawson Health Research Institute Studentship Award
 LHRI Internal Award ($9,000)

09/2010

Travel Award
 Department of Microbiology and Immunology, UWO ($1,000)
 Support for World Congress of Endourology Annual Meeting

2010-2011

Schulich Scholarship for Medical Research
 University of Western Ontario Internal Award ($2,270)

2010-2011

Schulich Graduate Enhancement Scholarship
 University of Western Ontario Internal Award ($5,000)

2010-2011

Western Graduate Research Scholarship
 University of Western Ontario Internal Award - Tuition
Scholarship ($5,118)

04/2010

Research Western Imagination Prize (Co-supervisor)
 London District Science and Technology Fair ($200)

2009-2010

Schulich Graduate Enhancement Scholarship
 University of Western Ontario Internal Award ($5,000)
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SCHOLARSHIPS, AWARDS AND HONOURS (CONTINUED)
2009-2010

Western Graduate Research Scholarship
 University of Western Ontario Internal Award - Tuition
Scholarship ($7,081)

10/2007

World Congress of Endourology Poster Award (Second Prize)
 International Endourological Society (Co-author) ($500)

2005

Ontario Scholar Award
 University of Western Ontario Internal Award ($1,500)

PEER REVIEWED PUBLICATIONS
1. Goneau LW, Yeoh NS, MacDonald KW, Cadieux PA, Burton JP, Razvi H,
Reid G. (2014) Selective target inactivation rather than global metabolic
dormancy causes antibiotic tolerance in uropathogens. Antimicrobial
Agents and Chemotherapy (doi:10.1128/AAC.02552-13). Featured as a
Current Topic in ASM's Microbe Magazine - "Two Persisters: One Hides,
Another Shuts Down Specific Targets".
2. Fahmy N, Woo M, Alameldin M, Lee JK, MacDonald K, Goneau LW,
Cadieux P, Burton P, Pautler S. (2013) Endogenous biotin expression in
renal and testicular tumors and literature review. Canadian Urological
Association Journal (Accepted December 2013).
3. Fahmy N, Woo M, Alameldin M, MacDonald K, Goneau LW, Cadieux P.
(2013) Ochratoxin A is not detectable in renal and testicular tumors.
Canadian Urological Association Journal (Accepted August 2013).
4. Bevan T, Goneau LW, Cadieux PA, Razvi H, Carriveau R. (2012)
Numerical simulation of peristaltic urine flow in a stented ureter. American
Journal of Biomedical Sciences 4(3):233-48.
5. Mendez-Probst CE, Goneau LW, MacDonald KW, Nott L, Elwood CN,
Lange D, Chew B, Denstedt JD, Cadieux PA. (2012) The use of triclosan
eluting ureteral stents effectively reduces ureteral stent symptoms: a
prospective randomized trial. British Journal of Urology International
110(5):749-54.
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PEER REVIEWED PUBLICATIONS (CONTINUED)
6. Erdeljan P, MacDonald KW, Goneau LW, Bevan T, Carriveau R, Razvi H,
Denstedt JD, Cadieux PA. (2011) Effects of subinhibitory concentrations
of ciprofloxacin on Staphylococcus saprophyticus adherence and
virulence in urinary tract infections. Journal of Endourology 26(1):32-7.
Third Prize (Basic Sciences Division).
7. Cadieux PA, Chew BH, Nott L, Seney S, Elwood CN, Wignall G, Goneau
LW, Denstedt JD. (2009) Use of triclosan-eluting ureteral stents in patients
with long-term stents. Journal of Endourology 23(7):1187-1194.
8. Wignall GR, Goneau LW, Chew BH, Denstedt JD, Cadieux PA. (2008)
The effects of triclosan on uropathogen susceptibility to clinically-relevant
antibiotics. Journal of Endourology 22(10):2349-2356.

SUBMITTED OR IN PREPARATION MANUSCRIPTS
1. Goneau LW, Jindal M, MacDonald K, Gupta M, Burton J, HatibovicKoffman S, Cadieux P. (2014) Novel Management Strategies for the
Control
of
Streptococcus
mutans
and
Aggregatibacter
actinomycetemcomitans Biofilms.
2. Goneau LW, Hannan TJ, Gloor GB, MacPhee RA, Scwartz DJ, Razvi H,
Burton JP, Hultgren SJ, Reid G. (2014) Inadequate antibiotic therapy
enhances the risk of chronic infection in a murine model of UTI.
3. Goneau LW, Delport J, Razvi H, Burton JP, Reid G. (2014) The dangers
of inappropriate antibiotic therapy - issues beyond resistance.

PUBLISHED COLLECTIVE WORKS
1. Goneau LW, MacDonald KW, Huynh MJ, Whiteside SA, Yang L, Cadieux
PA. (2012) Hormetic Effects of Antibiotics on Bacteria and their Potential
Role in Recurrent Urinary Tract Infection. Urotoday.com (Invited Beyond
the Abstract Commentary - Effects of Subinhibitory Concentrations of
Ciprofloxacin on Staphylococcus saprophyticus Adherence and Virulence
in
Urinary
Tract
Infections),
(ISSN
1939-4810
http://www.urotoday.com/infections-1165)
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PUBLISHED PEER REVIEWED ABSTRACTS
1. Goneau LW, Yeoh N, Cadieux P, Burton J, Hassan R, Reid G. (2013)
Management of Recurrent Urinary Tract Infections: Something's Wrong
with Diagnosis and Treatment. Canadian Urological Association Journal,
7(5-6Suppl2):S86.
2. Goneau LW, MacDonald K, Razvi H, Cadieux PA. (2012) Sub-Minimal
Inhibitory Concentrations of Antimicrobials Prime Staphylococcus
saprophyticus for Survival Within the Urinary Tract During Prophylaxis.
Canadian Urological Association Journal, 6(4):319:P98.
3. Nader F, Woo M, MacDonald K, Goneau LW, Cadieux PA, Pautler S.
(2012) Investigating Ochratoxin A and Biotin Levels in Patients with Renal
Carcinoma. Canadian Urological Association Journal, 6(4):317:P94.
4. Bathini V, Fuller A, Goneau LW, MacDonald K, Razvi H, Cadieux PA.
(2012) Urinary Device Attachment of Staphylococcus saprophyticus in the
Presence of Sub-Minimal Inhibitory Antimicrobial Concentrations.
Canadian Urological Association Journal, 6(4):317:P92.
5. Fahmy N, Fuller A, Goneau LW, MacDonald K, Erdeljan P, Bathini V,
Razvi H, Cadieux P. (2012) Sub-inhibitory Antibiotic Concentrations
Negatively Affects Both the Uropathogen Staphylococcus saprophyticus
and Host Immune Responses. Canadian Urological Association Journal,
6(3 Suppl1): S92.
6. Fuller A, Goneau LW, MacDonald K, Erdeljan, P, Bathini V, Razvi H,
Cadieux PA. (2011) Sub-Inhibitory Antibiotic Concentrations Enhance
Surface Attachment, Survival and Host Immune Evasion in the
Uropathogen Staphylococcus saprophyticus. Canadian Urological
Association Journal, 5(5 Suppl 3): S181. Selected as highlight at the
NSAUA 2011 Annual Meeting, New Orleans, USA.
7. Goneau LW, Mendez-Probst C, Razvi H, Cadieux PA. (2010) Effects of
Antimicrobials on Biofilm Formation in Staphylococcus saprophyticus.
Journal of Endourology 24(S1).
8. Cadieux PA, Chew BH, Goneau LW, Lange D, Vanjecek M, McCormick
JK, Denstedt JD. (2009) Recombinant oxalate decarboxylase YvrK
degrades oxalate in a dose- and time-dependent manner. Journal of
Urology 181(4):659-660.
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PUBLISHED PEER REVIEWED ABSTRACTS (CONTINUED)
9. Wignall G, Goneau LW, Chew BH, Denstedt JD, Cadieux PA. (2008)
Triclosan enhances antibiotic susceptibility in several common
uropathogens. Journal of Urology 179(4 Supp):84.
10. Wignall G, Chew BH, Denstedt JD, Goneau LW, Cadieux PA. (2007)
Triclosan renders several uropathogens increasingly susceptible to
relevant antibiotics. Journal of Endourology 21 (Supp 1):BR1-17. Selected
as a highlight at the WCE 2007 Annual Meeting, Cancun, Mexico.

INVITED PODIUM PRESENTATIONS
1. Goneau LW, Hannan TJ, Hultgren SJ, Burton JP, Razvi H, Reid G. (2014)
Time to re-evaluate antibiotic prophylaxis for recurrent urinary tract
infection. London Health Research Day, London, Canada. Featured in the
London Free Press Newspaper: http://www.lfpress.com/2014/03/18/studyby-western-phd-candidate-suggests-inappropriate-use-of-antibioticscould-make-matters-worse-in-some-infections.
2. Goneau LW, Cadieux PA, Burton J, Reid G. (2012) Persister cell traits of
uropathogenic bacteria in sepsis. The Infection and Immunity Research
Forum Annual Meeting, The University of Western Ontario, London.
Canada. Selected for Cedar Lane and Novus Biologicals 'Best in Show'
Oral Presentation Award.
3. Goneau LW, MacDonald K, Razvi H, Cadieux PA. (2012) Sub-Minimal
Inhibitory Concentrations of Antimicrobials Prime Staphylococcus
saprophyticus for Survival Within the Urinary Tract During Prophylaxis.
The Northeastern Section of the American Urology Association Annual
Meeting, Niagara Falls, Canada.
4. Goneau LW, MacDonald KW, Razvi H, Cadieux P. (2012) Sub-Minimal
Inhibitory Concentrations of Antimicrobials Prime Staphylococcus
saprophyticus for Survival Within the Urinary Tract During Prophylaxis.
The American Urology Association - Society for Infection and Inflammation
in Urology Annual Meeting, Atlanta, USA.
5. Goneau LW, MacDonald KW, Cadieux PA. (2011) Antimicrobial Induced
Tolerance Mechanisms in Staphylococcus saprophyticus and their Role in
Recurrent and Device Associated Urinary Tract Infection. The Infection
and Immunity Research Forum Annual Meeting, The University of
Western Ontario, London. Canada.
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INVITED PODIUM PRESENTATIONS (continued)
6. Goneau LW, Mendez-Probst C, Razvi H, Cadieux PA. (2010) Effects of
Antimicrobials on Biofilm Formation in Staphylococcus saprophyticus. The
World Congress of Endourology Annual Meeting, Chicago, USA.

INVITED SEMINAR PRESENTATIONS
1. Goneau LW, Cadieux PA. (2012) Hormetic Effects of Antibiotics on
Bacteria and their Potential Role in Recurrent Urinary Tract Infection.
Talks on Fridays (TOFs). LHRI, London, Canada.
2. Goneau LW, Cadieux PA. (2011) Sub-Inhibitory Antibiotic Treatment
Induces High Density Growth and Improves Staphylococcus
saprophyticus Survival Against Bactericidal Concentrations. Talks on
Fridays (TOFs). LHRI, London, Canada.
3. Goneau LW, Cadieux PA. (2010) Effects of Stress on Biofilm Formation in
Staphylococcus saprophyticus. Talks on Fridays (TOFs). LHRI, London,
Canada.

POSTER PRESENTATIONS
1. Goneau LW, Yeoh N, Cadieux P, Burton JP, Razvi H, Reid G. (2013)
Management of Recurrent Urinary Tract Infections: Something's Wrong
with Diagnosis and Treatment. The Canadian Urological Association
Annual Meeting, Niagara Falls, Canada.
2. Goneau LW, MacDonald K, Razvi H, Cadieux PA. (2012) Sub-Minimal
Inhibitory Concentrations of Antimicrobials Prime Staphylococcus
saprophyticus for Survival Within the Urinary Tract During Prophylaxis.
The Northeastern Section of the American Urology Association Annual
Meeting, Niagara Falls, Canada.
3. Goneau LW, Huynh MJ, MacDonald KM, Cadieux PA (2012) Effects of
Sub-Minimal Inhibitory Concentrations of Antibiotics on Bacteria and their
Potential Role in Recurrent Urinary Tract Infection. London Health
Research Day, Infection and Immunity, London, Canada.
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POSTER PRESENTATIONS (CONTINUED)
4. Huynh M, Bathini V, Fuller A, Goneau LW, MacDonald KW, Razvi H,
Cadieux PA. (2012) Urinary Device Attachment of Staphylococcus
saprophyticus in the Presence of Sub-Minimal Inhibitory Antimicrobial
Concentrations. Canadian National Medical Student Research
Symposium (CNMSRS), University of Manitoba, Winnipeg, Canada.
Selected as Best in Show Presentation Award (New Trainee Category)
(Co-author and supervisor).
5. Fuller A, Goneau LW, MacDonald KW, Erdeljan P, Bathini V, Razvi H,
Cadieux PA (2011) Sub-Inhibitory Antibiotic Concentrations Enhance
Surface Attachment, Survival and Host Immune Evasion in the
Uropathogen Staphylococcus saprophyticus. Northeastern Section of the
American Urological Association Annual Meeting, New Orleans, USA (Coauthor).
6. Goneau LW, MacDonald KW, Erdeljan P, Fuller A, Fernandez A, Razvi H,
Cadieux PA. (2011) Sub-Inhibitory Antibiotic Concentrations Enhance
Surface Attachment and Survival in Staphylococcus saprophyticus. The
Society for Infection and Inflammation in Urology Division of the American
Urological Association Annual Meeting, Washington D.C., USA.
7. MacDonald KW, Goneau LW, Erdeljan P, Fuller A, Carreno A, Razvi H,
Cadieux PA. (2011) Sub-Inhibitory Levels of Ciprofloxacin Enhance
Staphylococcus saprophyticus Adherence to Bladder Cells and Reduce
Pro-inflammatory Cytokine Expression. The Society for Infection and
Inflammation in Urology Division of the American Urological Association
Annual Meeting, Washington D.C., USA (Co-author).
8. Goneau LW, MacDonald KW, Cadieux PA. (2011) Sub-Inhibitory
Antibiotic Treatment Induces High Density Growth and Improves
Staphylococcus
saprophyticus
Survival
Against
Bactericidal
Concentrations. The Annual Infection and Immunity Research Forum,
Department of Microbiology and Immunology, Schulich School of Medicine
and Dentistry, University of Western Ontario.
9. Goneau LW, MacDonald KW, Cadieux PA. (2011) Antimicrobial Induced
Tolerance Mechanisms in Staphylococcus saprophyticus and their Role in
Recurrent and Device Associated Urinary Tract Infection. Lawson
Research Day. Clinical Investigations and Therapeutics, London, Canada.
10. Goneau LW, Mendez-Probst C, Razvi H, Cadieux PA. (2010) Effects of
Antimicrobials on Biofilm Formation in Staphylococcus saprophyticus. The
World Congress of Endourology Annual Meeting, Chicago, USA.

264

POSTER PRESENTATIONS (CONTINUED)
11. Goneau LW, Cadieux PA. (2010) The Effect of Stress on Staphylococcus
saprophyticus Surface Attachment and Subsequent Biofilm Formation.
Lawson Research Day. Clinical Investigations and Therapeutics, London,
Canada.
12. Goneau LW, Wignall GR, Vanjecek M, Cadieux PA. (2009) Investigating
biofilm formation, structure and antibiotic resistance in uropathogens. The
Annual Infection and Immunity Research Forum, Department of
Microbiology and Immunology, Schulich School of Medicine and Dentistry,
University of Western Ontario.

